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ABSTRACT 
Stroke is a disease with high morbidity and mortality rates, classified among the most common 
causes of death and acquired disability worldwide. Thus, assessing its epidemiology may play 
a crucial role in reducing its impact on the population and the society. Stroke late burden is 
attributable to developing countries mainly, as people in developed countries have a better 
access to optimal care and an increased awareness on stroke symptoms and risk factors. 
However, in less developed countries, where population confronts the huge impact of 
urbanization and globalization with a great increase in the prevalence of cardiovascular risk 
factors, the incidence of stroke remains high. Lebanon is lacking data on the epidemiology of 
stroke. Therefore, it was necessary to conduct this study and highlight some features of the 
disease epidemiology.  
We carried out a multicenter prospective incidence-based cohort study. We included 203 
participants aged 18 years and more from 8 hospitals in Beirut between August 2015 and 
August 2016 with confirmed diagnosis of stroke. Patients were followed for a 1-year period 
(at hospital admission and discharge, and by home visits at 3, 6 and 12 months). 
Hypertension was the most powerful and prevalent risk factor for stroke. Only 2.5% of 
ischemic strokes received thrombolytic therapy. Cumulative mortality rates were 13.3% at 1-
month and 21.2% at 1-year. Stroke severity and complications were predictors of death at 1-
month and 1-year. Low socioeconomic status, dependency in daily living activities, and co-
morbidities were additional 1-year mortality predictors. The quality of life was relatively low 
in stroke patients and more than 15% of them were depressed. The main determinants of 
quality of life were functional status, dependency in daily living activities, age, and depression. 
The main determinants of depression were functional status and quality of life. The direct in-
hospital cost for all cases was US$1,413,069 for 2626 days (US$538 per in-hospital day). The 
average in-hospital cost per stroke patient was US$6961±15,663. Hemorrhagic strokes were 
the most costly, transient ischemic attack being the least costly. Cost drivers were hospital 
and intensive care unit length of stay, type of stroke, stroke severity, modified Rankin Scale, 
third party payer, surgery and infectious complications. 
Primary prevention is of paramount importance in reducing the burden of stroke. Awareness 
campaigns on stroke symptoms especially among hypertensive population would help limit 
the incidence of the disease and therefore decrease the high financial and social burden of 
stroke (cost of illness and quality of life). The establishment of stroke units and increasing the 
percentage of thrombolysis may reduce short-term mortality and long term disabilities and 
therefore improve the quality of life of stroke patients. 
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RESUME 
L’accident vasculaire cérébral (AVC) est une maladie avec des taux de morbidité et de 
mortalité élevés, il est classé parmi les causes les plus fréquentes de décès et d’invalidité 
acquise dans le monde entier. Ainsi, évaluer son épidémiologie peut jouer un rôle crucial dans 
la réduction de son impact sur la population et la société. Le fardeau de l’AVC est attribué 
principalement aux pays en voie de développement, puisque les gens dans les pays 
développés ont une meilleure prise en charge et une sensibilisation accrue sur les symptômes 
et les facteurs de risque de l’AVC. Toutefois, dans les pays moins développés, où la population 
confronte l’énorme impact de l’urbanisation et de la mondialisation avec une augmentation 
accrue de la prévalence des facteurs de risque cardiovasculaire, l’incidence des AVC reste 
élevée. Peu de données épidémiologiques existent sur les AVC au Liban. Par conséquent, il 
était nécessaire de mener cette étude.  
Nous avons effectué une étude de cohorte multicentrique, prospective, basé sur l’incidence. 
Nous avons inclus 203 participants âgés de 18 ans et plus de 8 hôpitaux à Beyrouth entre Août 
2015 et Août 2016 avec un diagnostic d’AVC confirmé. Les patients ont été suivis pendant une 
période d’un an (à l’admission à l’hôpital, à la sortie de l’hôpital et à 3, 6 et 12 mois par des 
visites à domicile). 
L’hypertension est le facteur de risque le plus puissant et le plus fréquent de l’AVC. Seulement 
2,5 % des AVC ischémiques ont subi une thrombolyse. Le taux de mortalité cumulé était 13,3% 
à 1 mois et 21,2% à 1 an. Les complications et la gravité de l’AVC étaient des prédicteurs de 
décès à 1 mois et 1 an. Le niveau socio-économique bas, la dépendance dans les activités 
quotidiennes et les comorbidités étaient prédicteurs de mortalité supplémentaire à 1 an. La 
qualité de vie est relativement faible chez les patients atteints d’AVC et plus de 15 % d'entre 
eux étaient déprimés. Les principaux déterminants de la qualité de vie étaient: l’état 
fonctionnel, la dépendance dans les activités de la vie quotidienne, l’âge et la dépression. Les 
principaux déterminants de la dépression étaient l’état fonctionnel et la qualité de vie. Le coût 
direct hospitalier de tous les cas d’AVC était US$ 1,413,069 pour 2626 jours (538 US$ par jour 
à l’hôpital). Le coût moyen hospitalier par patient était US$ 6961±15, 663. Les AVC 
hémorragiques ont été les plus coûteux, l'accident ischémique transitoire étant le moins 
coûteux. Les prédicteurs de coûts étaient : la longueur du séjour hospitalier et dans l'unité de 
soins intensifs, le type d’AVC, la gravité de l’AVC, l'échelle de Rankin modifiée, les tiers 
payeurs, la chirurgie et les complications infectieuses. 
La prévention primaire est d’une importance primordiale dans la réduction de la charge de 
l’AVC. Les campagnes de sensibilisation sur les symptômes de cette maladie surtout pour la 
population hypertendue contribueront à limiter l’incidence de la maladie et donc à diminuer 
le fardeau financier et social élevé de l’AVC (le coût de la maladie et la qualité de vie). La mise 
en place d’unités spécialisées pour les AVC et l’augmentation du pourcentage de patients 
thrombolysés peuvent réduire la mortalité à court terme et les incapacités de longue durée et 
donc améliorer la qualité de vie des patients atteints d’AVC. 
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RESUME SUBSTANTIEL 
INTRODUCTION 
I- DEFINITION ET TYPES 
Les accidents vasculaires cérébraux (AVC) font partie d'un groupe de maladies chroniques 
appelées les maladies cardiovasculaires (MCV). L’Organisation Mondiale de la Santé (OMS) 
définit un AVC comme « le développement rapide de signes cliniques localisés ou globaux de 
déficit ou dysfonction cérébrale avec des symptômes durant plus de 24 heures pouvant conduire 
à la mort, sans autre cause apparente qu‘une origine vasculaire » (WHO MONICA Project 
Investigators, 1988). Les AVC se caractérisent par leur grande diversité et la forte invalidité 
qu'ils peuvent engendrer à long terme. Ils recouvrent un ensemble de syndromes se manifestant 
par l’apparition brutale d’un déficit neurologique dû à des lésions cérébrales d’origine 
vasculaire. 
On distingue: 
 Les Accidents Ischémiques: 
 Transitoires (AIT): un AIT est un déficit neurologique focal, d'installation brutale, et 
entièrement régressif et sans signe d'infarctus constitué à l'imagerie cérébrale. 
 Constitués: un AVC constitué est un déficit neurologique de topographie vasculaire durable, 
consécutif, le plus souvent, à l'occlusion d'une artère cérébrale.  
 Les Accidents Hémorragiques: 
 Sous-arachnoïdiens ou méningés dus à la rupture des anévrismes artériels du polygone de 
Willis (dans l'espace sous-arachnoïdien). 
 Cérébro-méningés dus à la rupture des malformations artério-veineuses. 
 Cérébraux ou intraparenchymateux dus à la rupture des microanévrismes de Charcot et 
Bouchard situés sur les artérioles perforantes (c'est dans ce dernier cas qu'on parle d'AVC 
hémorragique). 
En moyenne, 87% des AVC sont ischémiques. Ces derniers résultent le plus souvent d'une 
occlusion vasculaire dont les 2 principaux mécanismes sont la thrombose et l'embolie. 
L'embolie peut avoir comme point de départ soit le cœur soit une plaque d'athérome qui est à 
l'origine aussi des thromboses (occlusion complète de l'artère) (AHA/ASA; 2018). 
 10 
La classification TOAST (Adams et al., 1999):  
 Les athéroscléroses des gros vaisseaux 
 La cardiopathie emboligène 
 Les maladies des petits vaisseaux ou lacunes 
 Autres causes (notamment des troubles hématologiques) 
 Les AVC de cause indéterminée (dans le cas où l'évaluation est incomplète ou négative, ou 
s'il y a plus d'une cause identifiée) 
II- FACTEURS DE RISQUE DES AVC  
FACTEURS DE RISQUE MODIFIABLES 
Hypertension artérielle (HTA): La relation entre la tension artérielle et le risque d'AVC est 
étiologiquement et fortement significative, rendant l'HTA le premier facteur de risque de l'AVC 
ischémique et hémorragique. En effet, le risque d'AVC attribuable à l'hypertension atteint 35% 
pour tous les types d’AVC (O‘Donnell et al., 2010). 
Tabagisme: Le tabagisme (cigarettes, cigares, pipes et nargileh) actif ou passif est un facteur 
de risque indépendant de l'AVC ischémique et de l'hémorragie sous-arachnoïdienne et en un 
moindre degré de l’hémorragie intracérébrale. Les fumeurs actuels ont un risque d'AVC 2 à 4 
fois plus élevé que les non-fumeurs ou ceux qui ont cessé de fumer depuis plus de 10 ans 
(Meschia et al., 2014). 
Diabète mellitus: Les diabétiques sont 2 fois plus à risque de subir un AVC que les personnes 
non diabétiques, ce risque concernant les AVC ischémiques beaucoup plus que les AVC 
hémorragiques (O‘Donnell et al., 2010). 
Régime alimentaire: Les études épidémiologiques ont mis en évidence un effet protecteur d'un 
régime alimentaire pauvre en sel et riche en fruits et légumes ainsi qu’un régime alimentaire 
Méditerranéen sur l'incidence d'un AVC (Estruch et al., 2013; Larsson et al., 2013). 
Manque d'activité physique: L’inactivité physique augmente le risque d’AVC (Willey et al., 
2017). Une activité physique régulière était associée à un risque réduit d’AVC (O’Donnell et 
al., 2010). 
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Surpoids et obésité: Le surpoids et l’obésité sont des facteurs de risque majeurs de maladies 
cardiovasculaires, y compris les AVC (Goldstein et al., 2011). 
Dyslipidémie: Les études épidémiologiques montrent que le taux de cholestérol total (surtout 
le LDL) est plus ou moins corrélé à l'incidence d'un AVC: Pour des taux plus élevés, l'incidence 
d'un AVC ischémique augmente (Kurth et al., 2007) alors que celle d'un AVC hémorragique 
diminue (Sturgeon et al., 2007). 
Fibrillation auriculaire (FA): La FA (paroxystique ou chronique) multiplie le risque d'AVC 
cardioembolique par un chiffre allant de 4 à 5 (Turakhia et al., 2015). De plus, la FA est la 
source cardiaque de thromboembolie la plus fréquente dans les cas des AVC ischémiques 
(O‘Donnell et al., 2010). 
Autres troubles cardiaques: Infarctus du myocarde, maladies valvulaires 
Syndrome métabolique: Le syndrome métabolique est associée à un risque plus élevé d'AVC 
(Mottilo et al., 2010). 
Maladie rénale chronique: Une méta-analyse a montré une augmentation de 43% du risque 
d'AVC chez les patients présentant un DFG <60 mL.m -11,73 m-2 (Lee et al., 2010). 
L'apnée du sommeil: Le risque d'AVC ischémique et hémorragique est plus élevé avec l'apnée 
du sommeil. Dans une méta-analyse de 5 études, l'apnée obstructive du sommeil est associée à 
l’AVC, avec un OR de 2,2 (IC à 95%, 1,6–3,2) (Loke et al., 2012). 
Alcoolisme: Le risque d'AVC est augmenté avec la consommation excessive d'alcool. La 
plupart des études montrent une association en forme de J entre le nombre de verres consommés 
par jour et le risque d'AVC ischémique: La consommation légère à modérée d'alcool aurait un 
effet protecteur contre le risque d'AVC ischémique mais non pas hémorragique  (O‘Donnell et 
al., 2010). 
Abus de drogues: Le risque d'AVC ischémique et hémorragique est plus élevé avec l'abus de 
ces drogues (AHA/ASA). 
Habitudes de sommeil: Des études récentes ont commencé à clarifier les raisons pour 
lesquelles les personnes qui dorment régulièrement et de bonne qualité tendent à présenter 
moins de risques d'AVC (AHA/ASA). Dans une méta-analyse récente de 10 études, une relation 
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en forme de J a été rapportée entre la durée du sommeil et le risque d'AVC, le risque le plus 
faible étant observé chez les personnes ayant une durée de sommeil de 6 à 7 heures par jour (Li 
et al., 2016). 
FACTEURS DE RISQUE NON MODIFIABLES  
Age: L'âge augmente le risque d'AVC par ses effets cumulatifs sur le système cardiovasculaire. 
Les personnes sont plus susceptibles d'avoir un AVC après l'âge de 55 ans (Wang et al., 2013). 
La probabilité d'avoir un AVC double presque tous les 10 ans après l'âge de 55 ans (Rothwell 
et al., 2005). 
Facteurs génétiques: Des études génétiques ont identifié des variantes génétiques associés à 
un risque d'ischémie cérébrale (Flossmann et al., 2004) et d'ICH (Chauhan and Debette, 2016). 
Une histoire familiale d'AVC augmente le risque d'AVC de 25% (Seshadri et al., 2010). 
Race: Les statistiques montrent que les Afro-Américains (Hispaniques) ont un risque beaucoup 
plus élevé de décès par AVC que les Caucasiens (White et al., 2005). Le risque d'avoir un 
premier AVC est de deux fois plus élevé pour les Noirs que pour les Blancs (Benjamin et al., 
2017) et les Noirs ont le taux de décès par AVC le plus élevé (Vital Signs, 2017). 
Sexe: Les femmes sont significativement plus âgées lors de leur tout premier AVC, et ont une 
incidence d'AVC supérieure à 85 ans, et inférieure à tous les autres âges (Haast et al., 2012). Le 
risque d'AVC est augmenté de 9% par année d'âge chez les hommes et de 10% chez les femmes 
(95% IC= 9-10%) (Asplund et al., 2009). Les femmes ménopausées sont plus à risque que les 
non-ménopausées de développer un AVC (Boardman et al., 2015). 
Le statut socio-économique: L'éducation, le revenu et l'occupation sont les 3 principaux 
déterminants du statut socioéconomique. Les études ont montré une association négative entre 
le risque d'AVC et le statut socioéconomique (CDC, 2012). 
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III- PRISE EN CHARGE PRECOCE DES AVC 
PHASE PRE-HOSPITALIERE ET EVALUATION DU PATIENT: 
Suspecter un AVC / Echelle FAST: 
La reconnaissance des symptômes devant faire évoquer un AVC ou AIT est primordial auprès 
des acteurs du premier secours (membres de famille, ambulanciers, secouristes, médecins 
généralistes, etc.). Dans ce but, un outil simple et rapide est utilisé en général pour ne pas 
s'attarder à offrir la prise en charge nécessaire aux patients d'AVC. Cet outil est le test FAST: 
 F pour Face: perte de force ou engourdissement du visage. 
 A pour Arm: perte de force ou engourdissement au niveau d'un membre supérieur. 
 S pour Speech: trouble de la parole. 
 T pour Time: pour agir le plus rapidement possible. 
Plusieurs pays, tels que le Royaume-Uni et la France, ont lancé des campagnes nationales de 
sensibilisation de la population aux symptômes des AVC: les campagnes "Act FAST" (Powers 
et al., 2018). 
Les patients présentant un dépistage positif de l'AVC et/ou une forte suspicion d'AVC devraient 
être transportés rapidement vers les établissements de santé les plus proches capables 
d'administrer de manière compétente l'altéplase IV (Classe I, LOE B) (Powers et al., 2018). 
PHASE HOSPITALIERE 
Evaluer la sévérité de l'AVC / Echelle NIHSS: 
Le NIHSS est le plus couramment utilisé. Il est composé de 11 questions qui marquent chacune 
une capacité neurologique spécifique et dont les réponses prennent un score allant de 0 (réponse 
normale) à 2, 3 ou 4 (dysfonctionnement sévère). Les scores individuels de chaque élément sont 
additionnés pour donner le score total NIHSS. Les questions portent sur le niveau de 
conscience, la vision, la paralysie faciale, la motricité et l'ataxie des membres, la sensibilité, le 
langage, l'extinction et la négligence. 
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Le score total prend un chiffre allant de 0 à 42: 
 Un score de 1 à 4 indique un AVC mineur. 
 Un score de 5 à 15 indique un AVC modéré. 
 Un score de 16 à 20 indique un AVC modéré à sévère. 
 Un score de 21 à 42 indique un AVC sévère. 
Il est important d'évaluer la sévérité de l'AVC le plus tôt possible après le début des symptômes 
pour instaurer le traitement le plus adéquat (notamment décider si le patient est candidat d'une 
thrombolyse) et pour juger de l'efficacité de ce dernier et des mesures de réhabilitation 
instaurées plus tard au patient (NIHSS diminue ou augmente). De plus, le NIHSS permet de 
prédire l'état du patient après AVC: Un score ≤6 prévoit un bon pronostic alors qu'un score ≥16 
prévoit une forte probabilité de décès ou de handicap sévère (Adams et al., 1999).   
IMAGERIE CEREBRALE ET VASCULAIRE 
Idéalement, l'imagerie doit être initiée dans un délai maximal de 25min depuis l'arrivée du 
patient à l'hôpital et interprétée dans un délai de 45min ("Door to Imaging initiation"≤25min; 
"Door to Imaging interpretation"≤ 45min). La neuro-imagerie rapide avec CT scanner ou IRM 
est recommandée pour distinguer l’AVC ischémique de l’AVC hémorragique. L'IRM (imagerie 
par résonance magnétique) est l'examen le plus performant pour montrer précocement des 
signes d’ischémie récente, et elle visualise l’hémorragie intracrânienne. Le CT scanner est très 
sensible pour identifier une hémorragie aiguë et est considéré comme le «gold standard». 
LE TRAITEMENT DES AVC ISCHEMIQUES 
LA THROMBOLYSE INTRAVEINEUSE (IV) 
La thrombolyse IV par l'altéplase est le traitement de choix (Gold Standard) des AVC 
ischémiques aigus. L'activateur tissulaire du plasminogène recombinant (rtPA ou altéplase) a 
été approuvé en 1996 par l'agence Américaine des produits alimentaires et médicaux (FDA) 
pour le traitement des AVC ischémiques aigus. Cependant, ce traitement ne peut se faire que 
dans les 3 à 4.5h qui suivent le début des symptômes. Idéalement, le traitement doit être initié 
dans les 60min suivant l'admission du patient à l'hôpital ("Door to needle" ≤60min).  
Dose: 0.9mg/kg (dose maximale 90mg); 10% de la dose en bolus IV et 90% en infusion/ 1h 
(Powers et al., 2018). 
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LES INTERVENTIONS ENDOVASCULAIRES 
- La thrombolyse intra-artérielle (IA): peut être utilisée au cas par cas si la thrombolyse IV n'est 
pas possible, après concertation entre neurologues vasculaires et neuroradiologues, et ce jusqu’à 
6 heures pour les occlusions de l’artère cérébrale moyenne, voire au-delà de 6 heures pour les 
occlusions du tronc basilaire du fait de leur gravité extrême (Powers et al., 2018). 
- La revascularisation mécanique par thrombectomie ("MERCI Retrieval System", "Penumbra 
System", "Solitaire Flow Restoration Device", Trevo Retriever") avec ou sans thrombolyse 
pharmacologique: A évaluer (Powers et al., 2018). 
ADMINISTRATION D'ANTIAGREGANTS PLAQUETTAIRES: 
- A initier l'aspirine (dose initiale de 325mg) dans les 24-48h suivant le début de l'AVC. 
- L'aspirine ne doit pas substituer un traitement éligible par l'altéplase IV. 
- L'utilité du clopidogrel dans le traitement des AVC aigus n'est pas bien établie. 
- L'administration IV des inhibiteurs du récepteur de la glycoprotéine IIb/IIIa n'est pas 
recommandée. 
TRAITEMENT DES COMPLICATIONS AIGUËS 
- L'hypotension et l'hypovolémie doivent être corrigées pour maintenir les niveaux de perfusion 
systémique nécessaires au soutien de la fonction des organes (Powers et al., 2018). 
- Les patients qui ont une tension artérielle élevée et qui sont par ailleurs admissibles à un 
traitement par rtPA IV doivent voir leur tension artérielle baissée avec précaution de manière à 
ce que leur pression artérielle systolique soit <185 mm Hg et leur pression artérielle diastolique 
<110 mm Hg avant le début du traitement par fibrinolytique. 
- Les arythmies cardiaques susceptibles de réduire le débit cardiaque doivent être corrigées 
- L'hypoglycémie (glycémie <60 mg/dL) doit être traitée chez les patients atteints d'AVC aigu. 
Le but est d'atteindre la normoglycémie. 
- Un supplément d'oxygène doit être fourni chez les patients avec hypoxie pour maintenir la 
saturation en oxygène >94%. 
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LE TRAITEMENT DES AVC HEMORRAGIQUES: 
Les stratégies thérapeutiques doivent d'abord cibler la cessation de l'élargissement de 
l'hématome et la prévention des conséquences délétères de l'effet de masse évoqué par 
l'hémorragie elle-même et l'œdème qui l'entoure. Le développement d'une hydrocéphalie est à 
surveiller, et des mesures chirurgicales adéquates (Dérivation externe du liquide céphalo-
rachidien en cas d'hydrocéphalie aiguë, évacuation d'un hématome cérébelleux compressif, 
traitement curatif d'une malformation vasculaire, etc.) doivent être prises à temps. 
 Mesures antiœdémateuses:  
 Position semi-assise (30°) 
 Restriction hydrique  
 Les corticoïdes sont sans intérêt 
 Le Mannitol peut être utilisé. 
 Traitement des troubles de coagulation: 
 Arrêt des anticoagulants 
 Selon le cas: Plasma frais congelé, Concentré plaquettaire (si thrombopénie), sulfate de 
protamine (si surdosage en héparine), Vitamine K ou concentré de complexe 
prothrombinique (si surdosage en anti-Vitamine K). 
 Gestion du glucose 
Le glucose doit être surveillé. L'hyperglycémie et l'hypoglycémie doivent être évitées. 
 Traitement des crises convulsives: 
Un traitement prophylactique n'est pas recommandé 
 Contrôle de la tension artérielle: 
 Diminution progressive 
 Maintenir la TAS ≤ 140 mm Hg 
 Nicardipine IV pour les tensions très élevées. 
IV- LES AVC EN CHIFFRES 
 En 2013, on comptait dans le monde près de 25,7 millions de personnes ayant subi un 
AVC (71% ischémique), dont 10,3 millions de personnes ayant eu un AVC pour la 
première fois (Feigin et al., 2015). 
 Environ deux sur trois AVC étaient ischémiques (Feigin et al., 2014). 
 5,2 millions (31%) des AVC étaient chez les moins de 65 ans (Feigin et al., 2014). 
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 En 2013, 10,3 millions de nouveaux AVC (67% ischémique) ont été enregistrés dans le 
monde (Feigin et al., 2015). 
 Les AVC sont la deuxième cause de mortalité la plus fréquente dans le monde après les 
cardiopathies ischémiques (Donnan et al., 2008; Lozano et al., 2012; Murray et al., 
1997; WHO, 2014) avec 6,7 millions de décès en 2012 (environ 12% du total) (WHO, 
2014). 
 Selon les données de l'OMS, les AVC étaient la troisième cause de perte de DALY dans 
le monde en 2012. Au total, 113 millions de DALY ont été perdues à la suite d'un AVC 
en 2013 (Feigin et al., 2015). 
QUALITE DE VIE POST-AVC 
Plusieurs études ont montré que de loin la plus grande partie des patients éprouvent et signalent 
une baisse de la qualité de vie après un AVC (Nydevik and Hulter-Asberg, 1992; Williams et 
al., 1999). 
Descriptions génériques des mesures de la qualité de vie 
- Medical Outcomes Short Form Health Survey (SF-36) 
- Medical Outcomes Short Form Health Survey (SF-12) 
- Sickness Impact Profile (SIP) 
- Euroqol 
Mesures de la qualité de vie spécifiques à l'AVC 
- The Stroke Specific Quality of Life Measure (SSQOL) 
- The Stroke Adapted Sickness Impact Profile (SASIP30) 
- The Stroke Impact Scale (SIS) 
DEPRESSION POST-AVC 
Environ un tiers des victimes d'AVC souffrent de dépression après leur AVC (Ayerbe et al., 
2015; Hackett et al., 2005). La dépression post-AVC est associée à une mortalité plus élevée 
(Bartoli et al., 2013). 
SCORES D'EVALUATION DE L'ETAT FONCTIONNEL DU PATIENT APRES AVC 
L'AVC cause un plus grand nombre d'incapacités que toute autre condition (Adamson et al., 
2004). Environ 3% des hommes et 2% des femmes ont déclaré être handicapés à la suite d'un 
AVC (CDC, 2009). 
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Le "Modified Rankin Scale" (mRS) 
Le mRS mesure le degré d'indépendance de la personne plutôt que sa performance dans 
certaines tâches. Il prend un chiffre allant de 0 (pas de symptômes) à 5 (handicap sévère). Le 
décès est noté 6 sur le mRS. Un résultat "favorable" défini pour des scores mRS ≤2. Le mRS 
est largement utilisé dans les études cliniques pour évaluer l'efficacité d'un traitement. 
Le "Barthel Index" (BI) 
Le BI est un score mesurant la performance du patient dans 10 activités de la vie quotidienne: 
l'alimentation, le bain, la continence rectale, la continence urinaire, les déplacements, les 
escaliers, l'habillement, les soins personnels, l'usage des toilettes et le transfert du lit au fauteuil. 
Les catégories de réponse à chaque question prennent un chiffre croissant de 5 en 5, de la 
dépendance vers l'autonomie. Le score total prend un chiffre allant de 0 (dépendance totale) à 
100 (complète autonomie). 
COST OF STROKE 
Les AVC coûtent aux États-Unis environ 34 milliards de dollars américains chaque année. Ce 
total comprend le coût des services de santé, des médicaments pour traiter les AVC et des 
journées de travail manquées (Benjamin et al., 2017). Aux États-Unis, le coût total des AVC en 
2010 était estimé à 73,7 milliards de dollars américains par la «US National Stroke 
Association»; ceci inclut le coût direct des médicaments pour traiter les AVC ainsi que les 
services de santé, par exemple dans les hôpitaux ou les maisons de retraite, par les médecins, 
les soins de santé à domicile, etc. (représentant plus de 60% du coût total) et les coûts indirects 
tels que la perte de productivité (près de 40% du coût total) (National Stroke Association, 2015). 
Au Brésil, le coût total moyen de l’hospitalisation initiale était de 4 101±4 254 dollars 
américains pour les AVC hémorragiques et de 1 902±1 426 dollars américains pour les AVC 
ischémiques. Les dépenses nationales totales en soins de santé pour le traitement aigu des AVC 
hémorragique incident s'élevaient à 122,4 millions de dollars américains (fourchette 30,8-
274,2) et à 326,9 millions de dollars américains pour les AVC ischémiques (fourchette 82,4-
732,2) (Christensen et al., 2009). 
En Argentine, le coût total moyen de l'hospitalisation initiale était de 12 285±14 336 dollars 
américains pour les AVC hémorragiques et de 3 888±4018 dollars américains pour les AVC 
ischémiques. Les dépenses nationales totales en soins de santé pour le traitement aigu des AVC 
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hémorragiques incident s'élevaient à 194,2 millions de dollars américains (fourchette 97,1-
388,4) et à 239,9 millions de dollars américains pour les AVC ischémiques (fourchette 119,9 à 
479,7) (Christensen et al., 2009). 
Au Royaume-Uni, une étude publiée en 2009 a tenté d'estimer le coût annuel des AVC pour 
l'économie du Royaume-Uni (Saka et al., 2009). La recherche a inclus le diagnostic, les soins 
hospitaliers et les soins ambulatoires dans son estimation des coûts directs; son estimation des 
coûts indirects comprenait la perte de revenus et le versement de prestations sociales aux 
survivants d'un AVC. Au total, les recherches ont évalué à 8,9 milliards de livres sterling (12,9 
milliards de dollars américains) le coût total du traitement des AVC et de la perte de productivité 
résultant de ces AVC, les soins directs représentant environ la moitié de ce montant, les coûts 
des soins informels 27%. et des coûts indirects pour 24%. 
En Italie, les coûts sociaux et de soins de santé sur un an s'élevaient respectivement à 11 747€ 
et 19 953€. Les soins informels représentaient 6 656€ (33,4% du total), suivis de 
l'hospitalisation initiale (5 573 euros; 27,9% du total), de la rééducation lors du suivi (4 112€, 
20,6%), des réadmissions (439€) et les visites de médecins spécialistes et généraux (326€). Le 
coût moyen des médicaments par patient au cours de la période de suivi était d’environ 50€ par 
mois. Les coûts liés à la fourniture de services de garde rémunérés et informels ont évolué de 
manière différente et ont persisté au fil du temps (allant de 639 à 597 € par mois respectivement 
dans la première et la deuxième partie de l'année) (Fattore et al., 2012). 
En Grèce, le coût direct à l'hôpital pour tous les cas d'AVC était de 1 551 445€ pour un total de 
4674 jours (332€ par jour à l'hôpital). Le coût moyen à l'hôpital par patient ayant subi un AVC 
était de 3 625±2 595€. Les AVC hémorragiques étaient beaucoup plus coûteux que les AVC 
ischémiques (moyenne: 5305±4205€ et 3214±1976, respectivement) et les AVC lacunaires les 
moins chers parmi les sous-types d’AVC ischémique (Gioldasis et al., 2008). 
Dans les 27 pays de l'Union européenne, le coût économique annuel des AVC était estimé à 27 
milliards d'euros: 18,5 milliards d'euros (68,5%) pour les coûts directs et 8,5 milliards d'euros 
(31,5%) pour les coûts indirects. Un montant supplémentaire de 11,1 milliards d'euros a été 
calculé pour la valeur des soins informels (British Geriatrics Society, 2009). Dans une autre 
étude de l'Union européenne, le fardeau financier des AVC représentait environ 62 milliards 
d'euros (70 milliards de dollars américains) par an et représentait environ 2 à 3% de l'ensemble 
des dépenses de santé de la région (StopAfib, 2012). 
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En Turquie, le coût moyen des AVC était de 1 677±2964 dollars américains (29,9% des 
médicaments, 19,9% en laboratoire, 12,8% en neuroimagerie et 38% en lits et en personnel) 
(Asil et al., 2011). 
Au Pakistan, le coût total moyen était de 70 714 roupies (1 117 dollars américains), ce qui 
comprenait le coût moyen en radiologie; 12 507 roupies (208 dollars américains), coût moyen 
d'un laboratoire; 8365 roupies (139 dollars américains), coût moyen de la pharmacie; 13 320 
roupies (222 dollars américains) et les frais moyens par lit / chambre; 27 552 roupies (459 
dollars américains) (Khealani et al., 2003). 
Les AVC touchent principalement les individus au sommet de leur vie productive (Walter et 
al., 2016). Les personnes en âge de travailler qui ont eu un AVC sont deux à trois fois plus 
susceptibles d'être au chômage huit ans après leur AVC (Maaijwee et al., 2011). Environ 1 
survivant d'un AVC sur 6 subit une perte de revenu après un AVC (McKevitt et al., 2011).  
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SITUATION AU LIBAN 
Le Liban est un pays arabe du Moyen-Orient classé parmi les pays à revenu intermédiaire de la 
tranche supérieure de la région de la Méditerranée orientale (WHO, 2015). Les études 
disponibles sur les maladies non transmissibles ont montré une prévalence alarmante des 
facteurs de risque cardiovasculaires tels que l'hypertension artérielle 36% (Matar et al., 2015), 
le diabète 14% (Tohme et al., 2005), l'obésité 26% (Chamieh et al., 2015), et des facteurs de 
risque comportementaux tels que le tabagisme (cigarettes 38,5% et pipe à eau 22,4%) (Sibai et 
Hwalla, 2008) et l'activité physique insuffisante (38%) (WHO, 2015) chez les adultes Libanais. 
Cependant, les études sur les AVC au Liban sont limitées. 
Le taux d'incidence des AVC au Liban n'a pas été étudié jusqu’à présent. Les études montrant 
la prévalence de l'AVC sont rares et montrent une prévalence varient entre 0,5% et 3,9% (Farah 
et al., 2015; Jurus et al., 2009; Lahoud et al., 2016). 
Un score de risque d'AVC (ROSS) a été mis au point pour dépister les individus à risque d'AVC 
dans la population Libanaise. Une étude cas-contrôle en milieu hospitalier a été menée pour la 
génération du score. Un score <2 points indiquait une valeur prédictive négative élevée de 
l'AVC de 94,4%. Un score >10 points avait une valeur prédictive positive de l'AVC supérieure 
à 85,4% (El-Hajj et al., 2018a). 
Un score de diagnostic d'AVC (DS-stroke) à l'urgence au sein de la population Libanaise à 
l'aide de facteurs de risque et de symptômes d'AVC a été mis au point pour diagnostiquer les 
patients atteints d’AVC au service des urgences. Une étude cas-contrôle en milieu hospitalier a 
été menée pour la génération du score. Un score <4 points indiquait une valeur prédictive 
négative élevée pour les AVC de 97,3%. Un score ≥4 points indiquait une valeur prédictive 
positive de l'AVC de 91,3% (El-Hajj et al., 2018b). 
Une étude épidémiologique nationale a évalué l'association entre la pollution auto-déclarée 
d'origine intérieure et extérieure et les AVC et les mini-AVC au Liban (Salameh et al., 2018). 
Une étude rétrospective a évalué l'existence de mutations génétiques (mutations du gène 
MTHFR et du facteur V) dans différents types d'AVC chez de jeunes adultes auparavant en 
bonne santé (Araji et al., 2014). 
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Une étude rétrospective a analysé la prévalence de tous les AVC hémorragique et ischémique 
ainsi que les sous-types d'AVC ischémique dans une population de patients hospitalisés dans 2 
hôpitaux Libanais. Les sous-types d'AVC ischémique ont ensuite été classés selon la 
classification TOAST (Trial of Org 10172 dans le traitement de l'AVC aigu) (Adams et al., 
1993) et leurs corrélations avec les facteurs de risque d'AVC validés et avec les caractéristiques 
sociodémographiques de l'échantillon ont été évaluées (Lahoud et al., 2017). 
En outre, les AVC sont la deuxième cause de mortalité au Liban après les cardiopathies 
ischémiques, faisant 2 000 victimes en 2012 (9,4% du nombre total de décès) (OMS, 2015). 
C'est en outre une des principales causes d'invalidité permanente chez les adultes (OMS, 2015). 
Cependant, le pays manque d'unités de soins de l'AVC organisées, ce qui rend le statut des soins 
aigus peu clair et discutable. Ainsi, la situation actuelle dans le pays insiste sur la nécessité de 
lancer des études épidémiologiques pour évaluer les soins et les conséquences post-AVC 
(mortalité, handicap, qualité de vie, etc.). Les prédicteurs de décès à l'hôpital peuvent également 
jouer un rôle majeur dans l'amélioration de la gestion et du pronostic des AVC. Une étude 
rétrospective en milieu hospitalier a évalué les soins de l'AVC aigu et les résultats à la sortie 
(Lahoud et al., 2018). Une autre étude rétrospective a examiné les caractéristiques et les 
résultats des patients, en plus des obstacles à l'utilisation de la thrombolyse dans un centre de 
soins tertiaires à Beyrouth, au Liban (El Sayed et al., 2014). Une étude réalisée en milieu 
hospitalier a évalué les avantages et l'impact des interventions thérapeutiques en unité de soins 
intensifs sur la survie et la capacité fonctionnelle de patients victimes d'un AVC grave (Riachy 
et al., 2008). 
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OBJECTIFS 
Malgré le fardeau élevé des AVC au Liban, les données nationales épidémiologiques, cliniques 
et socioéconomiques sur les AVC sont rares et incomplètes, en particulier les études 
prospectives. Par conséquent, nous avons décidé de mener une étude de cohorte multicentrique 
prostective medico-économique sur la gestion des AVC au Liban. 
Les objectifs de cette thèse étaient: 
- D'évaluer les pratiques actuelles des médecins Libanais impliqués dans le traitement des AVC. 
- D'évaluer, d'un point de vue sociétal, les coûts financiers et économiques directs hospitaliers 
de la prise en charge de l'AVC aigu chez les patients hospitalisés atteints d'AVC au Liban 
(chambre et pension, laboratoire, examens généraux, médecins, médicaments, rééducation, etc.) 
approche ascendante (analyse cout de la maladie) et évaluer les prédicteurs de coûts. 
- Déterminer la qualité de vie des patients victimes d'un AVC un an après l'incidence de l'AVC 
et ses déterminants. 
- Comparer les résultats d'un outil de questionnaire générique (SF-36) et spécifique (SS-QOL). 
- Déterminer le taux de dépression post-AVC (en utilisant le GDS-15) et ses déterminants. 
- Calculer les taux de survie à un mois et à un an après un AVC et identifier les prédicteurs de 
mortalité. 
Ces objectifs ont été répartis sur 4 articles scientifiques: 
1- Facteurs de risque et prise en charge de l'AVC ischémique aigu au Liban: obstacles et 
solutions. 
2- Mortalité et prédicteurs de mortalité post-AVC: données d'une cohorte prospective 
multicentrique de patients Libanais atteints d'AVC. 
3- Qualité de vie des survivants d'un AVC à un an et de ses prédicteurs: une étude de cohorte 
prospective multicentrique. 
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4- Coût médical direct de l’hospitalisation pour AVC aigu au Liban: une étude prospective 
multicentrique du coût de la maladie basée sur l’incidence. 
 
La réalisation de ces objectifs conduit à l'objectif principal de toute étude épidémiologique: 
mieux comprendre et prévoir l'évolution d'une maladie et de ses facteurs de risque afin 
d'améliorer sa prévention primaire et secondaire et limiter son impact physique / psychique / 
socio-économique sur la population. 
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ETUDES 
Facteurs de risque et prise en charge de l'AVC ischémique aigu au Liban: 
Obstacles et solutions 
Résumé 
Introduction et Objectif 
La prise en charge de l'AVC aigu varie considérablement d'un pays à l'autre et au sein d'un 
même pays. Cette étude évalue les pratiques actuelles des médecins au Liban impliqués dans le 
traitement de l'AVC. 
Méthodes 
Nous avons mené une étude observationnelle prospective incluant des patients hospitalisés pour 
AVC aigu du 1er août 2015 au 31 juillet 2016 dans 8 hôpitaux Libanais. Les caractéristiques 
de base, les études de diagnostic, les traitements pendant l'hospitalisation et à la sortie ont été 
collectés et analysés. 
Résultats 
Deux cent trois cas d'AVC ont été enregistrés dont seuls cent soixante-treize patients (85%) 
présentant un événement ischémique ont été inclus dans l'étude. L'âge moyen était de 69,8±12,7 
ans. Tous les patients ont fait une imagerie cérébrale (scanner et/ou IRM) à l'admission. Tous 
les AVC ischémiques ont été gérés par un neurologue et ont eu une consultation avec un 
cardiologue. L’hypertension était le facteur de risque le plus répandu (78,6%), suivie de 
l’habitude de fumer (50,3%), du diabète (42,8%), de l’hypercholestérolémie (39,9%), des 
antécédents d’AVC ou d'AIT (17,3%) et de la fibrillation auriculaire (14,7%) ). Seuls 4 patients 
(2,5% des AVC ischémiques) ont reçu un traitement thrombolytique. Plus de 89% des patients 
ont reçu au moins un médicament antihypertenseur, 89,2% de la statine et 37,6% 
d'antidiabétique. 
Conclusion 
Il existe de nombreux défis ainsi que de potentiel d'amélioration des soins de l'AVC au Liban. 
Les traitements de reperfusion sont encore largement sous-utilisés et restent un défi majeur. 
Mots clés: AVC ischémique; management; Liban, facteurs de risque cardiovasculaires 
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La première étude met en lumière la situation critique des soins de l'AVC aigu dans les hôpitaux 
Libanais et la nécessité de mettre en place des unités d'AVC organisées pour améliorer la prise 
en charge aiguë des patients atteint d'AVC. Des campagnes de sensibilisation du public sur les 
symptômes de l'AVC, les facteurs de risque et la maladie peuvent aider les patients à arriver 
plus tôt dans les hôpitaux, avant que des lésions cérébrales graves ne se produisent. La situation 
actuelle dans le pays insiste sur la nécessité de lancer des études épidémiologiques pour évaluer 
les résultats après un AVC. Les prédicteurs de la mortalité à court et à long terme peuvent 
également jouer un rôle majeur dans l'amélioration de la gestion et du pronostic des AVC. Par 
conséquent, la deuxième étude visait à examiner les taux de mortalité au cours de la première 
année après un AVC aigu et les principaux prédicteurs de la mortalité à court terme (1-mois) et 
à long terme (1-an). 
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Mortalité et prédicteurs de décès après un AVC: données provenant d'une 
cohorte prospective multicentrique de patients Libanais atteint d'AVC 
Résumé 
Introduction et Objectif 
Malgré les efforts pour réduire le taux de mortalité par AVC, la maladie reste une des 
principales causes de décès au Liban, soulignant l’importance de la compréhension des facteurs 
de risque et de mortalité. Nous avons examiné le taux de mortalité au cours de la première année 
après AVC ainsi que les prédicteurs de mortalité à cours (1-mois) et à long terme (1-an). 
Méthodes  
Des données ont été collectées de manière prospective sur des patients hospitalisés pour AVC 
de 8 hôpitaux de Beyrouth au cours d'une période d'un an. Les patients ont été suivis pendant 
un an ou jusqu'à la mort. Les taux de mortalité ont été évalués à 1-mois et à 1-an après l'AVC 
et les prédicteurs de décès ont été évalués à l'aide du modèle de risque proportionnel de Cox. 
Résultats 
Au total, 203 patients victimes d'un AVC ont été inclus. Les données de survie ont été 
complétées pour plus de 97% des patients. Les taux de mortalité cumulatifs étaient de 13,3% à 
1-mois et de 21,2% à 1-an. Les facteurs prédictifs de mortalité à court et à long terme dans 
l'analyse univariée étaient le faible statut socio-économique, l'admission à l'unité de soins 
intensifs, le niveau de conscience réduit, la gravité de l'AVC et la présence de complications. 
L'état civil était également un préditeur de mortalité à court terme, tandis que l'âge >64 ans et 
le besoin de chirurgie étaient également des prédicteurs de mortalité à long terme. Dans 
l'analyse multivariée, la gravité de l'AVC et la présence de complications étaient les prédicteurs 
de décès à 1-mois et à 1-an. Le faible statut socioéconomique, la dépendance vis-à-vis des 
activités de la vie quotidienne ainsi que la présence de comorbidités étaient des prédicteurs 
supplémentaires de mortalité à 1-an. 
Conclusion  
Environ un patient sur cinq n'a pas survécu un an après un AVC. Une intervention agressive est 
nécessaire pour améliorer les connaissances, l'alerte et la prévention de l'AVC, afin de réduire 
ce taux élevé de mortalité par AVC au Liban. 
Mots clés: AVC; mortalité; prédicteurs; court terme; long terme; Liban 
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Les proportions élevées de décès 1-mois et 1-an après un AVC incitent à la nécessité de mettre 
en œuvre des mesures sérieuses pour améliorer les soins de l'AVC. La dépendance aux activités 
de la vie quotidienne était l’un des prédicteurs de mortalité à long terme. La dépendance aux 
activités de la vie quotidienne entraîne une baisse de la qualité de vie et une dépression. Nous 
avons donc pensé à évaluer la qualité de vie et le taux de dépression des survivants après 1-an 
l'AVC ainsi que leurs prédicteurs. 
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Qualité de vie des survivants d'un AVC à un an et ses prédicteurs: 
une étude de cohorte prospective multicentrique 
Résumé 
Introduction et Objectif 
Les AVC ont un impact majeur sur les survivants, notamment sur la qualité de vie liée à la santé 
(QVLS). Dans ce contexte, il est crucial d'identifier les facteurs influençant la QVLS chez les 
survivants d'un AVC afin de pouvoir les manipuler efficacement afin de maximiser 
l'amélioration de la QVLS. Nous avons cherché à évaluer la QVLS des patients un an après 
l’ACV et leurs prédicteurs. 
Méthodes 
Cette étude a été conçue comme une étude de cohorte prospective multicentrique dans laquelle 
150 patients atteint d'AVC ont été suivis à la sortie de l'hôpital, à 3, 6 et 12 mois après l'AVC. 
Les niveaux de QVLS ont été déterminés à 1-an en utilisant à la fois l’échelle générique: le 
Short Form (SF-36) et l’échelle spécifique à la maladie: Stroke Specific Quality Of Life (SS-
QOL). Les déterminants de la QVLS ont été recherchés parmi des variables telles que l'âge, le 
sexe, le statut socio-économique, le type et le nombre d'AVC, l'échelle NIHSS, l'échelle de 
Rankin modifiée, l'Indice de Barthel et la dépression (en utilisant Geriatric Depression Scale 
(GDS-15)). 
Résultats 
Un total de 150 patients victimes d'AVC ont été inclus. La moyenne du SS-QOL était de 3,7±1,1 
et celle du SF-36 de 57,2±25,5. Plus de 15% des patients victimes d'AVC étaient déprimés. Les 
principaux déterminants de la QVLS étaient le statut fonctionnel, la dépendance aux activités 
de la vie quotidienne, la gravité de l'AVC, l'âge et la dépression. Le statut fonctionnel et la 
QVLS (composante physique du SF-36) étaient les principaux déterminants de dépression. 
Conclusion 
La QVLS des patients victimes d'un AVC est relativement faible. Le fait que le principal 
déterminant de la QVLS soit le statut fonctionnel suggère qu'il peut être utile d’améliorer l'état 
fonctionnel physique pour améliorer la QVLS des patients victimes d’un AVC et ainsi réduire 
le taux élevé de dépression. 
Mots-clés: qualité de vie; prédicteurs; AVC; Liban; SF-36; SS-QOL 
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L'état fonctionnel physique était le principal facteur prédictif de la QVLS. Cependant, le statut 
émotionnel affecte également la QVLS. Les DALY représentent le fardeau de la maladie pour 
l'homme. Malgré la prévalence et le fardeau relativement élevés des AVC au Liban, son coût 
n’est pas connu. La quatrième étude visait donc à quantifier le fardeau de l'AVC en fournissant 
des données financières détaillées sur le coût direct hospitalier de l'AVC aigu au Liban et à en 
évaluer ses prédicteurs. 
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Coût direct médical de l'hospitalisation pour AVC aigu au Liban: étude 
prospective du coût de la maladie, multicentrique, basée sur l'incidence 
Résumé 
Introduction et Objectif 
Les AVC constituent un problème social et sanitaire majeur qui pèse lourdement sur les 
économies nationales. Nous avons fourni des données financières détaillées sur le coût direct 
hospitalier de l'AVC au Liban et en avons évalué les prédicteurs. 
Méthodes 
Il s'agissait d'une étude observationnelle, quantitative, prospective, multicentrique, basée sur 
l'incidence du coût de la maladie. Les dossiers médicaux et de facturation des patients ayant 
subi un AVC admis dans huit hôpitaux de Beyrouth au cours d'une année ont été analysés. Les 
coûts médicaux directs ont été calculés et les inducteurs de coûts ont été évalués à l'aide d'une 
analyse de régression linéaire multivariée. 
Résultats 
Au total, 203 patients ayant subi un AVC ont été inclus (homme: 58%; âge moyen: 68,8±12,9 
ans). Le coût direct à l'hôpital pour tous les cas était de 1 413 069 USD pour 2626 jours (538 
USD par jour d'hospitalisation). Le coût moyen à l'hôpital par patient ayant subi un AVC était 
de 6961±15.663 USD. Les AVC hémorragiques étaient les plus coûteux, les accidents 
ischémiques transitoires étaient les moins coûteux. Les inducteurs de coût étaient la durée du 
séjour à l'hôpital, la durée du séjour dans l'unité de soins intensifs, le type d'AVC, la gravité de 
l'AVC, l'échelle de Rankin modifiée, le tiers payeur, la chirurgie et les complications 
infectieuses. 
Conclusion 
Le coût médical direct de l'AVC aigu représente un lourd fardeau financier pour le système de 
santé Libanais. L’élaboration de politiques de santé publique et d’activités de prévention 
primaire ciblées doit être une priorité pour minimiser l’admission à l’avenir des cas d’AVC et 
pour limiter ces coûts. 
Mots clés: coût de la maladie, coûts hospitaliers, AVC, Liban, études prospectives, politique 
de la santé, incidence, analyse de régression, humains. 
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DISCUSSION 
Au Liban, nous avons constaté que la gestion des AVC est conforme aux lignes directrices 
fondées sur des preuves et à la pratique clinique. Cependant, les traitements de reperfusion sont 
encore largement sous-utilisés et restent un défi majeur. La mortalité par AVC est relativement 
élevée par rapport à d'autres pays (en particulier la mortalité à court terme). Des campagnes de 
sensibilisation du public (mettant l'accent sur les personnes à faible niveau d'éducation et statut 
socio-économique) sur les facteurs de risque de l'AVC, les symptômes et l'importance de 
traitement temps-dépendant de l'AVC sont nécessaires. La mise en place d'unité de traitement 
des AVC dans les hôpitaux, ainsi que des protocoles de gestion, constitueront une étape 
importante dans l'amélioration de la qualité de soins (cliniquement et économiquement). Cela 
peut limiter le taux de mortalité et les complications possibles après un AVC. 
Un contrôle plus agressif des facteurs de risque modifiables et nécessaires pour réduire 
l'incidence des AVC et donc la mortalité par AVC. L'hypertension artérielle est un facteur 
important dans la prévention primaire pour plusieurs raisons. L'hypertension artérielle est le 
facteur de risque le plus puissant des AVC, sa prévalence est élevée au Liban et la prise en 
charge des patients hypertendus reste sous-optimale. Ainsi, une meilleure prise en charge des 
patients hypertendus réduira le risque d’AVC. 
Améliorer la rééducation physique à l'hôpital et souligner l'importance de la rééducation 
physique après la sortie de l'hôpital est primordial pour les patients afin d'améliorer leurs 
fonction physique altérée et de se réintégrer socialement et professionnellement dans la société. 
Cela diminuera le déclin de la qualité de vie après un AVC qui était relativement élevé dans 
notre étude et limitera donc le taux de dépression après un AVC. Le fait de pouvoir continuer 
à travailler après un AVC est fondamental pour l'individu et la société. Cela réduira les coûts 
indirects (perte de productivité au travail et perte de productivité future) et les DALY. 
La gestion globale des AVC à l'hôpital ne différait pas entre le statut socio-économique et le 
tiers payeur privé par rapport à un tiers payant public, même si le coût hospitalier de l'AVC 
était très différent. Cela signifie que les patients reçoivent les mêmes soins, quelle que soit leur  
statut socio-économique et leur tiers payant. 
La somme de toutes ces mesures (incidence, prévalence, mortalité, qualité de vie, coût de la 
maladie, etc.) donnerait une image complète du fardeau de l'AVC au Liban. 
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Nos conclusions sont importantes pour les professionnels de la santé et les responsables des 
politiques de santé publique. Lorsque des données fiables sur le fardeau de l'AVC sont 
disponibles, la planification des soins de santé peut être prise en considération plus 
efficacement, idéalement avec la génération de données longitudinales pour surveiller utilement 
l'efficacité de toute intervention. Nos résultats montrent l'importance de réalisation de 
programmes de prévention primaire et secondaire et des campagnes de sensibilisation sur le 
danger des facteurs de risque comportementaux pour réduire la morbidité et la mortalité dues 
aux AVC. 
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PERSPECTIVES & CONCLUSION 
L'AVC est une priorité moins importante pour les services cliniques et de recherche que pour 
d'autres maladies ayant un impact similaire ou moindre sur la santé publique. Ceci est lié au 
manque de données comparatives facilement accessibles pour aider à préparer un argument 
politique en faveur de l'élaboration de stratégies nationales pour faire face au fardeau de l'AVC. 
Dans le futur proche, il serait intéressant de: 
Calculez exactement le taux d'incidence des AVC au Liban. 
Analyser les disparités régionales dans l'épidémiologie des AVC et leur influence sur les 
facteurs de risque et la gestion de la maladie. 
Évaluer la connaissance des symptômes et des facteurs de risque de l'AVC et l'attitude de la 
population envers les AVC. 
Estimer le rapport coût-efficacité des unités intégrées spécialisées pour AVC au Liban: 
améliorer les résultats pour les patients par rapport aux soins classiques. 
Évaluer la prise en charge chronique des AVC: prévention secondaire (évaluation de 
l’observance aux traitements des patients victimes d’un AVC, suivi médical, examens de 
routine, contrôle des facteurs de risque, taux de récidive d'AVC, etc.), soins de réadaptation 
chronique, taux de mortalité tardive et prévalence d'handicap due à l'AVC. 
Rechercher de solutions thérapeutiques plus efficaces pour prévenir les séquelles d'AVC est 
indispensable. Cela comprend l'utilisation de cellules souches et la recherche de nouveaux 
agents neuroprotecteurs. 
Plus de recherche dans les domaines de l'hypothermie (refroidissement thérapeutique), des 
thérapies à base de cellules souches et d'une "polypill" pour la prévention secondaire des AVC 
est nécessaire. 
Un autre sujet intéressant est de déterminer la qualité de vie des fournisseurs de soins aux 
patients victimes d'un AVC et de ses déterminants. De plus, il peut être raisonnable de 
déterminer le taux de dépression chez les fournisseurs de soins aux patients victimes d’un AVC 
et ses déterminants. 
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Les études présentées dans ce manuscrit peuvent éventuellement être répétées, mais d'une 
manière qui permet de les généraliser à l'ensemble du pays (meilleur échantillonnage de tous 
les gouvernorats, échantillon de plus grande taille, etc.) dans la communauté et pas uniquement 
dans les hôpitaux, en mesurant les facteurs de risque socio-économiques (éducation, travail, 
revenu), facteurs psychiques (stress et anxiété), toutes les comorbidités et les facteurs de risque 
potentiels. 
Il est absolument nécessaire de développer nos connaissances sur l'épidémiologie des AVC au 
Liban, afin de limiter l'impact et le fardeau de la maladie dans les années à venir. 
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embolism is an irregular heartbeat or rhythm disturbances with stasis of the blood, 
known as atrial fibrillation (AF). It creates conditions where clots can form in the heart, 
dislodge and travel to the brain (Figure 1). 
Silent cerebral infarction, or “silent stroke,” is a brain injury likely caused by a blood clot 
interrupting blood flow in the brain. It’s a risk factor for future strokes which could lead to 
progressive brain damage due to these strokes (AHA/ASA; 2018). 
 
Source: American Heart Association 2018 
Figure 1 Ischemic stroke illustration 
TOAST Subtype Classification System 
Diagnoses are based on clinical features and on data collected by tests such as brain imaging 
(CT/MRI), cardiac imaging (echocardiography, etc.), duplex imaging of extracranial 
arteries, arteriography, and laboratory assessments for a prothrombotic state. The physician 
can apply the clinical and imaging findings when first assessing the patient and then 
consider the results of other diagnostic tests later. An important part of the classification is 
the ability of the physician to categorize a specific subtype diagnosis as probable or possible 
based on the degree of certainty. A "probable" diagnosis is made if the clinical findings, 
neuroimaging data, and results of diagnostic studies are consistent with one subtype and 
other etiologies have been excluded. A "possible" diagnosis is made when the clinical 
findings and neuroimaging data suggest a specific subtype but other studies are not done. 
Because many patients will have a limited number of diagnostic tests, the probable and 
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possible subcategorizations allow the physician to make as precise a subgroup diagnosis as 
can be achieved (Adams et al., 1999).  
The TOAST classification denotes 5 subtypes of IS (Table 1):  
1) large-artery atherosclerosis: These patients will have clinical and brain imaging 
findings of either significant (>50%) stenosis or occlusion of a major brain artery or branch 
cortical artery, presumably due to atherosclerosis (Table 2). Clinical findings include those 
of cerebral cortical impairment (aphasia, neglect, restricted motor involvement, etc.) or 
brain stem or cerebellar dysfunction. A history of intermittent claudication, TIAs in the 
same vascular territory, a carotid bruit, or diminished pulses helps support the clinical 
diagnosis. Cortical or cerebellar lesions and brain stem or subcortical hemispheric infarcts 
greater than 1.5 cm in diameter on CT or MRI are considered to be of potential large-artery 
atherosclerotic origin. Supportive evidence by duplex imaging or arteriography of a stenosis 
of greater than 50% of an appropriate intracranial or extracranial artery is needed. 
Diagnostic studies should exclude potential sources of cardiogenic embolism. The diagnosis 
of stroke secondary to largeartery atherosclerosis cannot be made if duplex or arteriographic 
studies are normal or show only minimal changes (Adams et al., 1999). 
2) cardioembolism: This category includes patients with arterial occlusions presumably 
due to an embolus arising in the heart (Table 2). Cardiac sources are divided into high-risk 
and medium-risk groups based on the evidence of their relative propensities for embolism 
(Goldstein et al., 1989) (Table 3). At least one cardiac source for an embolus must be 
identified for a possible or probable diagnosis of cardioembolic stroke. Clinical and brain 
imaging findings are similar to those described for large-artery atherosclerosis. Evidence of 
a previous TIA or stroke in more than one vascular territory or systemic embolism supports 
a clinical diagnosis of cardiogenic stroke. Potential large-artery atherosclerotic sources of 
thrombosis or embolism should be eliminated. A stroke in a patient with a medium-risk 
cardiac source of embolism and no other cause of stroke is classified as a possible 
cardioembolic stroke (Adams et al., 1999). 
3) small-vessel occlusion (lacune): This category includes patients whose strokes are often 
labeled as lacunar infarcts in other classifications (Bamford et al., 1987) (Table 2). Lacunar 
cerebral infarctions are small deep infarcts in the territory of small penetrating arteries, due 
to a local disease of these vessels, mainly related to chronic hypertension. The patient should 
have one of the traditional clinical lacunar syndromes and should not have evidence of 
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cerebral cortical dysfunction. A history of diabetes mellitus (DM) or hypertension supports 
the clinical diagnosis. The patient should also have a normal CT/MRI examination or a 
relevant brain stem or subcortical hemispheric lesion with a diameter of less than 1.5 cm 
demonstrated. Potential cardiac sources for embolism should be absent, and evaluation of 
the large extracranial arteries should not demonstrate a stenosis of greater than 50% in an 
ipsilateral artery. Lacunes account for 15-25% of all IS (Bamford et al., 1987; Bejot et al., 
2008; Sacco et al., 2006). The incidence of lacunar strokes increases with age (mean age of 
first lacunar stroke, 65 y), and men may be affected more than women (Bejot et al., 2008) 
(Adams et al., 1999). 
4) stroke of other determined etiology: This category includes patients with rare causes 
of stroke, such as nonatherosclerotic vasculopathies, hypercoagulable states, or hematologic 
disorders. Patients in this group should have clinical and CT or MRI findings of an acute 
ischemic stroke (AIS), regardless of the size or location. Diagnostic studies such as blood 
tests or arteriography should reveal one of these unusual causes of stroke. Cardiac sources 
of embolism and large-artery atherosclerosis should be excluded by other studies (Adams 
et al., 1999). 
5) stroke of undetermined etiology: In several instances, the cause of a stroke cannot be 
determined with any degree of confidence. Some patients will have no likely etiology 
determined despite an extensive evaluation. In others, no cause is found but the evaluation 
was cursory. This category also includes patients with two or more potential causes of stroke 
so that the physician is unable to make a final diagnosis. For example, a patient with a 
medium-risk cardiac source of embolism who also has another possible cause of stroke 
identified would be classified as having a stroke of undetermined etiology. Other examples 
would be a patient who has AF and an ipsilateral stenosis of 50%, or the patient with a 
traditional lacunar syndrome and an ipsilateral carotid stenosis of 50% (Adams et al., 1999). 
Table 1  TOAST Classification of Subtypes of Acute Ischemic Stroke 
Large-artery atherosclerosis (embolus/thrombosis)*  
Cardioembolism (high-risk/medium-risk)*  
Small-vessel occlusion (lacune)* 
Stroke of other determined etiology* 
Stroke of undetermined etiology 
a. Two or more causes identified 
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b. Negative evaluation 
c. Incomplete evaluation 
TOAST, Trial of Org 10172 in Acute Stroke Treatment.  
*Possible or probable depending on results of ancillary studies. 
 
Table 2  Features of TOAST Classification of Subtypes of Ischemic Stroke 
 
 
Table 3  TOAST Classification of High- and Medium-Risk Sources of Cardioembolism 
High-risk sources  
Mechanical prosthetic valve 
Mitral stenosis with atrial fibrillation 
Atrial fibrillation (other than lone atrial fibrillation) 
Left atrial/atrial appendage thrombus 
Sick sinus syndrome 
Recent myocardial infarction (4 weeks) 
Left ventricular thrombus  
Dilated cardiomyopathy 
Akinetic left ventricular segment 
Atrial myxoma 
Infective endocarditis 
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Medium-risk sources 
Mitral valve prolapse 
Mitral annulus calcification 
Mitral stenosis without atrial fibrillation 
Left atrial turbulence (smoke) 
Atrial septal aneurysm 
Patent foramen ovale 
Atrial flutter 
Lone atrial fibrillation 
Bioprosthetic cardiac valve 
Nonbacterial thrombotic endocarditis 
Congestive heart failure 
Hypokinetic left ventricular segment 
Myocardial infarction (>4 weeks, <6 months) 
TOAST, Trial of Org 10172 in Acute Stroke Treatment.  
Bamford or Oxford stroke classification 
Bamford (or Oxford) classification system is the most commonly used classification system for 
IS (Figure 2). 
 
Figure 2 Bamford or Oxford Stroke Classification 
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Figure 3  Subarachnoid hemorrhage stroke illustration (American Heart Association 2018) 
 
Figure 4 Intracerebral hemorrhage stroke illustration (American Heart Association 2018) 
1.2 Transient ischemic attack 
1.2.1. Definition 
TIA is a "mini stroke" or ‘warning stroke’ that occurs when a blood clot blocks an artery for a 
short time. The only difference between a stroke and TIA is that with TIA the blockage is 
transient (temporary) (AHA/ASA, 2017). TIA is defined as a brief episode of neurologic 
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Figure 5 Risk of stroke following a TIA 
Individuals who have a TIA and survive the initial high-risk period have a 10-year stroke risk 
of roughly 19% and a combined 10-year stroke, myocardial infarction (MI), or vascular death 
risk of 43% (4% per year) (Clark et al., 2003). In the GCNKSS, the 1-year mortality rate after 
a TIA was 12% (Kleindorfer et al., 2005). 
In the population-based Oxford Vascular Study, among patients with TIA, disability levels 
(modified Rankin Scale >2) increased from 14% before the TIA to 23% at 5 years after the TIA 
(P=0.002). In this same study, the 5-year risk of institutionalization after TIA was 11% 
(Luengo-Fernandez et al., 2013). 
1.3 Recurrent Stroke 
In a cohort of 10 399 patients discharged with a primary diagnosis of stroke in the US in 2002, 
recurrent stroke rates were 1.8% at 1 month, 5% at 6 months, 8% at 1 year, and 18.1% at 4 
years (Feng et al., 2010). 
Among 1626 first-ever stroke patients in the South London Stroke Register, first stroke 
recurrence rates (95% CI) during the first, second, third, fourth, and fifth years were 8% (6.5%–
9.8%), 3.3% (2.2%–4.9%), 3.5% (2.1%–5.8%), 1.2% (0.4%–3.7%), and 1.8% (0.4%–7.4%), 
respectively. Cumulative risks of first stroke recurrence (95% CI) were 2.6% (1.9%–3.7%) at 
3 months, 8.0% (6.5%–9.8%) at 1 year, 14.1% (11.8%–16.7%) at 3 years, and 16.6% (13.5%–
20.4%) at 5 years (Hillen et al., 2003).  
Among 600 Scandinavian stroke patients followed up for 2 years, 55 (9.2%) had a recurrent 
stroke, 15 (2.5%) had a TIA, 4 (0.7%) had a coronary event, and 24 (4.0%) had died. Recurrent 
stroke occurred in 19.2% of patients with index stroke caused by large-artery disease, 4.9% 
with small-vessel disease, 8.2% with cardioembolic cause, 5.6% with cryptogenic cause, and 
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12.8% with other and undetermined causes combined (Redfors et al., 2012). Recurrent stroke 
is associated with a greater number of risk factors and a higher incidence of large-artery 
atherosclerosis than the first stroke (Lee et al., 2001). During a median 5.3 years of follow-up 
among 987 Atherosclerosis Risk in Communities (ARIC) participants with first-ever strokes, 
there were 183 recurrent strokes among 147 participants. Approximately 70% of recurrent 
strokes were of the same subtype; however, 28% were the same when the index stroke was 
lacunar. One-year stroke recurrence rates by index subtype were 7.9% for thrombotic, 6.5% for 
cardioembolic, and 6.5% for lacunar events (Jones et al., 2013). 
In a long-term follow-up study of recurrent vascular events among 724 first-ever TIA, stroke, 
or ICH patients aged 18 to 50 years in the Netherlands, cumulative 20-year risk of recurrent 
stroke was 17.3% (95% CI, 9.5%–25.1%) after TIA, 19.4% (95% CI, 14.6%–24.3%) after IS, 
and 9.8% (95% CI, 1.0%–18.7%) after ICH (Rutten-Jacobs et al., 2013). Among 1867 stroke 
patients aged 18 to 45 years, the 10-year cumulative risk of brain ischemia was 14.0% (95% 
CI, 11.4%–17.1%) (Pezzini et al., 2014). In the North Dublin Population Stroke Study, the 
cumulative 2-year stroke recurrence rate was 10.8%, and case fatality was 38.6% (Callaly et 
al., 2016). 
Stroke survivors are at greatest risk of having another stroke in the first 30 days following a 
stroke (Mohan et al., 2011). In fact, 1 in 20 stroke patients have another stroke while still in 
hospital (Royal College of Physicians SSNAP, 2016). 
 
(Johnston et al., 2000) 
 ???
??????????????????
??????? ??????????????????????????
?????????????????????????????????????????? ???????????????????????
? ?????????????
??????????????????????????????????????????????????????????????????????????????????????
????????? ???????? ??? ????? ?????? ??????? ???? ??? ???? ???????? ?????? ??? ??????? ???? ?????????
????????????????????????????????????????????????????????????????????????????????????????????????????
???????
????????????????????????????????????????????????????????????????
?
??????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????? ??????????????????????????
??????????????????????????????????????????? ????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????
??????????????????????????????? ???????? ????????????????? ???????????????????????????????????? ???
??????? ?????????? ????? ??? ????? ??????? ??? ????????? ???????? ????????????????? ???????? ???? ?????
?????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????
 ???
?????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????? ?? ???????????? ????????????????????????????? ???????????????
???????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????? ????
????????????????????????????????????????????????????????????????????????????????????????
??? ??????? ?????????? ??????? ??? ????? ????????? ???? ?????????????? ???????? ???? ??? ???????????
???????????????????????????????????????? ???????????????????????????????
? ????????
?????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????? ???????????? ???????????????????????????
??????????????????????????????????????????????? ???????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????
???????????? ??????? ???? ??????? ??? ?????? ??????? ????? ???????? ??? ??????? ?????? ???? ????????? ??
????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????
???????? ??? ???????? ????????? ????????????????????? ????? ??????? ??? ????????????????????? ????
???????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????
???????????????? ?????????? ??????? ????? ??? ????? ???????? ???????? ???? ??????????? ?????? ??
???????????????????????????????????????????????????????????????????? ??????????????????????????
 ???
??????????????????? ??????????????????????? ??? ?????????????? ???????????? ????? ?????? ????????
????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????
?? ????? ??????? ???? ??????????????????????????? ?????????????????????????????? ???? ????????? ???
???????? ???????? ???? ???????? ???????????? ???? ????? ??? ???????? ?? ?????????????? ?????????????
????????????????????????????????????????????????????? ???????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????
????? ???????? ???????????? ???????????? ??????? ?????? ??? ?????? ??? ?????? ??????? ?????
?????????????? ???????? ?????? ????????? ??? ????? ??????? ?????????? ???? ??????????? ????? ???
?????????? ????? ??? ????????????????? ??? ?????? ????? ???? ?????? ????? ?????? ???????? ????????????
???????????????????????????? ??? ?????????????????????????????????????????????????????????????
???????????????????????????????
?????????? ???????? ????? ?????????? ????? ??? ?????? ???????? ???? ?????????????????? ???????? ????
?????????????? ???????????????????????????????????????????????????????????????????????????????
????????????????????????????????????? ??????????????????????????????????????????????????????
??????????????????????????????????
? ?????????
???????????????????????????????????????????????????????????????????????????????????????????
???????? ??? ???? ??? ????? ?????? ?????????? ???????? ?????????? ???????????? ????????? ?????????
??????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????
???? ???? ???????? ?? ?????????????? ??? ??? ???????????? ??????? ???????? ?????????? ???? ????
????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????? ????????????? ????????????? ??????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????
 57 
Self-reported history of DM was associated with an increased risk of all stroke (OR=1.36, 99% 
CI=1.10–1.68) and IS (OR=1.60, 99% CI=1.29–1.99), but not ICH stroke (OR=0.87, 99% 
IC=0.60–1.24) (O‘Donnell et al., 2010). 
The duration of diabetes is also correlated with the risk of IS: each year of diabetes increases 
the risk by 3% (HR,1.03, 95% CI, 1.02–1.04) which will be triple after 10 years of illness (HR, 
3.2, 95% CI, 2.4–4.5) (Banerjee et al., 2012). A prospective study has shown that for blood 
glucose values ≥ 110mg/dL, each 10mg/dL increase is accompanied by an increased risk of 
stroke of 6% (95% CI, 0-12%, p= 0.05) (Sui et al., 2011). 
DM increases IS incidence at all ages, but this risk is most prominent (risk ratio for IS conferred 
by DM >5) before 65 years of age in both blacks and whites (Khoury et al., 2013; Kissela et al., 
2005). Overall, IS patients with DM are younger, more likely to be black, and more likely to 
have HBP, MI, and high cholesterol than nondiabetic patients (Khoury et al., 2013). 
The association between DM and stroke risk differs between sexes. A systematic review of 64 
cohort studies representing 775 385 individuals and 12 539 strokes revealed that the pooled 
fully adjusted RR of stroke associated with DM was 2.28 (95% CI 1.93–2.69) in women and 
1.83 (1.60–2.08) in men. Compared with men with DM, women with DM had a 27% greater 
RR for stroke when baseline differences in other major cardiovascular risk factors were taken 
into account (pooled RR, 1.27; 95% CI, 1.10–1.46) (Peters et al., 2014). 
DM is an independent risk factor for stroke recurrence; a meta-analysis of 18 studies involving 
43 899 participants with prior stroke revealed higher stroke recurrence in patients with DM than 
in those without (HR, 1.45; 95% CI, 1.32–1.59) (Shou et al., 2015). 
A population-based study of 1375 first-ever stroke patients 25 to 74 years old who were 
followed up for 23 years found that diabetic patients had a higher risk of death than nondiabetic 
patients (adjusted HR, 1.67; 95% CI, 1.58–1.76). The reduced survival of diabetic stroke 
patients was more pronounced in women (P=0.02) and younger individuals (P<0.001) 
(Eriksson et al., 2012). 
Data from the US revealed that from 1997 to 2006, the absolute number of AIS hospitalizations 
declined by 17%; however, the absolute number of AIS hospitalizations with comorbid DM 
rose by 27% (from 97 577 [20%] to 124 244 [30%]). Factors independently associated with 
higher odds of DM in AIS patients were black or “other” (versus white) race, congestive heart 
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association between nut consumption and cardiovascular outcomes (n=467 389) revealed no 
association between nut consumption and stroke (2 studies; RR, 1.05; 95% CI, 0.69–1.61) but 
did find an association with stroke mortality (3 studies; RR, 0.83; 95% CI, 0.69–1.00) (Mayhew 
et al., 2016). Another meta-analysis of 8 prospective studies (n=468 887) revealed that a diet 
with greater amounts of nuts was associated with lower risk of stroke (summary RR, 0.90; 95% 
CI, 0.81–0.99). Sex significantly modified the effects of nut consumption on stroke risk, and 
high nut intake was associated with reduced risk of stroke in women (SRR, 0.85; 95% CI, 0.75–
0.97) but not in men (SRR, 0.95; 95% CI, 0.82–1.11) (Shi et al., 2014). 
A meta-analysis of 8 prospective studies (n=410 921) revealed no significant association 
between consumption of refined grains and risk of stroke (Wu et al., 2015). 
A meta-analysis of 10 prospective cohort studies including 314 511 non-overlapping 
individuals revealed that higher monounsaturated fatty acid intake was not associated with risk 
of overall stroke (RR, 0.86; 95% CI, 0.74–1.00) and risk of IS (RR, 0.92; 95% CI, 0.79–1.08) 
but was associated with a reduced risk of hemorrhagic stroke (RR, 0.68; 95% CI, 0.49–0.96) 
(Cheng et al., 2016). 
In the Nurses Health and Health Professionals Follow-up Studies, each 1-serving increase in 
sugar-sweetened soda beverage was associated with a 13% increased risk of IS but not 
hemorrhagic stroke. Conversely, each 1-serving increase in low-calorie or diet soda was 
associated with a 7% increased risk of IS and 27% increased risk of hemorrhagic stroke 
(Bernstein et al., 2012). 
A meta-analysis of prospective cohort studies evaluating the impact of dairy intake on CVD 
noted that total dairy intake and calcium from dairy were associated with an inverse summary 
RR estimate for stroke (0.91, 95% CI=0.83–0.99 and 0.69, 95% CI=0.60–0.81) (Alexander et 
al., 2016). A meta-analysis of 21 studies (n=13 033) evaluating the effect of vitamin D on 
cardiovascular outcomes revealed that vitamin D supplementation was not associated with a 
lower risk of stroke (HR, 1.07; 95% CI, 0.91–1.29) (Ford et al., 2014). 
A meta-analysis of 14 cohorts (n=333 250) revealed that potassium intake is associated with a 
lower risk of stroke (RR, 0.80; 95% CI, 0.72–0.90). In addition, the dose-response analysis 
showed that for every 1 g per day (25.6 mmol per day) increase in vitamin K intake, there was 
a 10% reduction in stroke risk (RR, 0.90; 95% CI, 0.84–0.96) (D'Elia et al., 2014). 
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AF was the most common cardiac source of thromboembolism in cases with IS (203, 9%), with 
regional variation in prevalence: 86 (23%) in high-income countries, 14 (13%) in South 
America, 16 (7%) in Africa, 41 (6%) in India, and 46 (5%) in south east Asia (O‘Donnell et al., 
2010). Because AF is often asymptomatic (Page et al., 1994; Strickberger et al., 2005) and 
likely frequently undetected clinically, (Tayal et al., 2008) the stroke risk attributed to AF may 
be substantially underestimated (Elijovich et al., 2009). Screening for AF in patients with 
cryptogenic stroke or TIA by use of outpatient telemetry for 21 to 30 days has resulted in an 
AF detection rate of 12% to 23% (Elijovich et al., 2009; Flint et al., 2012; Tayal et al., 2008). 
Cardiac etiology was associated with an increased risk of IS (OR, 2.74, 99% CI, 2.03–3.72), 
but not ICH stroke (OR, 0.90, 99% CI, 0.52–1.56) (O‘Donnell et al., 2010). 
An analysis of patients from the Veterans Administration showed that among patients with 
device-documented AF, the presence of relatively brief amounts of AF raised the short-term 
risk of stroke 4- to 5-fold. This risk was highest in the initial 5 to 10 days after the episode of 
AF and declined rapidly after longer periods (Turakhia et al., 2015). 
Important risk factors for stroke in the setting of AF include advancing age, hypertension, HF, 
DM, previous stroke or TIA, vascular disease, and female sex (Gage et al., 2001; Lip et al., 
2010; Olesen et al., 2011). Additional biomarkers, including high levels of troponin and brain 
natriurectic peptide, increase the risk of stroke in the setting of AF independent of those well-
established clinical characteristics (Hijazi et al., 2012). 
CHADS2 and CHA2DS2-VASc Score for Stroke Risk Assessment in AF 
It is important to determine which patients with AF may benefit from oral anticoagulant (OAC) 
and possibly aspirin therapy to reduce the risk of stroke. The CHADS2 score was developed to 
more accurately predict the risk of stroke in patients with nonrheumatic AF (Gage et al., 2001). 
The index was derived by combining risk factors from prior studies and then testing their 
validity in a cohort of 1,773 Medicare-aged patients over 2,121 patient years (Atrial Fibrillation 
investigators, 1994; Stroke Prevention Atrial Fibrillation III Writing Committee, 1998) (Tables 
3,4). 
Table 2  CHADS2 Score: Stroke Risk Assessment in Atrial Fibrillation 
CHADS2 Risk Criteria Score 
Congestive heart failure 1 point 
Hypertension 1 point 
Age ≥ 75 years 1 point 
 65 
Diabetes mellitus 1 point 
Stroke/ transient ischemic attack 2 points 
Table 3  CHADS2 Score and Corresponding Annual Stroke Risk 
CHADS2 Score Adjusted Stroke Risk (%) 
0 1.9 
1 2.8 
2 4 
3 5.9 
4 8.5 
5 12.5 
6 18.2 
Although simple, the CHADS2 score does not include many common stroke risk factors, and 
its limitations have been highlighted by its non-inclusion of common stroke risk factors. 
Consequently, CHADS2 was expanded to include three additional independent risk factors: 
vascular disease (coronary artery disease, peripheral artery disease, aortic atherosclerosis), age 
65-74 years, and female sex (Friberg et al., 2012; Olesen et al., 2012; van Walraven et al., 2009). 
This new, more inclusive scoring system is the CHA2DS2-VASc score (Camm et al., 2012) 
(Tables 5-7). 
Table 4  CHA2DS2-VASc Score and Risk Criteria 
CHA2DS2-VASc Risk Criteria Score 
Congestive heart failure 1 point 
Hypertension 1 point 
Age ≥ 75 years 2 points 
Diabetes mellitus 1 point 
Stroke/transient ischemic attack 2 points 
Vascular disease (prior MI, 
PAD, or aortic plaque) 
1 point 
Age 65 to 74 years 1 point 
Sex category (ie, female sex) 1 point 
Table 5  CHA2DS2-VASc Score and Corresponding Annual Stroke Risk 
CHA2DS2-VASc Score Adjusted Stroke Risk (%) 
0 0 
1 1.3 
2 2.2 
3 3.2 
4 4.0 
5 6.7 
6 9.8 
7 9.6 
8 6.7 
9 15.2 
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that included additional studies (OR, 2.1; 95% CI, 1.5–2.9 and OR, 2.0; 95% CI, 1.4–2.9) (Dong 
et al., 2013; Li et al., 2014; Loke et al., 2012). 
In the Sleep Heart Health Study, obstructive sleep apnea measured by the obstructive AHI was 
associated with risk of incident IS in men after adjustment for confounders (P=0.016 for linear 
trend associated with quartiles of AHI) but not in women. Compared with men in the lowest 
quartile of AHI (0 to <4.1), men in the highest quartile (AHI >19) had an adjusted HR of 2.9 
(95% CI, 1.1–7.4) (Redline et al., 2010). 
A study found that acute infarction involving the brainstem (versus no brainstem involvement) 
was associated with the odds of sleep-disordered breathing, defined as an AHI ≥10, with an OR 
of 3.76 (95% CI, 1.44–9.81) after adjustment for demographics, risk factors, and stroke severity 
(Friberg et al., 2004). In this same study, IS subtype was not found to be associated with the 
presence or severity of sleep-disordered breathing (Brown et al., 2015). 
Moreover, obstructive sleep apnea is common after stroke, with prevalence well in excess of 
50% (Broadley et al., 2007; Johnson et al., 2016; Johnson et al., 2010; Lisabeth et al., 2017). 
Mexican Americans had a higher prevalence of post-stroke sleep-disordered breathing, defined 
as an AHI ≥10, than non-Hispanic whites after adjustments for confounders (prevalence ratio, 
1.21; 95% CI, 1.01–1.46) (Lisabeth et al., 2017). Obstructive sleep apnea is associated with 
higher post-stroke mortality (Martínez-García et al., 2009; Parra et al., 2004; Sahlin et al., 2008) 
and worse functional outcome (Turkington et al., 2002). 
No definitive study has been conducted to determine whether treatment with continuous 
positive airway pressure prevents stroke or improves post-stroke outcomes (Benjamin et al., 
2017). 
1.4.2. Uncontrollable risk factors 
1.4.2.1 Age  
People are most likely to have a stroke over the age of 55 (Wang et al., 2013). The 
likelihood of having a stroke nearly doubles every 10 years after age 55. (Rothwell 
et al., 2005). Aging has a remarkable effect on the heart and arterial system, leading 
to an increase in CVD including atherosclerosis, hypertension, MI, and stroke 
(Lakatta and Levy, 2003 part I). Aging cardiovascular tissues are exemplified by 
pathological alterations including hypertrophy, altered left ventricular diastolic 
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function, and diminished left ventricular systolic reverse capacity, increased arterial 
stiffness, and impaired endothelial function (Lakatta and Levy, 2003 part I & part 
II]. Aging of the vasculature results in increased arterial thickening and stiffness as 
well as dysfunctional endothelium. (Figure 6) Clinically, these changes result in 
increased systolic pressure and present major risk factors for development of 
atherosclerosis, hypertension, stroke, and AF (Lakatta & Levy, 2003 part II). 
 
Figure 6 Illustration of cardiovascular tissues aging 
Although stroke is more common among the elderly, a lot of people under 65 also have strokes 
(Figure 7). Around a quarter of strokes happen in people of working age (Stroke Association, 
2017). Approximately 10% of all strokes occur in individuals 18 to 50 years of age (Nedeltchev 
et al., 2005). Stroke patients >85 years of age make up 17% of all stroke patients, and in this 
age group, stroke is more prevalent in women than men (Dehlendorff et al., 2015; Elkind et al., 
2016; Russo et al., 2011). 
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10% for women (95% CI, 9-10%) (Asplund et al., 2009). In general, studies show a male/female 
ratio of 1.55 for IS and 1.60 for ICH. This ratio is 0.84 for SAH, which is more common among 
women (Appelros et al., 2009). Stroke kills more women than men (Bushnell C et al., 2014). 
Factors that may increase stroke risks for women include: pregnancy. (Bushnell C et al., 2014) 
history of preeclampsia/eclampsia or gestational diabetes, oral contraceptive use (especially 
when combined with smoking) (Xu et al., 2015) and post-menopausal hormone therapy 
(Appelros et al., 2009; Baillargeon et al., 2005; Bath and Gray, 2005; Boardman et al., 2015; 
James et al., 2005). 
In the setting of AF, women have a significantly higher risk of stroke than men (Avgil et al., 
2005; Dagres et al., 2007; Fang et al., 2005; Friberg et al., 2004; Poli et al. 2009). 
Analysis of data from the Framingham study found that women with natural menopause before 
42 years of age had twice the IS risk of women with natural menopause after 42 years of age; 
however, no association was found between age at natural menopause and risk of ischemic or 
hemorrhagic stroke in the Nurse’s Health Study (Lisabeth et al., 2009). 
Overall, RCT data indicate that the use of estrogen plus progestin, as well as estrogen alone, 
increases stroke risk in postmenopausal, generally healthy women and provides no protection 
for postmenopausal women with established CHD (Hendrix et al., 2006; Rossouw et al., 2002; 
Simon et al., 2001; Wassertheil-Smoller et al., 2003) and recent stroke or TIA (Viscoli et al., 
2001). In a nested case-control study in the United Kingdom, stroke risk was not increased for 
users of low-dose (≤50 μg) estrogen patches (RR, 0.81; 95% CI, 0.62–1.05) but was increased 
for users of high-dose (>50 μg) patches (RR, 1.89; 95% CI, 1.15–3.11) compared with nonusers 
(Renoux et al., 2010). Low-estrogen-dose oral contraceptives are associated with a 93% 
increased risk of IS, but the absolute increased risk is small (4.1 ISs per 100 000 nonsmoking, 
normotensive women) (Gillum et al., 2000; Gillum and Johnson, 2004; Roach et al., 2015). 
Migraine with aura is associated with IS in younger women, particularly if they smoke or use 
oral contraceptives. The combination of all 3 factors increases the risk ≈9-fold compared with 
women without any of these factors (MacClellan et al., 2007; Schürks et al., 2009). 
In a US study, the risk of IS or ICH during pregnancy and the first 6 weeks after giving birth 
was 2.4 times greater than for nonpregnant women of similar age and race. The excess risk of 
stroke (all types except SAH) attributable to the combined pregnancy/postpregnancy period 
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age, socioeconomic status, lifestyle, and physiological risk factors (OR, 1.94; 95% CI, 1.37–
2.74) in a cohort of 10 547 Australian women aged 47 to 52 years who were followed up for 12 
years (Jackson and Mishra, 2013). In a meta-analysis of 17 community-based or population-
based prospective studies published between 1994 and 2010 involving 206 641 participants, 
people with a history of depression experienced a 34% higher risk for the development of 
subsequent stroke after adjustment for potential confounding factors (pooled RR, 1.34; 95% CI, 
1.17–1.54). Associations were similar for men and women (Dong et al., 2012). Another meta-
analysis of 28 prospective cohort studies comprising 317 540 participants with a follow-up 
period that ranged from 2 to 29 years found that depression was associated with an increased 
risk of total stroke (pooled HR, 1.45; 95% CI, 1.29–1.63), fatal stroke (pooled HR, 1.55; 95% 
CI, 1.25–1.93), and IS (pooled HR, 1.25; 95% CI, 1.11–1.40) (Pan et al., 2011). 
1.5 Recognizing signs of stroke 
Emergency medical services leaders, in coordination with local, regional, and state agencies 
and in consultation with medical authorities and local experts, should develop triage paradigms 
and protocols to ensure that patients with a known or suspected stroke are rapidly identified and 
assessed by use of a validated and standardized instrument for stroke screening, such as the 
FAST (face, arm, speech test) scale, Los Angeles Prehospital Stroke Screen, or Cincinnati 
Prehospital Stroke Scale (Class I, LOE B) (Powers et al., 2018). 
The FAST test is an easy way to remember and recognize the signs of stroke. FAST is based 
on the Cincinnati Prehospital Stroke Scale and focuses on 3 symptoms: facial droop (F), arm 
drift (A) and speech problems (S), with “T” for “time” rounding out the acronym.  
The English mass media campaigns ‘Act FAST’ and ‘Be FAST’ aimed to raise stroke 
awareness and the need to call emergency services at the onset of suspected stroke (Figures 
10,11). 
 
Figure 9 "Act F.A.S.T." campaign to raise awareness of stroke symptoms and time 
importance 
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Figure 10 "Be FAST" campaign to raise awareness of stroke symptoms and time 
importance 
Patients with a positive stroke screen and/or a strong suspicion of stroke should be transported 
rapidly to the closest healthcare facilities that can capably administer IV alteplase (Class I, LOE 
B) (Powers et al., 2018). 
1.6 EARLY MANAGEMENT OF SROKE 
1.6.1. Emergency Evaluation and Diagnosis of AIS 
The evaluation and initial treatment of patients with stroke should be performed expeditiously. 
Because time is critical, a limited number of essential diagnostic tests are recommended. Stroke 
protocols and pathways should clearly define which tests must be performed prior to acute 
treatment decisions and which may be performed subsequent to acute stroke therapies. 
An organized protocol for the emergency evaluation of patients with suspected stroke is 
recommended. The goal is to complete an evaluation and to begin fibrinolytic treatment within 
60 minutes of the patient's arrival in an emergency department. Designation of an acute stroke 
team that includes physicians, nurses, and laboratory/radiology personnel is encouraged. 
Patients with stroke should have a careful clinical assessment, including neurological 
examination (Class I, LOE B) (Powers et al., 2018). 
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The use of a stroke rating scale, preferably the National Institutes of Health Stroke Scale 
(NIHSS), is recommended. (Class I, LOE B) (Powers et al., 2018). 
Stroke severity (NIHSS) 
NIHSS is composed of 11 questions each of which has a specific neurological capacity and 
whose responses take a score ranging from 0 (normal response) to 2, 3 or 4 (severe dysfunction). 
The individual scores of each element are summed to give the total NIHSS score. Questions 
include consciousness level, vision, facial paralysis, motor and limb ataxia, sensitivity, 
language, extinction, and neglect (Appendix 2). 
The total score takes a number from 0 to 42: 
 A score of 1 to 4 indicates a minor stroke. 
 A score of 5 to 14 indicates a moderate stroke. 
 A score of 15 to 20 indicates moderate to severe stroke. 
 A score of 21 to 42 indicates severe stroke. 
It is important to assess the severity of stroke as soon as possible after the onset of symptoms 
to establish the most appropriate treatment (including deciding if the patient is a candidate for 
thrombolysis) and to judge the effectiveness of this treatment. In addition, the NIHSS predicts 
the patient's condition after stroke: A score ≤ 6 predicts a good prognosis whereas a score ≥ 16 
predicts a high probability of death or severe disability (Adams et al., 1999). 
A limited number of hematologic, coagulation, and biochemistry tests are recommended during 
the initial emergency evaluation, and only the assessment of blood glucose must precede the 
initiation of IV rtPA (Class I, LOE B) (Powers et al., 2018). 
Baseline electrocardiography assessment is recommended in patients presenting with AIS but 
should not delay initiation of IV rtPA (Class I, LOE B). Baseline troponin assessment is 
recommended in patients presenting with AIS but should not delay initiation of IV rtPA (Class 
I, LOE C) (Powers et al., 2018). 
Usefulness of chest radiographs in the hyperacute stroke setting in the absence of evidence of 
acute pulmonary, cardiac or pulmonary vascular disease is unclear. If obtained, they should not 
unnecessarily delay administration of fibrinolysis (Class IIb, LOE B) (Powers et al., 2018). 
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1.6.2. Early Diagnosis: Brain and Vascular Imaging 
All patients admitted to hospital with suspected acute stroke should receive brain imaging 
evaluation on arrival to hospital. In most cases, noncontrast CT (NCCT) will provide the 
necessary information to make decisions about acute management (Class I, LOE B) (Powers et 
al., 2018).  
Systems should be established so that brain imaging studies can be performed within 20 minutes 
of arrival in the emergency department in at least 50% of patients who may be candidates for 
IV alteplase and/or mechanical thrombectomy (Class I, LOE B) (Powers et al., 2018). 
Head CT 
– NCCT is excellent in discriminating the presence of an intracranial hemorrhage which will 
preclude patients from thrombolytics. 
– Presence of a hyperdense middle cerebral artery sign is seen in roughly 1/3 of cases but 
correlates to large vessel occlusion. 
– Presence of extensive early ischemic changes on NCCT correlates to an 8-fold risk of 
symptomatic hemorrhage with IV tPA. 
MRI Brain 
– Diffusion weighted imaging is highly specific and sensitive in detecting ischemia. 
– The gradient recall echo (GRE) sequence may assist in detecting thrombus with higher 
sensitivity compared to NCCT. 
– MR is sensitive at detecting acute hemorrhage and comparable to NCCT and reasonable to 
use for early imaging. 
– Limitations of MR are patient movement, pacemakers, metal implants or claustrophobia. 
CT Angiography (CTA) 
– The accuracy of CTA for evaluation of large-vessel intracranial stenoses and occlusions is 
very high. 
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– Because CTA provides a static image of vascular anatomy, it is inferior to digital subtraction 
angiography (DSA) for the demonstration of flow rates and direction. 
– Direct comparisons of CTA source images and MRI/diffusion weighted imaging (DWI) have 
demonstrated very similar sensitivity of these two techniques for detecting ischemic regions. 
MR Angiography (MRA) 
Time of flight MRA is useful in identifying acute proximal large-vessel occlusions but cannot 
reliably identify distal or branch occlusions. 
Transcranial Doppler (TCD) 
– TCD accuracy is less compared to CTA and MRA for steno-occlusive disease, with a 
sensitivity and specificity of TCD ranging from 55-90% and 90-95%, respectively. 
– TCD usefulness is limited in patients with poor bony windows, and its overall accuracy is 
dependent on the experience of the technician, interpreter, and the patient's vascular anatomy. 
Conventional Angiography 
– DSA remains the "gold standard" for the detection of many types of cerebrovascular lesions 
and diseases. 
– DSA is an invasive test and can cause serious complications such as stroke and death. 
– The largest series of cases to date reported a rate of stroke or death of less than 0.2%. 
– A CTA or MRA may obviate the need for catheter angiography. 
For patients with acute cerebral ischemic symptoms that have not yet resolved 
Emergency imaging of the brain is recommended before initiating any specific therapy to treat 
AIS. In most instances, NCCT will provide the necessary information to make decisions about 
emergency management (Class I, LOE A). Either NCCT or MRI is recommended before IV 
rtPA administration to exclude ICH (absolute contraindication) and to determine whether CT 
hypodensity or MRI hyperintensity of ischemia is present (Class I, LOE A) (Powers et al., 
2018). 
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IV fibrinolytic therapy is recommended in the setting of early ischemic changes on CT (other 
than frank hypodensity), regardless of their extent (Class I, LOE A). A non-invasive intracranial 
vascular study is strongly recommended during the initial imaging evaluation of the acute stroke 
patient if either IA fibrinolysis or mechanical thrombectomy is contemplated for management 
but should not delay IV rtPA if indicated (Class I, LOE A) (Powers et al., 2018). 
In IV fibrinolysis candidates, the brain imaging study should be interpreted within 45 minutes 
of patient arrival in the emergency department by a physician with expertise in reading CT and 
MRI studies of the brain parenchyma (Class I, LOE C) (Powers et al., 2018). 
CT perfusion and MRI perfusion and diffusion imaging, including measures of infarct core and 
penumbra, may be considered for selecting patients for acute reperfusion therapy beyond IV 
fibrinolytic time windows. These techniques provide additional information that may improve 
diagnosis, mechanism, and severity of IS and allow more informed clinical decision-making 
(Class IIb, LOE B) (Powers et al., 2018). 
Frank hypodensity on NCCT may increase the risk of hemorrhage with fibrinolysis and should 
be considered in treatment decisions. If frank hypodensity involves more than one third of the 
middle cerebral artery territory, IV rtPA treatment should be withheld (Class III, LOE A) 
(Powers et al., 2018). 
For patients with acute cerebral ischemic symptoms that have resolved 
Noninvasive imaging of the cervical vessels should be performed routinely as part of the 
evaluation of patients with suspected TIAs (Class I, LOE A). Noninvasive imaging by means 
of CTA or MRA of the intracranial vasculature is recommended to exclude the presence of 
proximal intracranial stenosis and/or occlusion and should be obtained when knowledge of 
intracranial steno-occlusive disease will alter management. Reliable diagnosis of the presence 
and degree of intracranial stenosis requires the performance of catheter angiography to confirm 
abnormalities detected with noninvasive testing (Class I, LOE A) (Powers et al., 2018). 
Patients with transient ischemic neurologic symptoms should undergo neuroimaging evaluation 
within 24 hours of symptom onset or as soon as possible in patients with delayed presentations. 
MRI, including DWI, is the preferred brain diagnostic imaging modality. If MRI is not 
available, head CT should be performed (Class I, LOE B) (Powers et al., 2018). 
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1.6.3. General Supportive Care and Treatment of Acute Complications 
Cardiac monitoring is recommended to screen for AF and other potentially serious cardiac 
arrhythmias that would necessitate emergency cardiac interventions. Cardiac monitoring should 
be performed for at least the first 24 hours (Class I, LOE B). Cardiac arrhythmias that might be 
reducing cardiac output should be corrected (Class I, LOE C) (Powers et al., 2018). 
Blood pressure 
Hypotension and hypovolemia should be corrected to maintain systemic perfusion levels 
necessary to support organ function (Class I, LOE C). Hypovolemia should be corrected with 
IV normal saline. (Class I, LOE C) (Powers et al., 2018). 
Patients who have elevated BP and are otherwise eligible for treatment of with IV rtPA should 
have their BP carefully lowered so that their SBP is <185 mm Hg and their DBP is <110 mm 
Hg before fibrinolytic therapy is initiated. If medications are given to lower BP, the clinician 
should be sure that the BP is stabilized at the lower level before treating with IV rtPA and 
maintained below 180/105 mm Hg for at least the first 24 hours after IV rtPA treatment (Class 
I, LOE B) (Powers et al., 2018). 
Restarting antihypertensive medications is relatively safe and reasonable after the first 24 hours 
for patients who have preexisting hypertension and are neurologically stable unless a specific 
contraindication to restarting treatment is known (Class IIa, LOE B). No data are available to 
guide selection of medications for the lowering of BP in the setting of AIS. The antihypertensive 
medications and doses included in Table 10 are reasonable choices based on general consensus 
(Class IIa, LOE C) (Powers et al., 2018). 
Table 9  Options to treat arterial hypertension in patients with AIS who are candidates for 
acute reperfusion therapy* 
Patient otherwise eligible for acute reperfusion therapy except that BP is >185/110 mmHg: 
   Labetalol 10–20 mg IV over 1–2 min, may repeat 1 time; or 
   Nicardipine 5 mg/h IV, titrate up by 2.5 mg/h every 5–15 min, maximum 15 mg/h; when 
desired BP reached, adjust to maintain proper BP limits; or 
   Clevidipine 1–2 mg/h IV, titrate by doubling the dose every 2–5 min until desired BP 
reached; maximum 21 mg/h 
   Other agents (eg, hydralazine, enalaprilat) may also be considered 
If BP is not maintained ≤185/110 mmHg, do not administer alteplase 
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Management of BP during and after alteplase or other acute reperfusion therapy to maintain 
BP ≤180/105 mmHg: 
   Monitor BP every 15 min for 2 h from the start of alteplase therapy, then every 30 min for 6 
h, and then every hour for 16 h 
If systolic BP >180–230 mmHg or diastolic BP >105–120 mmHg: 
   Labetalol 10 mg IV followed by continuous IV infusion 2–8 mg/min; or 
   Nicardipine 5 mg/h IV, titrate up to desired effect by 2.5 mg/h every 5–15 min, maximum 
15 mg/h; or 
   Clevidipine 1–2 mg/h IV, titrate by doubling the dose every 2–5 min until desired BP 
reached; maximum 21 mg/h 
If BP not controlled or diastolic BP >140 mmHg, consider IV sodium nitroprusside 
AIS indicates acute ischemic stroke; BP, blood pressure; IV, intravenous. 
*Different treatment options may be appropriate in patients who have comorbid conditions that 
may benefit from acute reductions in BP such as acute coronary event, acute heart failure, aortic 
dissection, or preeclampsia/eclampsia. 
In patients with markedly elevated BP who do not receive fibrinolysis a reasonable goal is to 
lower BP by 15% during the first 24 hours after onset of stroke. The level of BP that would 
mandate such treatment is not known, but consensus exists that medications should be withheld 
unless the SBP is >220 mm Hg or the DBP is >120 mm Hg (Class I, LOE C) (Powers et al., 
2018). 
The management of arterial hypertension in patients not undergoing reperfusion strategies 
remains challenging. Data to guide recommendations for treatment are inconclusive or 
conflicting. Many patients have spontaneous declines in BP during the first 24 hours after onset 
of stroke. Until more definitive data are available, the benefit of treating arterial hypertension 
in the setting of AIS is not well established. Patients who have malignant hypertension or other 
medical indications for aggressive treatment of PB should be treated accordingly (Class IIb, 
LOE C) (Powers et al., 2018). 
Airway, Breathing, Oxygenation, Temperature and Glycemia 
Stroke is a primary failure of focal tissue oxygenation and energy supply. Systemic hypoxemia 
should be avoided and, if present, corrected to limit further cellular damage. 
Airway support and ventilatory assistance are recommended for the treatment of patients with 
acute stroke who have decreased consciousness or who have bulbar dysfunction causing 
compromise of the airway (Class I, LOE C). Supplemental oxygen should be provided to 
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maintain oxygen saturation >94% (Class I, LOE C). Supplemental oxygen is not recommended 
in nonhypoxic patients with AIS (Class III, LOE B) (Powers et al., 2018). 
Sources of hyperthermia (temperature >38°C) should be identified and treated, and antipyretic 
medications should be administered to lower temperature in hyperthermic patients with stroke 
(Class I, LOE C) (Powers et al., 2018). 
Hypoglycemia (blood glucose <60 mg/dL) should be treated in patients with AIS. The goal is 
to achieve normoglycemia (Class I, LOE C). Evidence indicates that persistent in-hospital 
hyperglycemia during the first 24 hours after stroke is associated with worse outcomes than 
normoglycemia, and thus it is reasonable to treat hyperglycemia to achieve blood glucose levels 
in a range of 140-180 mg/dL, and to closely monitor to prevent hypoglycemia in patients with 
AIS (Class IIa, LOE C) (Powers et al., 2018). 
1.6.4. Intravenous Fibrinolysis 
In the National Institute of Neurological Disorders and Stroke (NINDS) rtPA Stroke Trial, 
treatment with IV rtPA was associated with an increase in the odds of a favorable outcome (OR 
1.9; 95% CI 1.2-2.9); the benefit was similar 1 year after stroke. The earlier that treatment is 
initiated, the better the result. 
Early minimal neurologic symptoms or neurologic deterioration temporally associated with any 
intracranial hemorrhage occurred in 6.4% of patients treated with IV rtPA and 0.6% of patients 
given placebo; however, mortality in the 2 treatment groups was similar at 3 months (17% 
versus 20%) (NINDS rtPA Stroke Study Group, 19995). 
IV rtPA (0.9 mg/kg, maximum dose 90 mg) is recommended for selected patients who may be 
treated within 3 hours of onset of IS (Class I, LOE A). In patients eligible for IV rtPA, benefit 
of therapy is time-dependent, and treatment should be initiated as quickly as possible. The door 
to needle time (time of bolus administration) should be within 60 minutes from hospital arrival 
(Class I, LOE A) (Powers et al., 2018). 
In patients undergoing fibrinolytic therapy, physicians should be aware of and prepared to 
emergently treat potential side effects including bleeding complications and angioedema that 
may cause partial airway obstruction (Class I, LOE B) (Powers et al., 2018). 
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IV rtPA is reasonable in patients with a seizure at the time of onset of stroke if evidence suggests 
that residual impairments are secondary to stroke and not a postictal phenomenon (Class IIa, 
LOE C) (Powers et al., 2018). 
The effectiveness of sonothrombolysis for treatment of patients with acute stroke is not well 
established (Class IIb, LOE B) (Powers et al., 2018). 
The usefulness of IV administration of tenecteplase, reteplase, desmoteplase, urokinase, or 
other fibrinolytic agents, and the IV administration of ancrod or other defibrinogenating agents 
is not well established and should only be used in the setting of a clinical trial (Class IIb, LOE 
B). The IV administration of streptokinase for treatment of stroke is not recommended (Class 
III, LOE A) (Powers et al., 2018). 
The use of IV fibrinolysis in patients with conditions of mild stroke deficits, rapidly improving 
stroke symptoms, major surgery in the preceding 3 months, and recent MI may be considered, 
and potential increased risk should be weighed against the anticipated benefits. These 
circumstances require further study (Class IIb, LOE C) (Powers et al., 2018). 
The use of IV rtPA in patients taking direct thrombin inhibitors or direct factor Xa inhibitors 
may be harmful and is not recommended unless sensitive laboratory tests such as aPTT, INR, 
platelet count, and ECT, or TT, or appropriate direct factor Xa activity assays are normal, or 
the patient has not received a dose of these agents for more than 2 days (assuming normal renal 
metabolizing function). Similar consideration should be given to patients being considered for 
IA rtPA (Class III, LOE C) (Powers et al., 2018). 
Extended IV rtPA window 
European Cooperative Acute Stroke Study III results indicated that IV rtPA can improve 
outcomes for, carefully selected patients treated 3–4.5 hours after stroke (Hacke et al., 2008). 
A meta-analysis of 12 IV rtPA trials confirmed the benefits of IV rtPA administered within 6 
hours from symptom onset (OR 1.17, 95% CI 1.06 –1.29; p=0·001) and reinforced the 
importance of timely treatment because the benefit of IV rtPA is greatest in patients treated 
within 3 hrs from symptom onset (Wardlaw et al., 2012). 
Health systems should set a goal of increasing their percentage of stroke patients treated within 
60 minutes of presentation to hospital (door to needle time of 60 minutes) to at least 80% 
(Powers et al., 2018). 
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IV rtPA (0.9 mg/kg, maximum dose 90 mg) is recommended for administration to eligible 
patients who can be treated in the time period of 3–4.5 hours after stroke onset. The eligibility 
criteria for treatment in this time period are similar to those for persons treated at earlier time 
periods within 3 hours, with the following additional exclusion criteria: patients older than 80 
years, those taking oral anticoagulants regardless of INR, those with a baseline NIHSS score 
>25, those with imaging evidence of ischemic injury involving more than one-third of the 
middle cerebral artery territory, or those with both a history of stroke and diabetes (Class I, 
LOE B) (Powers et al., 2018). 
For patients who can be treated in the time period of 3–4.5 hours after stroke but have one or 
more of the following exclusion criteria: 1) patients older than 80 years, 2) those taking oral 
anticoagulants, even with INR ≤1.7, 3) those with a baseline NIHSS >25, or 4) those with both 
a history of both stroke and diabetes, the effectiveness of IV treatment with rtPA is not well-
established, and requires further study (Class IIb, LOE C) (Powers et al., 2018). 
1.6.5. Endovascular Interventions 
IA fibrinolysis or mechanical thrombectomy are reasonable in patients who have 
contraindications to the use of IV fibrinolysis (Class IIa, LOE C) (Powers et al., 2018). 
Rescue IA fibrinolysis or mechanical thrombectomy may be reasonable approaches to 
recanalization in patients with large artery occlusion who have not responded to IV fibrinolysis. 
Additional randomized trial data are needed (Class IIb, LOE B) (Powers et al., 2018). 
• Intra-Arterial Fibrinolysis 
– Prolyse in Acute Cerebral Thromboembolism II study showed a 15% absolute difference in 
good outcome favoring IA pro-urokinase (p<0.04) (del Zoppo et al., 1998). 
– Middle cerebral artery Embolism Local fibrinolytic intervention Trial terminated early but 
showed for mRS 0-1 better outcomes compared to control (Abou-Chebl, 2011). 
Patients eligible for IV rtPA should receive IV rtPA even if IA treatments are being considered 
(Class I, LOE A) (Powers et al., 2018). 
Results of IA fibrinolysis are likely dependent on efficient and timely systems based approach 
similar to IV tPA. IA fibrinolysis is beneficial for treatment of carefully selected patients with 
major ISs of <6 hours duration due to occlusions of the middle cerebral artery, who are not 
otherwise candidates for IV rtPA. As with IV fibrinolytic therapy, reduced time from symptom 
 88 
onset to reperfusion with intra-arterial therapies is highly correlated with better clinical 
outcomes, and all efforts must be undertaken to minimize delays to definitive therapy. The 
optimal dose of IA rtPA remains is not well established and does not have Food and Drug 
Administration approval for IA use (Class I, LOE B) (Powers et al., 2018). 
IA treatment requires the patient to be at an experienced stroke center with rapid access to 
cerebral angiography and qualified interventionalists. An emphasis on expeditious assessment 
and treatment should be made. Facilities are encouraged to define criteria to credential 
individuals who can perform IA revascularization procedures. Outcomes on all patients should 
be tracked (Class I, LOE C) (Powers et al., 2018). 
• Mechanical Clot Disruption/Extraction 
Recanalization by mechanical thrombectomy may occur due to a combination of thrombus 
fragmentation, thrombus retrieval, and enhancement of fibrinolytic penetration. There are 
currently four devices cleared by the Food and Drug Administration for recanalization of 
arterial occlusion in patients with IS (Merci, Penumbra, Solitaire, Trevo). When mechanical 
thrombectomy is pursued, stent retrievers, such as Solitaire FR and Trevo, are generally 
preferred to coil retrievers such as Merci. The relative effectiveness of the Penumbra System 
vs. stent retrievers is not yet characterized (Class I, LOE A) (Powers et al., 2018). 
The Merci, Penumbra System, Solitaire FR, and Trevo thrombectomy devices can be useful in 
achieving recanalization alone or in combination with pharmacological fibrinolysis in carefully 
selected patients. Their ability to improve patient outcomes has not yet been established. These 
devices should continue to be studied in RCT to determine the efficacy of such treatments in 
improving patient outcomes (Class IIa, LOE B) (Powers et al., 2018). 
The usefulness of mechanical thrombectomy devices other than the Merci retriever, the 
Penumbra System, Solitaire FR, and Trevo is not well established. These devices should be 
used in the setting of clinical trials (Class IIb, LOE C) (Powers et al., 2018). 
The usefulness of emergent intracranial angioplasty and/or stenting is not well established. 
These devices should be used in the setting of clinical trials (Class IIb, LOE C) (Powers et al., 
2018). 
The usefulness of emergent angioplasty and/or stenting of the extracranial carotid or vertebral 
arteries in unselected patients is not well established. Use of these techniques may be considered 
in certain circumstances, such as in the treatment of AIS from cervical atherosclerosis or 
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dissection. Additional randomized trial data are needed (Class IIb, LOE C) (Powers et al., 
2018). 
1.6.6. Anticoagulants 
The results of several clinical trials demonstrate an increased risk of bleeding complications 
with early administration of either unfractionated heparin or low molecular weight heparin. 
Early administration of unfractionated heparin or low molecular weight heparin does not lower 
the risk of early recurrent stroke, including among persons with cardioembolic sources. The 
PREVAIL study gives the strongest evidence of the superiority of low molecular weight heparin 
in prevention of venous thromboembolism following IS (Muir, 2008). 
The role of anticoagulants as an adjunct in addition to mechanical or pharmacological 
fibrinolysis has not been established. 
At present, the usefulness of argatroban or other thrombin inhibitors for treatment of patients 
with AIS is not well established. These agents should be used in the setting of clinical trials 
(Class IIb, LOE B) (Powers et al., 2018). 
The usefulness of urgent anticoagulation in patients with severe stenosis of an internal carotid 
artery ipsilateral to an IS is not well established (Class IIb, LOE B) (Powers et al., 2018). 
Urgent anticoagulation, with the goal of preventing early recurrent stroke, halting neurological 
worsening, or improving outcomes after AIS, is not recommended for treatment of patients with 
AIS (Class III, LOE A) (Powers et al., 2018). 
Urgent anticoagulation for the management of noncerebrovascular conditions is not 
recommended for patients with moderate-to-severe strokes because of an increased risk of 
serious intracranial hemorrhagic complications (Class III, LOE A) (Powers et al., 2018). 
Initiation of anticoagulant therapy within 24 hours of treatment with IV rtPA is not 
recommended (Class III, LOE B) (Powers et al., 2018). 
1.6.7. Antiplatelet Agents 
Currently available data demonstrate a small but statistically significant decline in mortality 
and unfavorable outcomes with the administration of aspirin within 48 hours following stroke. 
Oral administration of aspirin (initial dose is 325 mg) within 24 to 48 hours after stroke onset 
is recommended for treatment of most patients (Class I, LOE A).  
Aspirin is not recommended as a substitute for other acute interventions for treatment of stroke, 
including IV rtPA (Class III, LOE B).  
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The administration of aspirin (or other antiplatelet agents) as an adjunctive therapy within 24 
hours of IV fibrinolysis is not recommended (Class III, LOE C) (Powers et al., 2018). 
Data regarding the utility of other antiplatelet agents, including clopidogrel alone or in 
combination with aspirin, for the treatment of AIS are limited. The usefulness of clopidogrel 
for the treatment of AIS is not well established. Further research testing the usefulness of the 
emergency administration of clopidogrel in the treatment of patients with acute stroke is 
required (Class IIb, LOE C) (Powers et al., 2018). 
Research of intravenously administered antiplatelet agents is ongoing. The efficacy of 
intravenous tirofiban and eptifibatide are not well established and should be used in the setting 
of clinical trials (Class IIb, LOE C) (Powers et al., 2018). 
The administration of other IV antiplatelet agents that inhibit the glycoprotein IIb/IIIa receptor 
is not recommended. Further research testing the usefulness of emergency administration of 
these medications as a treatment option in patients with AIS is required (Class III, LOE B) 
(Powers et al., 2018). 
1.6.8. Volume Expansion, Vasodilators, and Induced Hypertension 
The usefulness of drug-induced hypertension in patients with AIS is not well established. 
Induced hypertension should be performed in the setting of clinical trials (Class IIb, LOE B). 
In exceptional cases with systemic hypotension producing neurologic sequelae, a physician 
may prescribe vasopressors to improve cerebral blood flow. If drug-induced hypertension is 
used, close neurological and cardiac monitoring is recommended (Class I, LOE C) (Powers et 
al., 2018). 
The administration of high dose albumin is not well established as a treatment for most patients 
with AIS until further definitive evidence regarding efficacy becomes available (Class IIb, LOE 
B) (Powers et al., 2018). 
At present, use of devices to augment cerebral blood flow for the treatment of patients with AIS 
is not well established. These devices should be used in the setting of clinical trials (Class IIb, 
LOE B) (Powers et al., 2018). 
Hemodilution by volume expansion is not recommended for treatment of patients with AIS 
(Class III, LOE A) (Powers et al., 2018). 
The administration of vasodilatory agents, such as pentoxifylline, is not recommended for 
treatment of patients with AIS (Class III, LOE A) (Powers et al., 2018). 
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1.6.9. Neuroprotective agents 
Among patients already taking statins at the time of onset of IS, continuation of statin therapy 
during the acute period is reasonable (Class IIa, LOE B) (Powers et al., 2018). 
The utility of induced hypothermia for the treatment of patients with IS is not well established, 
and further trials are recommended (Class IIb, LOE B) (Powers et al., 2018). 
At present, transcranial near-infrared laser therapy is not well established for the treatment of 
AIS, and further trials are recommended (Class IIb, LOE B) (Powers et al., 2018). 
At present, no other pharmacologic agents with putative neuroprotective actions have 
demonstrated efficacy in improving outcomes after IS, and therefore other neuroprotective 
agents are not recommended (Class III, LOE A) (Powers et al., 2018). 
Data on the utility of hyperbaric oxygen are inconclusive, and some data imply that the 
intervention may be harmful. Thus, with the exception of stroke secondary to air embolization, 
this intervention is not recommended for treatment of patients with AIS (Class III, LOE B) 
(Powers et al., 2018). 
1.6.10. Surgical Interventions 
Emergent carotid endarterectomy and other operations for treatment of patients with AIS may 
have serious risks and the indications must be considered carefully for each individual patient. 
Additional RCTs should be designed and undertaken to examine the safety and efficacy of 
carotid endarterectomy in various subsets of patients with acute stroke, to establish the optimal 
timing for revascularization, and to define its role in the emergency management of stroke 
(Powers et al., 2018). 
The usefulness of emergent or urgent carotid endarterectomy when clinical indicators or brain 
imaging suggest a small infarct core with large territory at risk (e.g. penumbra), compromised 
by inadequate flow from a critical carotid stenosis or occlusion, or in the case of acute 
neurologic deficit after carotid endarterectomy, where acute thrombosis of the surgical site is 
suspected, is not well established (Class IIb, LOE B) (Powers et al., 2018). 
In patients with unstable neurologic status --either stroke-in-evolution or crescendo TIA-- the 
efficacy of emergent or urgent carotid endarterectomy is not well established (Class IIb, LOE 
B) (Powers et al., 2018). 
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1.6.11. Admission to the Hospital and General Acute Treatment (After 
Hospitalization) 
Approximately 25% of patients may have neurological worsening during the first 24 to 48 hours 
after stroke and it is difficult to predict which patients will deteriorate (Powers et al., 2018). 
The importance of dedicated stroke nursing care in the management of stroke patients cannot 
be overstated. The use of comprehensive specialized stroke care (stroke units) incorporating 
rehabilitation is recommended (Class I, LOE A). The use of standardized stroke care order sets 
is recommended to improve general management (Class I, LOE B) (Powers et al., 2018). 
Patients with suspected pneumonia or urinary tract infections should be treated with appropriate 
antibiotics (Class I, LOE A). Routine use of prophylactic antibiotics has not been shown to be 
beneficial (Class III, LOE B). Routine placement of indwelling bladder catheters is not 
recommended because of the associated risk of catheter associated urinary tract infections 
(Class III, LOE C) (Powers et al., 2018). 
Subcutaneous administration of anticoagulants is recommended for treatment of immobilized 
patients to prevent deep vein thrombosis (Class I, LOE A). The use of aspirin is reasonable for 
treatment of patients who cannot receive anticoagulants for deep vein thrombosis prophylaxis 
(Class IIa, LOE A). The use of intermittent external compression devices is reasonable for 
treatment of patients who cannot receive anticoagulants (Class IIa, LOE B) (Powers et al., 
2018). 
Assessment of swallowing before starting eating, drinking, or receiving oral medications is 
recommended (Class I, LOE B). Patients who cannot take solid food and liquids orally should 
receive nasogastric, nasoduodenal, or percutaneous endoscopic gastrostomy tube feedings to 
maintain hydration and nutrition while undergoing efforts to restore swallowing (Class I, LOE 
B). In selecting between nasogastric versus percutaneous endoscopic gastrostomy tube routes 
of feeding in patients who cannot take solid food or liquids orally, it is reasonable to prefer 
nasogastric tube feeding until 2-3 weeks post stroke onset (Class IIa, LOE B) (Powers et al., 
2018). 
Early mobilization of less severely affected patients and measures to prevent subacute 
complications of stroke are recommended (Class I, LOE C) (Powers et al., 2018). 
Treatment of concomitant medical diseases is recommended (Class I, LOE C) (Powers et al., 
2018). 
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Early institution of interventions to prevent recurrent stroke is recommended (Class I, LOE C) 
(Powers et al., 2018). 
1.6.12. Treatment of Acute Neurological Complications  
Given the complexity of severe stroke and potential complications, multidisciplinary care teams 
comprised of neurologists, neurointensivists, and neurosurgeons, as well as dedicated stroke 
nursing, are required to optimally manage these complex patients. 
Patients with major infarctions are at high risk for complicating brain edema and increased 
intracranial pressure. Measures to lessen the risk of edema and close monitoring of the patient 
for signs of neurological worsening during the first days after stroke are recommended. Early 
transfer of patients at risk for malignant brain edema to an institution with neurosurgical 
expertise should be considered (Class I, LOE A).  
Decompressive surgery for malignant edema of the cerebral hemisphere is effective and 
potentially life-saving. Advanced patient age and patient/family valuations of achievable 
outcome states may affect decisions regarding surgery (Class I, LOE B).  
Although aggressive medical measures have been recommended for treatment of deteriorating 
patients with malignant brain edema after large cerebral infarction, the usefulness of these 
measures is not well established (Class IIb, LOE C).  
Because of lack of evidence of efficacy and the potential to increase the risk of infectious 
complications, corticosteroids (in conventional or large doses) are not recommended for 
treatment of cerebral edema and increased intracranial pressure complicating IS (Class III, LOE 
A) (Powers et al., 2018). 
Decompressive surgical evacuation of a space occupying cerebellar infarction is effective in 
preventing and treating herniation and brain stem compression (Class I, LOE B) (Powers et al., 
2018).  
Placement of a ventricular drain is useful in patients with acute hydrocephalus secondary to IS 
(Class I, LOE C) (Powers et al., 2018). 
Recurrent seizures after stroke should be treated in a manner similar to other acute neurological 
conditions and anti-epileptic agents selected by specific patient characteristics (Class I, LOE 
B). Prophylactic use of anticonvulsants is not recommended (Class III, LOE C) (Powers et al., 
2018). 
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surgical removal of the hemorrhage as soon as possible (Class I; LOE B) (Hemphill et al., 
2015). 
1.7.8. Prevention of Recurrent ICH 
When stratifying a patient’s risk for recurrent ICH may affect management decisions, it is 
reasonable to consider the following risk factors for ICH recurrence: (1) lobar location of the 
initial ICH; (2) older age; (3) presence and number of microbleeds on gradient echo MRI; (4) 
ongoing anticoagulation; and (5) presence of apolipoprotein E ε2 or ε4 alleles (Class IIa; LOE 
B) (Hemphill et al., 2015). 
BP should be controlled in all ICH patients (Class I; LOE A). Measures to control BP should 
begin immediately after ICH onset (Class I; LOE A). A long-term goal of BP <130 mmHg 
systolic and 80 mmHg diastolic is reasonable (Class IIa; LOE B) (Hemphill et al., 2015). 
Lifestyle modifications, including avoidance of alcohol use greater than 2 drinks per day, 
tobacco use, and illicit drug use, as well as treatment of obstructive sleep apnea, are probably 
beneficial (Class IIa; LOE B) (Hemphill et al., 2015). 
Avoidance of long-term anticoagulation with warfarin as a treatment for nonvalvular AF is 
probably recommended after warfarin-associated spontaneous lobar ICH because of the 
relatively high risk of recurrence (Class IIa; LOE B) (Hemphill et al., 2015). 
Anticoagulation after nonlobar ICH and antiplatelet monotherapy after any ICH might be 
considered, particularly when there are strong indications for these agents (Class IIb; LOE B) 
(Hemphill et al., 2015). 
The optimal timing to resume oral anticoagulation after anticoagulant-related ICH is uncertain. 
Avoidance of oral anticoagulation for at least 4 weeks, in patients without mechanical heart 
valves, might decrease the risk of ICH recurrence (Class IIb; LOEB) (Hemphill et al., 2015). 
If indicated, aspirin monotherapy can probably be restarted in the days after ICH, although the 
optimal timing is uncertain (Class IIa; LOE B) (Hemphill et al., 2015). 
The usefulness of dabigatran, rivaroxaban, or apixaban in patients with AF and past ICH to 
decrease the risk of recurrence is uncertain (Class IIb; LOE C) (Hemphill et al., 2015). 
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There are insufficient data to recommend restrictions on the use of statins in ICH patients (Class 
IIb; LOE C) (Hemphill et al., 2015). 
1.7.9. Rehabilitation and Recovery 
Given the potentially serious nature and complex pattern of evolving disability and the 
increasing evidence for efficacy, it is recommended that all patients with ICH have access to 
multidisciplinary rehabilitation (Class I; LOE A) (Hemphill et al., 2015).  
Where possible, rehabilitation can be beneficial when begun as early as possible and continued 
in the community as part of a well-coordinated (“seamless”) program of accelerated hospital 
discharge and home-based resettlement to promote ongoing recovery (Class IIa; LOE B) 
(Hemphill et al., 2015). 
1.8. Global Burden of Stroke 
Stroke remains a significant burden across the globe. Although global age-adjusted mortality 
rates for ischemic and hemorrhagic stroke decreased between 1990 and 2013, the absolute 
number of people who have strokes annually, as well as related deaths and Disability-Adjusted 
Life Years (DALY)s lost, increased. The majority of global stroke burden is in low- and middle-
income countries (LIMC) (Feigin et al., 2014; Feigin et al., 2015; GBD 2013 Mortality and 
Causes of Death Collaborators, 2015). On average, stroke occurs 15 years earlier in LIMC when 
compared to those in high-income countries (HIC) (Owolabi et al., 2009) and 70% of strokes 
occur in LIMC (Feigin et al., 2014). Data from 2013 indicate that 75.2% of deaths caused by 
stroke and 81% of DALYs lost as a result of stroke across the globe occur in LIMC too (Feigin 
et al., 2015).  
1.8.1. Stroke Prevalence  
 In 2013, there were globally almost 25.7 million stroke survivors (71% with IS), with 
10.3 million people having a first stroke (Feigin et al., 2015).  
 Approximately 2 of every 3 first strokes were IS (Feigin et al., 2014). 
 5.2 million (31%) first strokes were in those <65 years of age (Feigin et al., 2014).  
 Stroke prevalence was 1.47% in Italy, 1.7% in UK and 3% in the USA (Zhang et al., 
2012). In China, stroke prevalence varied between 1.8% in the rurales areas and 9.4% 
in the urban areas (Sousa et al., 2009). With the exeption of Peru (2.7%), stroke 
prevalence in Latin America varied between 6 and 8%. In India, the prevalence was 
quite low and varied between 1 and 2% (Ferri et al., 2011). 
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 In 2010, the number of cases of stroke in the European Union member states plus 
Iceland, Norway and Switzerland was estimated to be 8.2 million (Gustavsson et al., 
2011). 
1.8.2. Stroke Incidence  
Over the last four decades, the stroke incidence in LIMC has more than doubled. During these 
decades stroke incidence has declined by 42% in HIC (Feigin et al., 2014).  
Incidence rates for stroke ranged from 41 per 100 000 population per year in Nigeria (1971–
74) to 316 per 100 000 per year in urban Dar-es-Salaam (Tanzania), when adjusted to the WHO 
world standard population. Some regions had three to fivefold greater incidence than other 
countries (Thrift et al., 2014) (Figures 11,12).  
 
Figure 11 Stroke incidence age-adjusted to the WHO World Population 
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Figure 12 Stroke incidence in the world (per 100,000 person-years) (Feigin et al., 2014) 
In 2013, there were globally 10.3 million new strokes (67% IS) (Feigin et al., 2015). 
In 2010, there were an estimated 11.6 million events of incident IS and 5.3 million events of 
incident hemorrhagic stroke, 63% and 80%, respectively, in LIMC (Krishnamurthi et al., 2013).  
Between 1990 and 2010 (Krishnamurthi et al., 2013): 
 Incidence of IS was significantly reduced by 13% (95% CI, 6%–18%) in HIC. No 
significant change was seen in LIMC. 
 Incidence of hemorrhagic stroke decreased by 19% in HIC. Rates increased by 22% in 
LIMC, with a 19% increase in those aged <75 years. 
In developed countries, the incidence of stroke is declining, largely due to efforts to lower BP 
and reduce smoking. However, the overall rate of stroke remains high due to the aging of the 
population (Stroke statistics). 
1.8.3. Stroke Mortality 
Measuring how many people die each year and why they died is one of the most important 
means – along with gauging how diseases and injuries are affecting people – for assessing the 
effectiveness of a country’s health system. 
Cause-of-death statistics help health authorities determine the focus of their public health 
actions. A country in which deaths from HD and diabetes rise rapidly over a period of a few 
years, for example, has a strong interest in starting a vigorous programme to encourage 
lifestyles to help prevent these illnesses. Similarly, if a country recognizes that many children 
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are dying of pneumonia, but only a small portion of the budget is dedicated to providing 
effective treatment, it can increase spending in this area. 
HIC have systems in place for collecting information on causes of death. Many LIMC do not 
have such systems, and the numbers of deaths from specific causes have to be estimated from 
incomplete data. Improvements in producing high quality cause-of-death data are crucial for 
improving health and reducing preventable deaths in these countries. 
Stroke is the second most frequent cause of death worldwide ranked after ischemic heart disease 
(Donnan et al., 2008; Lozano et al., 2012; Murray et al., 1997; WHO, 2014) (Figures 13-17), 
accounting for 6.7 million deaths in 2012 (approximately 12% of the total) (WHO, 2014). 
 
Figure 13 Top 10 global causes of deaths, 2016 (WHO 2018) 
 102 
 
Figure 14 Top 10 causes of deaths in high-income countries, 2016 (WHO 2018) 
 
Figure 15 Top 10 causes of deaths in upper-middle-income countries, 2016 (WHO 2018) 
 103 
 
Figure 16 Top 10 causes of deaths in lower-middle-income countries, 2016 (WHO 2018) 
 
Figure 17 Top 10 causes of deaths in low-income countries, 2016 (WHO 2018) 
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There are substantial geographic disparities in stroke mortality (Figure 18), with higher rates 
in the southeastern US, known as the “stroke belt”. These geographic differences have existed 
since at least 1940 (Lanska, 1993), and despite some minor shifts (Casper et al., 1995), they 
persist (Casper et al., 2008; Perry and Roccella, 1998). Within the stroke belt, a “buckle” region 
along the coastal plain of North Carolina, South Carolina, and Georgia has been identified with 
an even higher stroke mortality rate than the remainder of the stroke belt. Historically, the 
overall average stroke mortality has been ≈30% higher in the stroke belt than in the rest of the 
nation and ≈40% higher in the stroke buckle (Howard et al., 1997).  
 
 
Figure 18 Stroke death rates, Total Population 35+, 2014 through 2016 
 Every 5-6 seconds someone, somewhere, regardless of age or gender will die from stroke 
(Stroke Foundation; WHO, 2014). Almost 1 in 8 deaths worldwide are caused by stroke 
(WHO, 2014). 
 About 10-15% of people with SAH die before reaching hospital (Intercollegiate Stroke 
Woring Party, 2016). 
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 Eight to twelve percent of IS and 37% to 38% of haemorrhagic strokes result in death within 
30 days (Roger et al., 2012; Woo et al., 1999). 
 In 2013 (GBD 2013 Mortality and Causes of Death Collaborators, 2015): 
 Stroke deaths accounted for 11.8% of total deaths worldwide. There were 6.5 
million stroke deaths worldwide, making stroke the second-leading global cause of 
death behind IHD. A total of 3.3 million individuals died of IS and 3.2 million of 
hemorrhagic stroke. 
 The absolute number of stroke deaths increased 40.2% between 1990 and 2013; 
however, the age-standardized death rate decreased 22.5%. Age-standardized death 
rates decreased 19.6% and 25.9% for ischemic and hemorrhagic stroke, 
respectively, since 1990. 
 In 2010, the mean age of stroke-related death in HIC was 80.4 years compared with 72.1 
years in LIMC (Lozano et al., 2012). Between 1990 and 2010, IS mortality decreased 37% 
in HIC and 14% in LIMC. Hemorrhagic stroke mortality decreased 38% in HIC and 23% in 
LIMC (Krishnamurthi et al., 2013).  
 Europe averages approximately 650,000 stroke deaths each year (The internet stroke center). 
In 2008, there were approximately 1.3 million deaths from stroke in Europe, accounting for 
almost 14% of all deaths (WHO, 2008). 
 In 2000, stroke accounted for 7% of all deaths – 15,409 Canadians (The internet stroke 
center). 
 In the US in 2014 (NCHS, 2014): 
 Stroke accounted for ≈1 of every 20 deaths, on average, every 4 minutes someone 
died of a stroke. The number of deaths with stroke as an underlying cause was 133 
103. 
 Approximately 60% of stroke deaths occurred outside of an acute care hospital. 
 Non-Hispanic black men and women had higher age-adjusted death rates for stroke 
than non-Hispanic white, non-Hispanic Asian, non-Hispanic Indian or Alaska 
Native, and Hispanic men and women in the US. 
 Women accounted for 58% of US stroke deaths. More women than men die of 
stroke each year because of a larger number of elderly women than men. 
 From 2004 to 2014, the age-adjusted stroke death rate decreased 28.7% (from 51.2 
per 100 000 to 36.5 per 100 000), and the actual number of stroke deaths declined 
11.3% (from 150 074 deaths to 133 103 deaths). 
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The proportion of deaths due to stroke rose from 9.7% to 11.8% between 1990 and 2013 
(Figure 19). The increase in the contribution of deaths was largely attributable to LIMC (Feigin 
et al., 2015); there was no significant rise in the proportion of deaths due to stroke in HIC 
(Krishnamurthi et al., 2015). 
 
Figure 19 Trends in contribution to death due to ischemic and hemorrhagic stroke as a 
percentage of all conditions between developed and developing countries 
 
Source: Pooled data from the Framingham Heart Study, Atherosclerosis Risk in Communities 
Study, Cardiovascular Health Study, Multi-Ethnic Study of Atherosclerosis, Coronary Artery 
Risk Development in Young Adults, and Jackson Heart Study of the National Heart, Lung, 
and Blood Institute. 
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Figure 20 Probability of death within 1-year after first stroke 
 
Figure 21 Projected trends for stroke deaths by Word Bank income group 2002-30 
1.8.4. Disability-adjusted life years 
The measures of ill-health used so far (incidence, prevalence and mortality or years of life lost) 
do not give a complete picture of the burden of disease borne by individuals in different 
communities. DALY is the summary measure used to give an indication of overall burden of 
disease. One DALY represents the loss of the equivalent of one year of full health. Using 
DALYs, the burden of diseases that cause premature death but little disability (such as drowning 
or measles) can be compared to that of diseases that do not cause death but do cause disability 
(such as cataract causing blindness). 
DALYs for a year combine the following: 
 Years of life lost for years of life lost due to deaths in this year  
 Years lost due to disability for equivalent healthy years of life lost through living in 
states of less than full health for cases of disease and injury incident in this year.  
Stroke is a major cause of disability worldwide (Donnan et al., 2008). According to the World 
Heart Federation, stroke is the second leading cause of disability ranked after dementia (WHF, 
2017). Surviving stroke can be considered to be worse than death, with stroke victims facing 
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an uncertain future and a life that may be severely affected by disability such as loss of vision 
and/or speech, paralysis and confusion (WHF, 2017) 
According to the World Heart Federation, every year 15 million people worldwide have a 
stroke; of these, almost 6 million die and another 5 million are left with permanent disabilities 
(WHF, 2017). Stroke was the third leading cause of DALYs lost worldwide in 2012, according 
to WHO data. In all, 113 million DALYs were lost as a result of stroke in 2013 (Feigin et al., 
2015). The contribution of DALYs due to stroke as a share of all conditions rose from 3.5% to 
4.6% between 1990 and 2013 (Figure 22). The increase in the contribution of DALYs was 
largely attributable to LIMC (Feigin et al., 2015); there was no significant rise in the proportion 
of DALYs due to stroke in HIC (Krishnamurthi et al., 2015). 
 
Figure 22 Trends in contribution to DALYs due to ischemic and hemorrhagic stroke as a 
percentage of all conditions between developed and developing countries 
Stroke was among the top 18 diseases contributing to years lived with disability in 2010; of 
these 18 causes, only the age-standardized rates for stroke increased significantly between 
1990 and 2010 (P<0.05) (US Burden of Disease Collaborators, 2013). In 2010, 39.4 million 
DALYs were lost because of IS and 62.8 million because of hemorrhagic stroke (64% and 
85%, respectively, in LIMC) (Krishnamurthi et al., 2013).  The number of lost DALYs 
ranged from 398 (Australia) to 5227 (Afghanistan) per 100,000 in 2010 (Feigin et al., 2014). 
Around 78% of lost DALYs are found in LIMC (Feigin et al., 2014). 
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Medical Outcomes Short Form Health Survey (SF-12) 
The SF-12 is an abbreviated version of the SF-36. The SF-12 generates the physical and mental 
component summary (PCS and MCS, respectively) scores of the SF-36 with considerable 
accuracy, while imposing minimal burden on respondents (Ware et al., 1996). It was 
demonstrated that PCS and MCS scores of the SF-36 were replicable by the SF-12 (Pickard et 
al., 1999). 
Sickness Impact Profile (SIP) 
The SIP is a generic measure designed to subjectively evaluate the impact of illness/disease on 
physical and psychosocial functioning. The test consists of two domains (physical and 
psychosocial), twelve categories and 136 items. Physical categories include: ambulation, 
mobility, body care/movement. Psychosocial categories include: social interaction, 
communication, alertness behavior, emotional behavior, sleep and rest, eating, home 
management, recreation and pastimes, and employment. Questions are phrased in the present 
tense, and ask about how the patient is feeling at the time of test administration. Question 
responses are binary (“Yes/No”) and patients are asked to check items that apply to them 
(American Thoracic Society, 2007). The test was designed to measure the effectiveness or 
outcomes of health care (Bergner et al., 1981). Scores can be obtained for individual domains 
and categories, as well as an overall score. Items are weighted based on a standardized 
weighting method. The overall score is given as a percentage; a higher score indicates a poorer 
level of health. 
Euroqol 
Euroqol is a measurement scale which has been developed by the Euroqol group. It was created 
as a standardized generic scale used for the evaluation of patient health status and has been used 
for this objective in varying clinical populations. The Euroqol questionnaire consists of only 
six items and covers six domains (mood, mobility, daily practice, pain and discomfort, family 
and leisure activities and self-maintenance). The score for each item ranges from 1 to 3, 
whereby 1 signifies “no problems” and 3 represents “extreme problems”. In addition to this 
scale, the Euroqol uses a visual analogue scale from 0 to 100 to furnish a general estimate of 
health-related QOL, where 0 signifies “worst imaginable health” and 100 “best imaginable 
health” (Buck et al., 2000). 
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1.8.5.1.2 Stroke-specific quality of life measures 
Although stroke is a major problem, the best method for measuring the outcome of stroke is not 
clear, partly due to the heterogeneity of stroke signs and symptoms (Williams, 1998). 
Three disease-specific QOL measures were developed for the use in stroke survivors: 
The Stroke Specific Quality of Life Measure (SSQOL) 
This instrument is a tool for poststroke-specific QOL scales (Williams et al., 1999). Interviews 
with stroke patients formed the basis for 49-item and 12-domain questionnaire (Appendix 4). 
Patients must respond to each question of the SS-QOL with reference to the past week. Items 
are rated on a 5-point Likert scale. Higher scores indicate better functioning. The SS-QOL 
yields both domain scores and an overall SS-QOL summary score. The domain scores are 
unweighted averages of the associated items while the summary score is an unweighted average 
of all twelve domain scores. 
The Stroke Adapted Sickness Impact Profile (SASIP30) 
The SASIP30 was developed from the original 136-item Sickness Impact Profile (SIP-136), 
and assesses quality of life in patients who have sustained a stroke. The scale was developed 
specifically for use in stroke outcome research in order to overcome the major problem 
observed with the SIP-136, its length (van Straten et al., 1997). 
The Stroke Impact Scale (SIS) 
The Stroke Impact Scale (SIS) is a stroke-specific, self-report, health status measure. It was 
designed to assess multidimensional stroke outcomes, including strength, hand function 
Activities of Daily Living / Instrumental Activities of Daily Living (ADL/IADL), mobility, 
communication, emotion, memory and thinking, and participation. The SIS can be used both in 
clinical and in research settings. The SIS version 3.0 includes 59 items and assesses 8 domains. 
Each item is rated using a 5-point Likert scale (1 = an inability to complete the item; 5 = no 
difficulty experienced at all). An extra question on stroke recovery asks that the client rate on a 
scale from 0–100 how much the client feels that he/she has recovered from his/her stroke (0 = 
no recovery; 100 = full recovery). 
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 Around a third of stroke survivors experience some level of aphasia (Berthier, 2005; 
Dickey et al., 2010; Engelter et al., 2006). 
 Over three quarters of stroke survivors report arm weakness (Lawrence et al., 2001), 
which can make it difficult for people to carry out daily living activities.  
 Almost three quarters of stroke survivors report leg weakness (Lawrence et al., 2001), 
which can cause difficulty walking and balancing. Over half of people who have a stroke 
need help from another person to be able to walk (ISD Scotland, 2016). 
 Loss of bladder and bowel control is a common problem for stroke survivors. Around 
half of stroke survivors experience problems with bladder control (Lawrence et al., 
2001). 
 Around half of stroke survivors have problems swallowing (Lawrence et al., 2001). This 
can make eating and drinking difficult, and delays in hospital assessments for 
swallowing are associated with a higher risk of pneumonia (Bray et al., 2017). 
 Four out of 10 stroke survivors leave hospital requiring help with daily living activities 
but almost a third receive no social service visits (Royal College of Physicians SSNAP, 
2016). 
 Stroke is also a leading cause of dementia (Owolabi et al., 2015).  
Stroke is a leading cause of serious long-term disability in the US. Approximately 3% of men 
and 2% of women reported that they were disabled because of stroke (CDC, 2009). After stroke, 
women often have greater disability than men. For example, an analysis of community-living 
adults (>65 years of age) found that women were half as likely to be independent in activities 
of daily living after stroke, even after controlling for age, race, education, and marital status 
(Whitson et al., 2010). A meta-analysis of >25 studies examining sex differences in long-term 
outcomes among stroke survivors found that women tended to have worse functional recovery 
and hence greater long-term disability and handicap (Gall et al., 2012).  
1.8.7. Cost of Stroke 
Stroke is a costly disease from human, family and societal perspectives. Starting from human 
costs, stroke is the second leading cause of death worldwide, accounting for 10% of total deaths 
(Lopez et al., 2006), and a leading cause of disability (Donnan et al., 2008). Annually, about 16 
million first-ever strokes occur in the world, causing a total of 5.7 million deaths (Strong et al., 
2007). Stroke is one of the principal causes of hospital and care-home resource utilization 
(Wolfe, 2006). Despite its enormous impact on countries’ socio-economic development, this 
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growing crisis has received very little attention to date (Walter et al., 2017) and stroke research 
remains severely underfunded. There is therefore much research interest in quantifying the costs 
of stroke. 
A costing study consists of the measurement and valuation of resources related to an illness, 
under which resources consumed are measured and ascribed using a monetary value (Leal et 
al., 2006). One of the main types of costing study takes into account the costs incurred by 
patients from disease onset to end of follow-up or death, and is generally used to estimate the 
cost of a particular disease or event per patient (Payne et al., 2002).  
Cost of illness analysis is the main method of providing an overall view on the economic impact 
of a disease (Tarricone, 2006). Such studies have been used to set priorities for health care 
policies and describe resource allocations for various diseases. Results of costing studies are 
useful to inform decisions about service provision and resource allocation, and to estimate the 
cost-effectiveness of specific interventions to prevent or treat illness (Drummond et al., 2005). 
Reliable estimates of the costs of disease are also valuable to other researchers, particularly as 
an input to decision-analytic models, which are becoming ever more popular to assess the cost-
effectiveness of health care interventions. These allow synthesis of available evidence, 
including cost data, allow extrapolation of trial results, and are useful to determine cost-
effectiveness when RCTs are either too costly or inappropriate (Sculpher et al., 2006). Cost 
estimates can be derived from expert opinion or, as in most cases, from published research 
based on patient-level data (ie, observational studies or RCTs). 
Stroke costs the US an estimated US$ 34 billion each year. This total includes the cost of health 
care services, medicines to treat stroke, and missed days of work (Benjamin et al., 2017). In the 
US, the total cost of stroke in 2010 was estimated at US$ 73.7 billion by the US National Stroke 
Association; this includes the direct cost of medications to treat stroke as well as healthcare 
services, for example in hospitals or nursing homes, by physicians, home healthcare etc (making 
up more than 60% of the total costs) and indirect costs such as lost productivity (making up 
almost 40% of the total costs) (National Stroke Association, 2015). 
In Brazil, the mean total costs of initial hospitalization were US$4,101±4,254 for ICH and 
US$1,902±1,426 for IS. Aggregate national health care expenditures for acute treatment of 
incident ICH were US$ 122.4 million (range 30.8-274.2) and US$ 326.9 million for IS (range 
82.4-732.2) (Christensen et al., 2009). 
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In Argentine, the mean total costs of initial hospitalization were US$12,285±14,336 for ICH 
and US$3888±4018 for IS. Aggregate national healthcare expenditures for acute treatment of 
incident ICH were US$194.2 million (range 97.1-388.4) and US$239.9 million for IS (range 
119.9-479.7) (Christensen et al., 2009). 
In the United Kingdom, a research published in 2009 attempted to estimate the annual cost of 
stroke to the United Kingdom economy (Saka et al., 2009). The research included diagnosis, 
inpatient care and outpatient care in its estimate of direct costs; its estimate of indirect costs 
included income loss and social benefit payments to stroke survivors. In all, the research put 
the total cost of the treatment of stroke and the productivity loss arising from stroke at £ 8.9 
billion (US$ 12.9 billion) annually, with direct care accounting for around half of this amount, 
informal care costs for 27% and indirect costs for 24%. 
In Italy, one-year healthcare and societal costs amounted to €11,747 and €19,953 per stroke 
survivor, respectively. The major cost component of societal costs was informal care accounting 
for €6,656 (33.4% of total), followed by the initial hospitalisation, (€5,573; 27.9% of total), 
rehabilitation during follow up (€4,112; 20.6%), readmissions (€439) and specialist and general 
practioner visits (€326). Mean drug costs per patient over the follow-up period was about €50 
per month. Costs associated to the provision of paid and informal care followed different pattern 
and were persistent over time (ranging from €639 to €597 per month in the first and the second 
part of the year, respectively) (Fattore et al., 2012). 
In Greece, the direct in-hospital cost for all stroke cases was €1,551,445 for a total of 4674 days 
(€332 per day in-hospital). The mean in-hospital cost per stroke patient was €3625 ±2695. 
Hemorrhagic strokes were significantly more expensive than the ischemic strokes (mean 
€5305±4205 and €3214±1976, respectively) and lacunar strokes the least expensive among 
ischemic stroke subtypes (Gioldasis et al., 2008). 
In the European Union 27 countries, the annual economic cost of stroke was an estimated €27 
billion: €18.5 billion (68.5%) for direct costs and €8.5 billion (31.5%) for indirect costs. An 
additional €11.1 billion was calculated for the value of informal care (British Geriatrics Society, 
2009). In another European Union study, the financial burden of stroke was about €62 billion 
(US$70 billion) per year and accounted for around for 2-3% of the entire healthcare expenditure 
in the region (StopAfib organisation, 2012). 
In Europe, the cost of stroke was €64.1 billion €PPP 2010 (Gustavsson et al, 2011) (Figure 26) 
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Figure 26   Costs attributable to stroke in Europe in 2010. 
In Turkey, the average cost of stroke was US$1677±2964 (29.9% medicine, 19.9% laboratory, 
12.8% neuroimaging, and 38% beds and staff) (Asil et al., 2011). 
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In Pakistan, the average total cost was 70,714 rupees (US$1179) which included average 
radiology cost; 12,507 rupees (US$208), average laboratory cost; 8365 rupees (US$139), 
average pharmacy cost; 13,320 rupees (US$222) and average bed/room charges; 27,552 rupees 
(US$459) (Khealani et al., 2003). 
Strokes mainly affect individuals at the peak of their productive life (Walter et al., 2016). People 
of working age who have had a stroke are 2 to 3 times more likely to be unemployed 8 years 
after their stroke (Maaijwee et al., 2011). Around 1 in 6 stroke survivors experience a loss of 
income after stroke (McKevitt et al., 2011).  
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2. Situation in Lebanon  
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Lebanon is an Arab country of the Middle East region classified among upper-middle income 
country of the Eastern Mediterranean Region (WHO, 2015). Available studies on non 
communicable diseases have shown alarmingly high prevalence of cardiovascular risk factors 
such as hypertension 36% (Matar et al., 2015), diabetes 14% (Tohme et al., 2005), obesity 26% 
(Chamieh et al., 2015), and behavioral risk factors such as smoking (cigarettes 38.5% and 
waterpipe 22.4%) (Sibai and Hwalla, 2008) and insufficient physical activity (38%) (WHO, 
2015) among Lebanese adults. However, studies focusing on stroke in Lebanon are limited. 
The incidence rate of stroke in Lebanon has remained unstudied so far. The studies presenting 
the overall stroke prevalence rate are scarce and show a prevalence varying between 0.5% and 
3.9% (Farah et al., 2015; Jurus et al., 2009; Lahoud et al., 2016). 
A risk of stroke score (ROSS) was developed for screening individuals at risk of stroke in the 
Lebanese population. A hospital-based case-control study was conducted for the score 
generation. A score <2 points indicated a 94.4% high negative predictive value of stroke. A 
score >10 points had more than 85.4% positive predictive value of stroke (El-Hajj et al., 2018a).  
A diagnosis score for stroke (DS-stroke) at emergency among the Lebanese population by using 
stroke risk factors and symptoms was developed in order to diagnose stroke patients at 
emergency department. A hospital-based case-control study was conducted for the score 
generation. A score <4 points indicated a high negative predictive value of stroke of 97.3%. A 
score ≥4 points indicated a positive predictive value of stroke of 91.3% (El-Hajj et al., 2018b).  
A national epidemiological study assessed the association between self-reported indoor and 
outdoor pollution and stroke and mini-stroke in Lebanon (Salameh et al., 2018). 
A retrospective study evaluate the existence of genetic mutation (MTHFR and Factor V gene 
mutations) in different types of cerebral strokes in previously healthy young adults (Araji et al., 
2014). 
A retrospective study analyzed the prevalence of all hemorrhagic stroke and ischemic stroke 
subtypes in a Lebanese hospital-based inpatient population. Ischemic stroke subtypes were 
further categorized according to TOAST (Trial of Org 10172 in Acute Stroke Treatment) 
classification (Adams et al., 1993) and their correlations with validated stroke risk factors and 
with socio-demographic characteristics of the sample were evaluated (Lahoud et al., 2017). 
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Moreover, stroke is the second leading cause of death in Lebanon after ischemic heart disease, 
killing 2000 people in 2012 (9.4% of total death) (WHO, 2015). It is furthermore a major 
leading cause of permanent disability among adults (WHO, 2015). However, the country lacks 
organized stroke units which makes the status of acute care unclear and questionable. Thus, the 
current situation in the country urges the need to initiate epidemiological studies to assess stroke 
care and post-stroke outcomes (mortality, disability, QOL, etc.). Predictors of in-hospital death 
may also be of a major importance in improving stroke management and prognosis. One 
retrospective hospital-based study assessed acute stroke care and discharge outcome (Lahoud 
et al., 2018). Another retrospective study examined patient characteristics and outcomes in 
addition to barriers to rt-PA utilization in a tertiary care center in Beirut, Lebanon (El Sayed et 
al., 2014). A hospital-based study evaluated the benefits and impact of ICU therapeutic 
interventions on the survival and functional ability of severe stroke patients (Riachy et al., 
2008).  
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3. Objectives 
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Despite stroke high burden in Lebanon, national epidemiological, clinical and socio-economic 
data on stroke are rare and incomplete in Lebanon, especially prospective ones. Therefore we 
decided to conduct a multicenter prostective medico-economic cohort study of stroke 
management in Lebanon. 
 
The aims of this thesis were: 
- To assess the current practices of doctors in Lebanon routinely involved in stroke 
treatment (AIS management). 
- To estimate the financial and economic direct in-hospital costs of acute stroke care in 
Lebanese stroke hospitalized patients (room and board, laboratory, general exams, 
physicians, drugs, rehabilitation therapy, etc.) from a societal point of view using a 
buttom-up approach (COI analysis) and to evaluated cost drivers. 
- To determine the QOL of stroke patients one year after the stroke incidence and its 
determinants. 
- To compare the results of a generic (SF-36) and specific (SS-QOL) questionnaire tool. 
- To determine the post-stroke depression rate (using the GDS-15) and its determinants. 
- To calculate the one month and one year survival rates post-stroke and identify mortality 
predictors. 
 
These objectives were distributed over 4 scientific papers: 
1- Risk factors and Acute Ischemic Stroke Management in Lebanon: Obstacles and 
Solutions. 
2- Mortality and predictors of death post stroke: Data from a multicenter prospective 
cohort of Lebanese stroke patients. 
3- Quality of life of 1-year stroke survivors and its predictors: a multicenter prostective 
cohort study. 
4- Direct medical cost of hospitalization for acute stroke in Lebanon: a prospective 
incidence-based multicenter cost-of-illness study. 
 
The meeting of these objectives lead to the main objective of any epidemiological study: to 
better understand and predict the evolution of a disease and its risk factors in order to improve 
its primary and secondary prevention and limit its physical / psychic / socio-economic impact 
on the population.  
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4. Studies 
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Stroke units are not yet implemented and studies assessing acute stroke care in Lebanon are 
lacking. Thus, the first study was conducted to assess the current practices of doctors in acute 
stroke care and treatment in Lebanese hospitals. 
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Abstract 
Background and Aim 
Management of acute stroke varies greatly within and between different countries. This study 
assesses the current practices of doctors in Lebanon routinely involved in stroke treatment. 
Methods 
We conducted a prospective observational study that included patients who were hospitalized 
from August 1, 2015 to July 31, 2016, from 8 different Lebanese hospitals with a diagnosis of 
acute stroke. Baseline characteristics, diagnostic studies, treatments during hospitalization and 
at discharge were collected and analyzed.  
Results 
Two hundred and three strokes were recorded and only one hundred seventy three patients 
(85%) with ischemic event have been included in the study. The mean age was 69.8±12.7 years. 
All of the patients had brain imaging (CT scan and or MRI) at admission. All ischemic strokes 
were managed by neurologist and had a cardiologist consultation.  
Hypertension was the most prevalent risk factor (78.6%), followed by current cigarette smoking 
habit (50.3%), diabetes mellitus (42.8%), hypercholesterolemia (39.9%), previous stroke or 
TIA (17.3%) and atrial fibrillation (14.7%). 
Only 4 patients (2.5% of ischemic strokes) received thrombolytic therapy. More than 89% of 
patients were discharged on at least one anti-hypertensive drug, 89.2% on statin and 37.6% on 
anti-diabetic medications. 
Conclusion 
There are many challenges as well as potentials improvement of stroke care in Lebanon. 
Reperfusion therapy are still largely underused and remains a major challenge in achieving 
guideline-based reperfusion goals. 
Keywords: Ischemic Stroke; management; Lebanon, cardiovascular risk factors 
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Introduction 
Stroke is a leading cause of death worldwide and continues to cast serious disability on the 
individual making stroke an important cause of morbidity (1). It constitutes a serious public 
health problembecause stroke, not only affects the victim but also their caregivers, family, and 
the whole society (2). 
In most developed countries, the incidence of stroke is declining perhaps due to better 
understanding and awareness of its risk factors, but there is also an increase in percentage of 
survivors of stroke due to a better management of acute stroke and to advances in medical 
technology and reperfusion therapy in the last decade (3). In fact, prompt and efficacious 
management of acute stroke is probably the most important determinant of patient outcome as 
new ideas appear for acute treatment, rehabilitation and secondary prevention (4,5). Therefore, 
therapeutic nihilism is no longer justified. 
Local literature on stroke management published from Lebanon is scarce and not exactly 
known. The objective of this study is to present the current acute ischemic stroke management 
in Lebanon, in juxtaposition to that of the developed countries. This will help to find lacunae 
in management and aid in correction of those lacunae to improve patient care, and thereby 
improve the patient outcomes in acute stroke management. We also intend to highlight areas 
for future development and improvement in management. 
Methods 
This prospective study was conducted in 8 different hospitals in Beirut, over a period of 1-year 
after approval from the Institutional Ethics Committee. Participants (or their responsible 
caregivers where not possible) provided written informed consent. 
All acute stroke patients over the age of 18 years admitted to each participating hospital from 
August 2015 with confirmed diagnosis of stroke (confirmed by a neurologist with radiological 
evidence by either CT scan and/or MRI) were recruited. 
Patients who did not want to be the part of the study (negative consent), or those who had a 
stroke of more than one week were excluded. Patients were also excluded if they were suffering 
from severe pathologies (cancer, fatal renal, hepatic or respiratory insufficiency), or having a 
moderate to severe cognitive decline before their stroke. 
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When a patient confirmed to be a candidate in our study inclusion criteria, the prime investigator 
(R.A.) was contacted and took responsibility of taking consent, filling up the study proforma, 
and interviewing the patient.  
Study tools 
Stroke was defined according to the International Classification of Diseases (10th revision) and 
Transient Ischemic Attack (TIA) was defined as a brief episode of neurologic dysfunction 
resulting from focal temporary cerebral ischemia and not associated with cerebral infarction 
(6). 
A structured data form including demographics, characteristics, and diagnostic tests performed 
was completed for all patients.  
At presentation, standardized clinical quantification and assessment of the extent of stroke was 
done using the National Institute of Health Stroke Scale (NIHSS) (7). Stroke severity was 
classified as no stroke symptoms (score of 0), mild (score of 1 to 4), moderate (score of 5 to 
14), moderate/severe (score of 15 to 20) and severe (score of ≥21). 
Clinical classification of the ischemic stroke was assessed using the Oxfordshire Community 
Stroke Project (Bamford classification) (8), and clinical outcome was assessed using modified 
Rankin Scale (mRS) and Bathel Index (BI) (9). 
Patients were classified into 3 groups according to mRS (Independent [0 to 2 points], dependent 
[3 to 5 points] and dead [6 points]) and to four groups according to BI (Independent [96-100], 
mild dependence [75-95], moderate dependence [46-74] and severe dependence [0-45]) (10).  
Stroke etiology was classified using the Trial of Org 10172 in Acute Stroke Treatment 
(TOAST) criteria (11). 
Risk factors assessment 
The presence of a previous stroke or a concurrent medical illness was determined by history, 
physical examination and review of medical records. 
Hypertension, diabetesmellitus (type 1 or 2) and dyslipidemia were defined by the use of 
medications for these conditions at the time of study enrolment or at hospital discharge. 
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Atrial fibrillation (AF) was defined as reported by the respondent or diagnosed by ECG during 
hospitalisation. Current smokers were defined as persons who reported smoking at least 100 
cigarettes during their lifetime and who, at the time they participated in the study, reported 
smoking every day or some days. Former smokers were defined as those who have smoked at 
least 100 cigarettes in their lifetime but who have quit smoking since a minimum of 28 days. A 
researcher pharmacist did the data collection (12). 
Education level and monthly home income, were used as indicators of Socio-Economic Status 
(SES). Health insurance status was classified as public health insurance and private health 
insurance.  
Outcomes analyzed include in hospital mortality (excluding patients who transferred out or left 
against medical advice), ambulatory status at discharge, mRS at discharge, and discharge 
destination.  
Statistical analysis 
Data were entered and analyzed using Statistical Package for the Social Sciences (SPSS), 
version 20.0 (IBM Corporation, Armonk, NY, USA). Two researchers audited 5% randomly 
selected questionnaires. Data entry showed high reliability (error rate <1%). Data were 
presented as means±SDs or as percentages. Student’s test for means comparison between two 
groups (for quantitative variables) and Chi-square test (or exact Fisher) for comparing 
percentages (for nominal, ordinal and categorical variables) were used. Differences in treatment 
variables at admission and at discharge between survivors were assessed using McNemar (or 
exact McNemar). P ≤0.05 indicated statistical significance.  
Results 
Table 1 shows comparisons of socio demographic/clinical variables in the study (ischemic 
stroke (IS) vs TIA). 
Out of 203 recorded strokes, only one hundred seventy three patients with acute ischemic stroke 
or TIA were included in this study. The mean age of the study group was 69.8±12.7 years (IS 
group was 70.3±12.3 while that of the TIA group was 62.3±16.0 years, and the difference was 
significant (P = 0.035)). There were more males than females (60.1%). Hypertension was the 
most prevalent risk factor (78.6%), followed by current cigarette smoking habit (50.3%), 
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diabetes mellitus (42.8%), hypercholesterolemia (39.9%), previous stroke or TIA (17.3%) and 
atrial fibrillation (14.7%). There was no significant difference between the IS group and TIA 
group except for hypertension and dyslipidemia. Around 80% of the population had a public 
insurance, 20% were illiterate and more than 60% had a monthly home income less than 1,000 
USD. No significant difference was detected between the IS group and TIA group. 
Clinical outcomes 
Assessment of stroke severity and disability were carried out using NIHSS at presentation and 
mRS at discharge respectively (Supplementary file). The mean NIHSS score and mRS were 
9.3±8.6 and 3.3±2.0 respectively. TIA patients had significantly low scores compared to 
ischemic stroke patients (P<0.001). The mean Barthel index were (39.6±39.8) and (61.6±38.1) 
at admission and at discharge respectively. TIA patients had significantly higher scores 
compared to ischemic stroke patients (P<0.001) (Supplementary file). Hospital length of stay 
in TIA patients was significantly lower than that of ischemic stroke patients, so was the 
percentage of intensive care unit admission (P<0.001 for both). Around 80% of patients were 
discharged home (100% for TIA patients vs. 78% for ischemic stroke patients P<0.001) (Figure 
1).  
Diagnostic tests and medical consultations 
All ischemic strokes were managed by neurologist and had a cardiologist consultation. Around 
84% of diabetic patients had an endocrinologist consult and around 26% of stroke patients were 
seen by a physical medicine and rehabilitation.  
Cardiac evaluation, brain imaging and cervical vessels studies are shown in Table 2. Brain 
imaging (CT and/or MRI), brain vessels imaging (CT angiography and/or MRA) and cervical 
vessels imaging (carotid arteries CT angiography and/or cervical MRA and/or carotid duplex 
scanning) were done in 100%, 26.6% and 90.2% respectively. 
ECG was done for all of patients however only 22.0% of them had a 24-hour (Holter) ECG 
monitoring done. Almost 95% of patients had a TTE done and 9% of them had a TEE done 
(Table 2). 
Lipid panel was done for half of the patients. No significant difference was detected between 
the IS group and TIA group regarding diagnostic tests performed and medical consultation in 
patients. Only 2.5% of ischemic stroke patients had a venous thrombolytic therapy (Table 2).  
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Exactly 28% of ischemic stroke patients (around 40% of patients with left and/or right arm 
and/or leg weakness) received in-hospital physical rehabilitation by a physiotherapist (Table 
2). Only one (1.6%) of the 62 (38.5%) aphasic patients had a speech therapy specialist visit. 
Treatments 
Comparing treatment prior to the ictus and at discharge we found overall 47.9 % were taking 
antiplatelet drugs, 14.5% anticoagulants, 39.9 % statins and 78.6% antihypertensive prior to the 
ictus and 73.5 %, 32.4 %, 89.2 % and 89.2% respectively at discharge (P<0.001) (Table 3). 
Insurance status and SES influence on diagnostic tests performed and medical consultations 
When comparing stroke management between public and private Third Party Payer (TPP), no 
statistical significance was detected except for the 24-hour (Holter) ECG monitoring. Around 
40% of patients with private TPP had the 24-hour (Holter) ECG monitoring done vs. 18% only 
for public TPP (P=0.01) (Table 4). 
Incomplete and negative evaluation on TOAST classification 
When comparing stroke management between SES, low and middle SES patients had more 
brain CT done compared to high SES patients (P=0.020), these latter had more brain MRI done 
but the difference tended to be significant (P=0.063). However, middle and high SES had 
significantly more brain MRA done (P=0.005) (Table 4). 
All patients with incomplete evaluation on TOAST classification (n=23) had neurologist and 
cardiologist consults and a brain CT and/or MRI and ECG done. Cervical MRA and/or carotid 
duplex scanning and TTE (with or without TEE), were done in 91.3% (n=21) and 95.7% (n=22) 
respectively. However, 24-hour (Holter) ECG monitoring wasn't done to any of the 23 patients. 
All patients with negative evaluation on TOAST classification (n=17) had neurologist and 
cardiologist consults and a brain CT and/or MRI, ECG, 24-hour (Halter) ECG monitoring, 
cervical MRA and/or carotid duplex scanning and TTE (with or without TEE) done. 
Discussion 
The current study conducted on 173 patients presented with acute ischemic stroke or TIA 
provides a unique opportunity to study risk factors, and acute management of stroke in Lebanon. 
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The mean age of our patient population was around 70 years, which is compared with European 
registries and markedly higher compared with Middle East where clinical series showed a mean 
age of stroke within the sixth and seventh decade (14). Furthermore, as could be expected this 
study showed higher male prevalence (60%) than females in ischemic stroke. This higher 
prevalence can be explained by the hormonal constitutional factors, the higher rate of smoking 
and modifiable risk factors in men and a higher rate of stressful situations among males than 
females (15). 
Among the modifiable risk factors, arterial hypertension is considered the most important for 
cerebrovascular accident and is one of the most prevalent cardiovascular risk factors. In fact, 
the risk for stroke increases progressively with incremental increases in blood pressure as 
shown in numerous epidemiologic studies (16,17). In the present study, hypertension was the 
most common risk factor for ischemic stroke, which was detected in 78 % of all studied cases 
which is slightly higher than the prevalence reported in several studies from Arab and European 
countries (15,18,19). 
In our study, diabetes mellitus was recorded in 42% of patients. It is slightly lower than the 
prevalence reported in different Arab countries where diabetes mellitus was recorded in 55 % 
of patients (14) and slightly higher than in several occidental countries (15,19). 
Smoking was recorded in mostly half of the patients and dyslipidemia in 40% of all patients 
which is higher than those reported from other studies from the region (15) and from low to 
middle income countries (20). Even though most people who smoke are aware that smoking 
damage health, lack of awareness campaigns and programmes towards the dangers of smoking 
on vessels in our country explain this high smoking rate in our study. 
Our study showed that, the diagnostic approach to acute stroke in Lebanon was consistent with 
international recommendations (13). In fact, all stroke patients (100%) had documented brain 
imaging during their hospital stay within 24h and 75% of them had a brain MRI, which confirm 
the diagnosis of ischemic stroke vs. TIA. Severe stroke and agitation were the most frequent 
reason for not doing MRI. Unfortunately, the registry did not collect the exact timing of patients 
presentation to the emergency room and CT scans, thus we were unable to determine the 
proportion of patients scanned within 0–4.5h of symptom onset. However we believe that there 
is a delayed hospital presentation for stroke patients which explain in part the small percentage 
of patients treated with venous thrombolytic in our study (2.5%). In addition, lack of public 
awareness and knowledge about stroke symptoms and the absence of an organized and 
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comprehensive stroke program in the Lebanese hospitals are the biggest obstacles to receiving 
proper acute stroke treatment. 
During the study period, a high percentage of patients were documented as having received 
cardiac work up, cervical vessels imaging and the specialist consultations recommended by 
several international practice guidelines as part of routine ischemic stroke care (21).   
Even though all patients with incomplete evaluation on TOAST classification had an ECG 
done, none of them did 24-hour Holter monitoring. The ideal method for the determination of 
AF, a risk factor for ischemic stroke or TIAs (22), in patients with stroke is not known (23). A 
single ECG recording upon presentation with stroke was shown to detect a new diagnosis of 
AF in 2% to 3% of patients (24). Holter monitoring has been used in several stroke units to 
identify potentially underdiagnosed AF. It has been suggested that every additional 24 hours of 
monitoring detects previously undiagnosed AF in an additional 2% to 4% of patients (24). 
However, a very high percentage of asymptomatic patients remain undiagnosed leading to a 
potential risk of thromboembolism (25). Considering that a significant risk reduction can be 
achieved by oral anticoagulants, identifying AF is clinically relevant (26).  
For patients with a negative evaluation on TOAST classification, prolonged rhythm monitoring 
(in addition to Holter) might detect a cardioembolic cause and reduce this number. In fact, it 
was shown to be useful for the detection of AF after cryptogenic stroke (27,28). This suggests 
a substantial number of undiagnosed patients despite screening by 24-hour Holter monitoring. 
Furthermore, a review found that 24- to 72- hour Holter monitoring detected 4.6% of 
consecutive patients with IS (29). Prolonging to 72- hour Holter monitoring might detect more 
AF stroke etiology.  
In addition, numerous studies have indicated that health insurance can reduce disparities in 
access to care and health outcomes (30,31). Studies have also reported that insurance status and 
lower SES are independent indicators of stroke outcome (32,33). We did not find any relation 
between insurance status and the management of stroke except that private TPP had higher 
number of 24-hour (Holter) ECG monitoring. Only higher SES was positively correlated to a 
higher number of MRI. These findings might be partly explained by the fact that our study was 
done in Beirut (urban area) and it is known that rural populations have lower access to 
healthcare and a higher economic burden than urban residents. 
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Finally, in line with several studies (34-36) and in accordance with international 
recommendations (6), we found a high percentage of medication prescriptions for our patients 
at discharge regarding the control of their modifiable risk factors including blood pressure, 
diabetes mellitus, dyslipidemia, antiplatelet and anticoagulant prescription. 
The small sample size in this study is a major limitation. It is however important to mention 
that all stroke patients during the study period were approached and more than 90% of them 
participated to the study. Another limitation of this study is that it was conducted only in Beirut. 
Therefore, some of our results may not be generalizable to other regions of Lebanon. A larger 
multicenter study covering the whole geographic area of Lebanon is recommended. However, 
despite these limitations, this study produced important epidemiological data regarding stroke 
patient’s risk factor and acute stroke management. 
Conclusion  
Despite overall good adherence to diagnostic evidence-based and clinical practice guidelines 
reperfusion therapy are still largely underused and remains a major challenge in achieving 
guideline-based reperfusion goals. It is therefore essential that patients be aware of the 
symptoms of stroke, as well as the importance of presenting immediately to a medical facility 
from the time of symptom onset for evaluation and subsequent rapid and appropriate 
management.  
The implementation of stroke unit at the hospitals, as well as stroke management protocols, will 
be important steps toward improving the standard of care.  
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Table 1:  Demographics and risk factors 
 Both IS+TIA 
(n=173;100%) 
IS 
(n=161;93.1%) 
TIA 
(n=12;6.9%) 
P-value 
Age (mean±SD) 69.8±12.7 70.3±12.3 62.3±16.0 0.035 
Gender–Male (n (%)) 104(60.1%) 96(59.6%) 8(66.7%) 
NS 
 
Risk factors     
-Hypertension 136(78.6%) 126(78.3%) 10(83.3%) 0.020 
-Dyslipidemia 69(39.9%) 60(37.3%) 9(75.0%) 0.014 
-Diabetes Mellitus 74(42.8%) 70(43.5%) 4(33.3%) NS 
-Atrial Fibrillation 25(14.5%) 22(13.7%) 3(25.0%) NS 
-Smoker    NS* 
▪ former smoker 27(15.6%) 24(14.9%) 3(25.0%)  
▪current smoker 87(50.3%) 82(50.9%) 5(41.7%)  
Previous stroke/TIA 30(17.3%) 29(18.0%) 1(8.3%) NS 
TPP    NS 
Public 140(80.9%) 129(80.1%) 11(91.7%)  
Private 33(19.1%) 32(19.9%) 1(8.3%)  
Education    NS* 
Illiterate 35(20.2%) 34(21.1%) 1(8.3%)  
Elementary 71(41.0%) 67(41.6%) 4(33.3%)  
Secondary 31(17.9%) 27(16.8%) 4(33.3%)  
≥High school 36(20.8%) 33(20.5%) 3(25.0%)  
Monthly home income (USD)    NS* 
<500  54(31.2%) 52(32.3%) 2(16.7%)  
[500-1,000[ 53(30.6%) 48(29.8%) 5(41.7%)  
[1,000-1,500] 28(16.2%) 26(16.1%) 2(16.7%)  
>1,500 38(22.0%) 35(21.7%) 3(25.0%)  
*Non parametric tests used. 
IS= ischemic stroke; TIA= transient ischemic attack; TPP= third party payer. 
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Supplementary file  
 Both IS+TIA 
 (n=173;100%) 
IS 
(n=161;93.1%) 
TIA 
(n=12;6.9%) 
P-value 
NIHSS on admission 9.3±8.6 10.0±8.6 0.7±1.0 <0.001 
No stroke symptom 10(5.8%) 3(1.9%) 7(58.3%) 
<0.001* 
Minor stroke 59(34.1%) 54(33.5%) 5(41.7%) 
Moderate stroke 63(36.4%) 63(39.1%) 0(0.0%) 
Moderate/severe stroke 17(9.8%) 17(10.6%) 0(0.0%) 
Severe stroke 24(13.9%) 24(14.9%) 0(0.0%) 
BI at admission 39.6±39.8 36.9±39.3 77.1±25.4 <0.001 
LOS 9.4±8.7 9.9±8.8 3.4±1.6 <0.001 
ICU admission 79(45.7%) 78(48.4%) 1(8.3%) <0.001 
ICU LOS 3.3±6.6 3.6±6.8 0.2±0.6 <0.001 
mRS at discharge 3.3±2.0 3.5±1.9 0.6±0.9 <0.001 
No symptoms 22(12.7%) 15(9.3%) 7(58.3%) 
<0.001* 
No significant disability 24(13.9%) 20(12.4%) 4(33.3%) 
Slight disability 11(6.4%) 11(6.8%) 0(0.0%) 
Moderate disability 26(15.0%) 25(15.5%) 1(8.3%) 
Moderate severe disability 27(15.6%) 27(16.8%) 0(0.0%) 
Severe disability 43(24.9%) 43(26.7%) 0(0.0%) 
Dead 20(11.6%) 20(12.4%) 0(0.0%) 
BI at discharge 61.6±38.1 58.5±38.1 97.9±4.5 <0.001 
Independence 46(26.6%) 37(26.2%) 9(75.0%) 
<0.001* 
Mild dependence 30(17.3%) 27(19.1%) 3(25.0%) 
Moderate dependence 26(15.0%) 26(18.4%) 0(0.0%) 
Severe dependence 51(29.5%) 51(36.2%) 0(0.0%) 
Discharge destination    <0.001* 
Home 68(39.3%) 56(34.8%) 12(100%)  
Home with help 69(39.9%) 69(42.9%) 0(0%)  
Rehabilitation center/ 
Nursing home 
16(9.2%) 16(9.9%) 0(0%)  
Death 20(11.6%) 20(12.4%) 0(0%)  
TOAST classification    0.014 
LA 37(21.4%) 36(22.4%) 1(8.3%)  
CE 55(31.8%) 53(32.9%) 2(16.7%)  
SV 27(15.6%) 27(16.8%) 0(0%)  
UC 54(31.2%) 45(27.9%) 9(75.0%) 0.017* 
- Rare other causes 1 (0.6%) 1 (0.6%) 0 (0%)  
- ≥ 2 causes 4 (2.3%) 4 (2.5%) 0 (0%)  
- NE 19 (11.0%) 17 (10.6%) 2 (16.7%)  
- IE 30 (17.3%) 23 (14.3%) 7 (58.3%)  
*Non parametric tests used.  
(mean±SD) 
IS= ischemic stroke; TIA= transient ischemic attack; LOS= length of stay; ICU= intensive care unit; 
NIHSS= National Institution of Health Stroke Scale; mRS= modified Rankin Scale; BI= Barthel 
Index; TOAST= Trial of Org 10172 in Acute Stroke Treatment; LA= large-artery atherosclerosis; CE= 
cardioembolism; SV= small-vessel occlusion; UC= unclassified; NE= negative evaluation; IE= 
incomplete evaluation 
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Table 2:  Diagnostic tests performed and medical consultation in patients with ischemic event 
 
 Both IS+TIA 
 (n=173;100%) 
IS 
(n=161;93.1%) 
TIA 
(n=12;6.9%) 
P-value 
Brain imaging  
(CT and/or MRI) 
173(100%) 161(100%) 12(100%) NS 
•Brain CT 138(79.8%) 130(80.7%) 8(66.7%) NS 
•Brain MRI  135(75.0%) 126(78.3%) 9(75.0%) NS 
Brain vessels imaging 46(26.6%) 43(26.7%) 3(25.0%) NS 
•Brain CT angiography 5(2.9%) 5(3.1%) 0(0.0%) NS* 
•Brain MRA 44(25.4%) 41(25.5%) 3(25.0%) NS 
Cervical vessels imaging 150(86.7%) 138(85.7%) 12(100%) NS 
•Carotidarteries CT 
angiography 
5(2.9%) 5(3.1%) 0(0.0%) NS* 
•Cervical MRA 16(9.2%) 16(9.9%) 0(0.0%) NS* 
•Carotid duplex scanning 145(83.8%) 133(82.6%) 12(100%) NS 
TEE 15(8.7%) 14(8.7%) 1(8.3%) NS 
TTE 164(94.8%) 153(95.0%) 11(91.7%) NS 
ECG 171(98.8%) 159(98.8%) 12(100%) NS* 
Lipid panel 88(50.9%) 84(52.2%) 4(33.3%) NS 
24-hour Holter monitoring 38(22.0%) 37(23.0%) 1(8.3%) NS 
Physical rehabilitation 45(26.0%) 45(28.0%) 0(0.0%) 0.033 
Neurologist 172(99.4%) 161(100%) 11(91.7%) NS* 
Cardiologist 171(98.8%) 160(99.4%) 11(91.7%) NS* 
Endocrinologist 43(24.9%) 41(25.5%) 2(16.7%) NS 
Thrombolytic therapy - 4(2.5%) - - 
*Non parametric tests used. 
IS= ischemic stroke; TIA= transient ischemic attack. 
Table 3:  Treatments at admission and at discharge  
 All 
(n=173;100%) 
IS 
(n=161;93.1%) 
 Admission Discharge P-value Admission Discharge P-value 
HT therapy 136(78.6%) 132(89.2%) <0.001 126(78.3%) 122(89.7%) <0.001 
DL therapy 69(39.9%) 132(89.2%) <0.001 60(37.3%) 123(90.4%) <0.001 
DM therapy 74(42.8%) 56(37.6%) NS (0.065) 70(43.5%) 53(38.7%) NS 
AP therapy 79(47.9%) 108(73.5%) <0.001 75(48.7%) 100(74.1%) <0.001 
AF therapy 25(14.5%) 48(32.4%) <0.001 22(13.7%) 45(33.1%) <0.001 
AD therapy 21(12.1%) 14(9.5%) NS 20(12.4%) 13(9.6%) NS 
HT= hypertension; DL= dyslipidemia; DM= diabetes mellitus; AP= antiplatelet; AF= atrial 
fibrillation; AD = antidepression. 
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Table 4:  Diagnostic tests performed and medical consultations by insurance status and SES 
 Both IS+TIA 
(n=173;100%) 
 TPP SES (USD) 
 
Private 
33(19.1%) 
Public 
140(80.9%) 
P-value <500 
54(31.2%) 
[500-1000[ 
53(30.6%) 
[1000-1500[ 
28(16.2%) 
≥1500 
38(22.0%) 
P-value 
Brain CT 23(69.7%) 115(82.1%) NS 43(79.6%) 47(88.7%) 24(85.7%) 24(63.2%) 0.020 
Brain MRI         
 -With contrast 2(6.1%) 22(15.7%) NS 9(16.7%) 8(15.1%) 2(7.1%) 5(13.2%) NS 
 -Without contrast 27(81.8%) 108(77.1%) NS 43(79.6%) 37(69.8%) 20(71.4%) 35(92.1%) NS (0.063) 
Brain MRA 8(24.2%) 36(25.7%) NS 9(16.7%) 8(15.1%) 14(50.0%) 13(34.2%) 0.001 
Cervical MRA 4(12.1%) 12(8.6%) NS 5(9.3%) 3(5.7%) 3(10.7%) 5(13.2%) NS* 
Carotid duplex 
scanning 
29(87.9%) 116(82.9%) NS 47(87.0%) 47(88.7%) 26(92.9%) 31(81.6%) NS 
TEE 4(12.1%) 11(7.9%) NS 3(5.6%) 4(7.5%) 3(10.7%) 5(13.2%) NS* 
TTE 32(97.0%) 132(94.3%) NS 52(96.3%) 51(96.2%) 26(92.9%) 35(92.1%) NS* 
ECG 33(100%) 138(98.6%) NS* 54(100%) 53(100%) 28(100%) 38(100%) NS* 
Lipid panel 18(54.5%) 70(50.0%) NS 27(50.0%) 30(56.6%) 13(46.4%) 18(47.4%) NS 
24-hour Holter 13(39.4%) 25(17.9%) 0.010 10(18.5%) 14(26.4%) 5(17.9%) 9(23.7%) NS 
Neurologist 33(100%) 139(99.3%) NS* 55(100%) 52(98.1%) 28(100%) 38(100%) NS* 
Cardiologist 32(97.0%) 139(99.3%) NS* 54(100%) 52(98.1%) 28(100%) 37(97.4%) NS* 
Endocrinologist 6(24.9%) 37(26.4%) NS 9(16.7%) 13(24.5%) 8(28.6%) 13(34.2%) NS 
*Non parametric tests used. 
IS= ischemic stroke; TIA= transient ischemic attack; TPP= third party payer; SES= socioeconomic status 
 
 142 
 
Figure 1:  Discharge mode/destination 
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The first study sheds the light on the critical situation of acute stroke care in Lebanese hospitals, 
and the need to implement organized stroke units to improve stroke patients’ acute 
management. Public awareness campaigns on stroke symptoms, risk factors and the time-
depending nature of the disease may help patients arrive earlier to hospitals, before severe brain 
damage occurs. The current situation in the country urges the need to initiate epidemiological 
studies to assess post-stroke outcomes. Predictors of short-term and long-term mortality may 
also be of a major importance in improving stroke management and prognosis. Therefore, the 
second study was conducted to examine mortality rates during the first year after acute stroke 
and the major short-term (1-month) and long-term (1-year) mortality predictors. 
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Abstract 
Background: Despite efforts to reduce stroke mortality rates, the disease remains a leading 
cause of death in Lebanon highlighting the importance of understanding risk factors and 
subsequent mortality. We examined mortality rates during the first year after acute stroke and 
the major short-term (1-month) and long-term (1-year) mortality predictors. 
Methods: Data were collected prospectively on hospitalized stroke patients from eight 
hospitals in Beirut during a 1-year period. Patients were followed up for 1-year or until death. 
Mortality rates were assessed at 1-month and at 1-year post stroke and predictors of death were 
evaluated using Cox proportional hazard model.  
Results: A total of 203 stroke patients were included. Survival data were completed for over 
97% of patients. Cumulative mortality rates were 13.3% at 1-month and 21.2% at 1-year. 
Predictors of short-term and long-term mortality in univariate analysis were low socioeconomic 
status, intensive care unit admission, decreased level of consciousness, stroke severity and 
presence of complications. Marital status also predicted short-term mortality, while age >64 
years and surgery need were also long-term mortality predictors. In multivariate analysis, stroke 
severity and presence of complications were predictors of death at 1-month and at 1-year. Low 
socioeconomic status, dependency in daily living activities, and the presence of co-morbidities 
were additional predictors of 1-year mortality. 
Conclusion: Approximately one over five of patients did not survive 1-year after stroke. There 
is a need for aggressive intervention to improve stroke knowledge, warning and prevention 
which may reduce this high stroke mortality rate in Lebanon. 
Keywords: Stroke; mortality; predictors; short-term; long-term; Lebanon 
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Introduction 
Stroke is the third leading cause of death(1) with an annual 6 million fatal events worldwide.(2) 
Most of these stroke deaths are found in the developing countries and account for as much as 
87% of all the stroke deaths.(3) 
According to the WHO, 15 million people suffer stroke worldwide each year. Of these, 5 
million die, and another 5 million are left permanently disabled.(4) 
The prognosis after acute stroke varies greatly in individual patients, depending on stroke 
severity, stroke characteristics (location and size) and on the patient's premorbid condition, age 
and post-stroke complications.(5) In fact, post-stroke complication is a leading cause of death 
accounting for 23–50% of total deaths in patients with ischemic stroke.(6) 
Stroke mortality is an important outcome measure in stroke epidemiology studies and clinical 
trials, and data on stroke mortality are critical for monitoring disease trends and planning public 
health interventions. Furthermore, identifying predictors of mortality after acute stroke is of 
paramount importance for clinicians, so that specific therapies and management strategies can 
be applied to patients at high risk of dying with a consequent reduction in stroke mortality and 
disability. 
There is paucity in literature in regards to the data about stroke mortality due to a lack of studies 
in Lebanon.(7) The aim of this study was to investigate the stroke mortality rates and examine 
its major potential predictors of short-term and long-term mortality in a multicenter hospital-
based cohort of Lebanese stroke patients.   
Methods 
The ethical committees of all the participating hospitals approved the study. Participants (or 
their responsible caregivers where not possible) provided written informed consent. 
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Study design 
Stroke patients aged ≥18 years, admitted during 1-year period from August 2015 in 8 different 
hospitals in Beirut were included prospectively in this study and followed up for one year or 
until death. Stroke was defined according to the International Classification of Diseases (10th 
revision) including subarachnoid hemorrhage, intracerebral hemorrhage and cerebral 
infarction; Transient Ischemic Attack (TIA) was defined as a brief episode of neurologic 
dysfunction resulting from focal temporary cerebral ischemia and not associated with cerebral 
infarction.(8) Patients admitted after seven days of symptoms onset or those who had difficulty 
accepting follow-up visits were excluded. Patients were also excluded if they were suffering 
from severe pathologies with unfavorable 1-year prognosis (cancer, fatal renal, hepatic or 
respiratory insufficiency), or having a moderate to severe cognitive decline before their stroke. 
Study tools 
A structured data form including demographics, characteristics, and diagnostic tests performed 
was completed for all patients. Stroke severity on admission was assessed with the National 
Institute of Health Stroke Scale (NIHSS)(9) and classified as no stroke symptoms (score of 0), 
mild (score of 1 to 4), moderate (score of 5 to 14), moderate/severe (score of 15–20) and severe 
(score of ≥21). Clinical classification of the ischemic stroke was assessed using the Oxfordshire 
Community Stroke Project (Bamford classification)(10), and clinical outcome was assessed 
using modified Rankin Scale (mRS).(11) Patients were classified into 3 groups according to mRS 
(Independent [0 to 2 points], dependent [3 to 5 points] and dead [6 points]) and to four groups 
according to BI (Independent [96-100], mild dependence [75-95], moderate dependence [46-
74] and severe dependence [0-45]).(12) Stroke etiology was classified using to the Trial of Org 
10172 in Acute Stroke Treatment (TOAST) criteria.(13) 
Mortality rates were prospectively assessed at 1-month, during the follow-up period and at 12-
months post-stroke by regular home visits. 
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Risk factors assessment 
The presence of a previous stroke was determined on the basis of history and review of medical 
records. The existence of concurrent medical illness was determined by history, physical 
examination, laboratory data, and review of medical records. Risk factors such as hypertension, 
diabetes mellitus (type 1 or 2), dyslipidemia and atrial fibrillation were defined by the use of 
medications for these conditions at the time of study enrolment or at hospital discharge. The 
data for baseline information on smoking status were also collected. 
Education level, employment status and monthly personal income were used as indicators of 
Socio-Economic Status (SES). 
Statistical analysis 
Cumulative mortality rates at 1-month and 1-year follow-ups were calculated for all stroke 
patients. Differences in baseline variables between survivors, non-survivors and lost to follow 
up at 1-year after the stroke were assessed withthe χ2 test (or exact Fisher) for proportions and 
ANOVA (analysis of variance) test (or Kruskal Wallis) for between-group comparison. 
Determinants of death were evaluated using the Cox proportional hazard model at 1-month, 1-
year and overall death. Univariate associations between mortality and each of the individual 
variables that were identified as possible predictors of mortality were assessed using Kaplan–
Meier survival analysis and significance determined using the log rank test. The identified 
predictors with a univariate p<0.2 were subjected to multivariate Cox regression analyses using 
forward stepwise selection. Hazard ratios for mortality were determined by univariate and 
multivariate Cox proportional hazards regression analyses, with data presented as hazard ratio 
with 95% CIs. Log minus log plots were evaluated to test the validity of the proportionality of 
hazards assumption over time; all variables met this assumption. The Kaplan-Meier mortality 
curves at 1-month, 1-year and overall mortality were presented. At 1-year follow-up, data 
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analysis was conducted only for 1-month survivors. The P-value of ≤0.05 was considered 
statistically significant. Analyses were performed with the SPSS 21.0 software. 
Results 
Two hundred and three patients were included in this study (approximately 5% of patients did 
not give their written consent and were therefore excluded from the study); the mean age was 
69±13 years and 58% were men (Table 1). Survival data during the study period were complete 
for over 97% of patients. No significant difference was observed between lost to follow up and 
followed up patients concerning socio-demographic and clinical characteristics (Tables 1 and 
2). 
Cumulative rates of mortality were 13.3% at 1-month and 21.2% at 1-year follow-up. The risk 
of death was highest in the first month. For 1-month survivors, the mortality rate during 3, 6 
and 12 months after the stroke was approximately 4.5%, 1.2% and 3.0% respectively. Fifteen 
of the 176 survivors at 1-month (8.5%) did not survive at 1-year after the stroke. Mortality 
curves at 1-month, 1-year (for 1-month survivors only) and overall mortality are shown in the 
figures 1-A, 1-B and 1-C. 
Table 1 presents the socio-demographic characteristics of the study population according to 
survival status at 1-month and 1-year. Survivors at 1-month (86.7%) and at 1-year (78.8%) were 
significantly younger than the deceased (mean age: 68±13 years for 1-month survivors vs. 
77±12 for 1-month deceased, p=0.001; 67±12 years for 1-year survivors vs. 76±12 for 1-year 
deceased, p<0.001). Gender, education and living status were not statistically significant factors 
for mortality. However, the proportion of 1-month deceased patients was significantly lower 
among married patients, compared with single/divorced/widowed patients (p=0.027). Higher 
1-month and 1-year death occurred in housewife and unemployed patients compared to 
employed and retired patients (p=0.044 and 0.004 respectively) and in patients with low 
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monthly personal income compared to high monthly personal income (p=0.034 and 0.012 
respectively). 
Table 2 presents the clinical characteristics of the patients by survival status at 1-month and 1-
year. No statistically significant difference was noted between survivors and non-survivors 
regarding stroke types. Hypertension was the only risk factor statistically significant between 
survivors and non-survivors for mortality at 1-year (p=0.012). No statistically significant 
difference was observed for other common risk factors such as diabetes mellitus, dyslipidemia, 
atrial fibrillation, coronary heart disease, recurrent stroke and smoking. Stroke severity and 
infectious complications were significantly associated to mortality at one and 12 months 
(p<0.001). Among 1-month survivors, mRS was significantly lower and BI was significantly 
higher among alive patients compared to deceased at 1-year. Cardio-embolic stroke had the 
highest mortality rate between ischemic strokes and the highest mortality rates were found for 
patients with partial anterior circulation stroke. 
Variables identified in the univariate survival analysis as independent predictors of death at 1-
month, 1-year and overall mortality are presented in table 3. Decreased level of consciousness, 
high NIHSS score and the presence of infectious complications were predictors of 1-month, 1-
year and overall mortality. Marital status, low monthly personal income and intensive care unit 
(ICU) admission were additional 1-month mortality predictors. High mRS, low BI score, 
surgery needed and the presence of co-morbid conditions such as recurrent stroke and atrial 
fibrillation were additional 1-year mortality predictors. Additional predictors of overall 
mortality were age >64 years, low monthly personal income, employment status, ICU 
admission, surgery needed and the presence of hypertension as a co-morbid condition. 
Variables identified in the multivariate survival analysis as independent predictors of death at 
1-month, 1-year and overall mortality are presented in table 4. Stroke severity and infectious 
complication occurrence were predictors of death at 1-month (HR=2.0, p=0.003; HR=4.2, 
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p=0.013 respectively) and overall death (HR=2.0, p<0.001; HR=4.1, p=0.001 respectively); 
however, disability in daily living activities (low BI score HR=0.14, p=0.002), atrial fibrillation 
(HR=4.6, p=0.035) and recurrent stroke (HR=4.7, p=0.023) were additional predictors of long-
term mortality for patients alive 1-month post stroke. 
Considering housewives as reference, unemployed patients had a higher mortality rate and 
employed or retired patients had a lower mortality rate (p=0.003). 
Discussion 
This prospective study was designed to find out both short- and long- term stroke mortality and 
their major determinants in hospitalized patients followed up for a year after an acute stroke. 
Cumulative mortality rates for stroke patients increased from approximately one over eight at 
1-month to one over five 1-year after the event. Almost one over twelve of survivors at 1-month 
did not survive at 1-year. In addition we found that the first two weeks after stroke onset 
comprise a critical period for stroke patients since 12% and 31% died within the first and second 
week respectively. The non-survivor’s percentage increased after the first two weeks getting to 
64% by the end of thirty days. Our findings are not surprising. A Canadian study reported close 
30-day and 1-year mortality rates after stroke of 13% and 24% respectively(14) which are 
consistent with our findings. However prior studies have reported lower 1-month and 1-year 
mortality rates(15-16) while others reported a slightly higher rates than ours.(17-18) 
Several factors are known to influence short- and long -term mortality. As expected, we found 
that initial stroke severity and infectious complications were independent determinants of short- 
and long-term mortality. Our findings support previous reports where stroke severity (14,16,19-21) 
and infectious complications(7,14,21-22) were independent strong predictor of short- and long-term 
mortality. Therefore, reducing stroke severity and the risk of infection will therefore be 
paramount in curtailing the mortality rate. Patients with initial stroke severity or higher risk for 
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infection may benefit from early treatment, preventative interventions and sooner outpatient 
follow-up. 
Recurrent stroke, hypertension and atrial fibrillation are positively associated with post-stroke 
death and this is consistent with previous studies.(23-25) Therefore, improved control of these 
factors can potentially prevent part of stroke mortality. International guidelines for management 
of stroke recommend optimal management of vascular risk factors as part of the secondary 
prevention treatment.(26) Efforts should be also done on primary prevention measures with 
emphasis mainly on more aggressive control of risk factors, especially that they are modifiable 
risk factors, in order the reduce stroke incidence and therefore stroke mortality. 
Patients having a higher BI (being independent in DLA) were significantly more likely to 
survive than those with a lower score. In fact, as proven in other studies(27), BI is a useful 
predictor for 1-year mortality and being dependent in DLA increase the long-term mortality 
rate.  
Unemployed patients had lower survival rate compared to the reference while employed 
patients had higher survival rate compared to the reference. Many studies show that persons in 
lower socioeconomic positions, such as low-income groups, have higher risk of dying from 
stroke.(28-29) Understanding the causal associations between SES and stroke will allow 
interventions to be appropriately targeted and assessed. 
Even though age, decreased level of consciousness, ICU admission and hypertension were 
removed when entered in the multivariate Cox regression, they were positively associated with 
death at both 1-month and 1-year periods and with overall death in the univariate analysis. In 
fact, they emerged as predictors of stroke mortality in many previous studies.(15-20,24) 
Strengths and Limitations of the Study 
This study has some limitations. The first limitation is the small number of patients. In fact, 
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Lebanon is a small country of approximately 4.3 million people in 2012.(30) Therefore, it was 
expected to have this number despite our effort to include all stroke patients in these 8 different 
hospitals in Beirut region. In addition, even though we have tried to screen all stroke patients 
in this study we might have missed some of them for different reasons (such as transferred 
patients to another hospital, etc…) which may also contribute to this small number of patient. 
However, we have no reason to believe that the associations we found would be different in 
larger more representative studies, except for some associations that may not show statistical 
significance because of the sample size of our study. Second, we did not include patients who 
died before hospitalization or died within less than 24 hour from admission which may give 
rise to a selection bias, and therefore we think that mortality rate is underestimated in our study. 
Third, even though patients came from all governorates, hospitals were limited to Beirut region. 
Future studies taking into account all the weak points and including a larger sample size from 
all Lebanon regions must be done to confirm our findings. 
Conclusion 
The important predictors of mortality found in our study were stroke severity and infectious 
complications. Low SES and the presence of comorbid conditions such as hypertension, atrial 
fibrillation and recurrent stroke were also predictors of long-term mortality. 
There should be public awareness campaigns to educate the public on stroke symptoms and risk 
factors and their modifiable nature. Primary and secondary prevention measures should be of 
utmost importance. This will reduce both the prevalence of stroke and the severity and therefore 
the mortality rate. 
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Table 1. Socio-demographic sample characteristics 
 
At enrolment Survivors at 1-
month follow 
up 
Deceased at 1-
month 
P-
value
* 
Survivors at 1-
year follow up 
Lost to follow 
up 
P-
value
** 
Deceased at 1-
year 
P-
value*** 
 N=203 N=176 N=27  N=156 N=5  N=42  
 N./ 
mean 
%/SD 
N./ 
mean 
%/SD 
N./ 
mean 
%/SD  
N./ 
mean 
%/SD 
N./ 
mean 
%/SD  
N./ 
mean 
%/SD  
Age mean 68.8 12.9 67.6 12.6 76.6 12.2 0.001 67.1 12.4 64.4 18.0 NS 75.8 12.0 <0.001 
Gender       NS     NS   NS 
 Male 117 57.6 105 59.0 12 48.0  91 58.3 4 80.0  22 52.4  
Female 86 42.4 73 41.0 13 52.0  65 41.7 1 20.0  20 47.6  
Marital status       0.027     NS   NS 
Single/ 
Divorced/ 
Widowed 
81 39.9 66 37.1 15 60.0  58 37.2 2 40.0  21 50.0  
Married 122 60.1 112 62.9 10 40.0  98 62.8 3 60.0  21 50.0  
Employment 
status 
      0.044     NS   0.004 
Employed 61 30.0 59 33.1 2 8.0  55 35.3 2 40.0  4 9.5  
Housewife 82 40.4 69 38.8 13 52.0  61 39.1 1 20.0  20 47.6  
Retired 21 10.3 18 10.1 3 12.0  16 10.3 1 20.0  4 9.5  
Unemployed 39 19.2 32 18.0 7 28.0  24 15.4 1 20.0  14 33.3  
Education       NS     NS   NS 
Illiterate 37 18.2 33 18.5 4 16.0  30 19.2 0 0.0  7 16.7  
Elementary 86 42.4 73 41.0 13 52.0  60 38.5 3 60.0  23 54.8  
Secondary 35 17.2 32 18.0 3 12.0  29 18.6 1 20.0  5 11.9  
High school 27 13.3 24 13.5 3 12.0  23 14.7 1 20.0  3 7.1  
University 18 8.9 16 9.0 2 8.0  14 9.0 0 0.0  4 9.5  
Monthly personal 
income (US$) 
      0.034     NS   0.012 
<500  137 67.5 113 64.2 24 88.9  98 62.8 2 40.0  37 88.1  
[500-1000] 44 21.7 43 24.4 1 3.7  40 25.6 2 40.0  2 4.8  
[1000-1500] 11 5.4 9 5.1 2 7.4  8 5.1 1 20.0  2 4.8  
>1500 11 5.4 11 6.3 0 0.0  10 6.4 0 0.0  1 2.4  
Living status       NS     NS   NS 
With family 178 87.7 160 89.9 19 76.0  139 89.1 5 100.0  35 83.3  
Alone 25 12.3 18 10.1 6 24.0  17 10.9 0 0.0  7 16.7  
* comparison patients with 1-month follow up (n=176) to dead at 1-month (n=27). 
**comparison patients with full follow up (n=156) to lost to follow up (n=5). 
*** comparison patients with full follow up (n=156) to dead (n=42).  
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Table 2. Clinical sample characteristics 
 At enrolment Survivors at 1-
month follow 
up 
Deceased at 1-
month 
P-
value
* 
Survivors at 1-
year follow up 
Lost to follow 
up 
P-
value
** 
Deceased at 1-
year 
P-
value**
* 
 N=203 N=176 N=27  N=156 N=5  N=42  
 N./ 
mean 
%/SD 
N./ 
mean 
%/SD 
N./ 
mean 
%/SD  
N./ 
mean 
%/SD 
N./ 
mean 
%/SD  
N./ 
mean 
%/SD  
Type of stroke       NS     NS   NS 
IS 161 79.3 139 79.0 22 81.5  123 78.8 3 60.0  35 83.3  
TIA 12 5.9 11 6.3 0 0.0  12 7.7 0 0.0  0 0.0  
PICH 14 6.9 14 8.0 3 11.1  10 6.4 0 0.0  4 9.5  
SAH 16 7.9 12 6.8 2 7.4  11 7.1 2 40.0  3 7.1  
Risk factors                
-Hypertension 153 75.7 130 73.9 24 88.9 NS 112 71.8 4 80.0 NS 38 90.5 0.012 
-Dyslipidemia 76 37.6 68 38.6 9 33.3 NS 59 37.8 1 20.0 NS 17 40.5 NS 
-DM 83 41.1 73 41.5 10 37.0 NS 63 40.4 2 40.0 NS 18 42.9 NS 
-AF 26 12.9 25 14.2 2 7.4 NS 19 12.2 0 0.0 NS 8 19.0 NS 
- CHD 54 26.6 49 27.8 5 18.5 NS 41 26.3 0 0.0 NS 13 31.0 NS 
-Smoker       NS     NS   NS 
 ▪ex-smoker 31 15.3 27 15.3 4 14.8  23 14.7 0 0.0  8 19.0  
 ▪current smoker 102 50.5 91 51.7 11 40.7  80 51.3 2 40.0  20 47.6  
First ever 
stroke/TIA 
171 84.2 148 84.1 23 85.2 NS 134 85.9 4 80.0 NS 33 78.6 NS 
NIHSS on 
admission 
      
<0.00
1 
    NS   <0.001 
0 13 6.4 13 7.4 0 0.0  13 8.3 0 0.0  0.0 0.0  
[1-4] 63 31.0 61 34.7 2 7.4  58 37.2 1 20.0  4 9.5  
[5-14] 67 33.0 63 35.8 4 14.8  57 36.5 2 40.0  8 19.0  
[15-20] 18 8.9 15 8.5 3 11.1  12 7.7 1 20.0  5 11.9  
≥21 42 20.7 24 13.6 18 66.7  16 10.3 1 20.0  25 59.5  
mRS at 
discharge 
    - - -     NS   <0.001 
[0–2] 61 30.0 61 34.7    60 38.5 1 20.0  0 0.0  
[3–5] 115 56.5 115 65.3    96 61.5 4 80.0  15 35.7  
6 27 13.3      0 0.0 0 0.0  27 64.3  
BI at discharge     - - -     NS    
[96-100] 49 27.8 49 27.8    48 30.8 1 20.0  0.0 0.0 <0.001 
[75-95] 32 18.2 32 18.2    32 20.5 0 0.0  0.0 0.0  
[46-74] 30 17.0 30 17.0    26 16.7 2 40.0  2 13.3  
[0-45] 65 36.9 65 36.9    50 32.1 2 40.0  13 86.7  
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 At enrolment Survivors at 1-
month follow 
up 
Deceased at 1-
month 
P-
value
* 
Survivors at 1-
year follow up 
Lost to follow 
up 
P-
value
** 
Deceased at 1-
year 
P-
value**
* 
 N=203 N=176 N=27  N=156 N=5  N=42  
 N./ 
mean 
%/SD 
N./ 
mean 
%/SD 
N./ 
mean 
%/SD  
N./ 
mean 
%/SD 
N./ 
mean 
%/SD  
N./ 
mean 
%/SD  
TOAST       NS     NS   0.045 
LA 37 21.4 31 20.5 6 27.3  28 20.7 0 0.0  9 25.7  
CE 55 31.8 46 30.5 9 40.9  38 28.1 1 33.3  16 45.7  
SV 27 15.6 26 17.2 1 4.5  26 19.3 1 33.3  1 2.9  
UC 54 31.2 48 31.8 6 27.3  43 31.9 1 33.3  9 25.7  
Bamford       NS     NS   0.020 
LACS 27 16.8 26 18.7 1 4.5  26 21.1 1 33.3  1 2.9  
POCS 31 19.3 26 18.7 5 22.7  21 17.1 0 0.0  10 28.6  
TACS 5 3.1 3 2.2 2 9.1  2 1.6 0 0.0  3 8.6  
PACS 96 47.3 82 59.0 14 63.6  72 58.5 2 66.7  21 60.0  
POCS+PACS 2 1.2 2 1.4 0 0.0  2 1.6 0 0.0  0 0.0  
Surgery 26 13.1 23 13.1 5 18.5 NS 16 10.3 2 40.0 NS 10 23.8 0.021 
Infectious 
complication 
60 30.3 40 22.7 22 81.5 
<0.00
1 
29 18.6 2 40.0 NS 31 73.8 <0.001 
IS=ischemic stroke; TIA=transit ischemic attack; PICH=primary intracerebral hemorrhage; SAH=subarachnoid hemorrhage; DM=diabetes mellitus; AF=atrial fibrillation; CHD=coronary heart 
disease; NIHSS= National Institution of Health Stroke Scale; mRS=modified Rankin Scale; BI=Barthel Index; TOAST=Trial of Org 10172 in Acute Stroke Treatment; LA=large-artery 
atherosclerosis; CE=cardioembolism; SV=small-vessel occlusion; UC=unclassified. 
 
* comparison patients with 1-month follow up (n=176) to dead at 1-month (n=27). 
**comparison patients with full follow up (n=156) to lost to follow up (n=5). 
*** comparison patients with full follow up (n=156) to dead (n=42). 
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Table 3. Univariate Cox survival regression for determinants of 1-month, 1-year and overall mortality in stroke patients.  
 1-month mortality 1-year mortality* Overall mortality 
 B HR 95% CI P B HR 95% CI P B HR 95% CI P 
Age             
≤64 years  1 (Ref.)        1 (Ref.)   
>64 years 0.9 2.5 [0.9-6.6] 0.065     0.8 2.2 [1.1-4.5] 0.039 
Marital status             
Single/ 
Divorced/ 
Widowed 
 1 (Ref.)           
Married -0.8 0.4 [0.2-0.9] 0.034         
Monthly personal 
income (US$) 
-0.7 0.5 [0.2-1.0] 0.050     -0.7 0.5 [0.3-0.9] 0.021 
Living situation             
With family  1 (Ref.)           
Other 0.8 2.2 [0.9-5.4] 0.092         
Intensive care unit 2.5 12.5 [3.0-52.9] <0.001     1.5 4.6 [2.1-9.9] <0.001 
Decreased level of 
consciousness 
1.0 2.7 [1.7-4.3] <0.001 1.1 3.0 [1.6-5.5] <0.001 1.0 2.8 [1.9-4.1] <0.001 
Stroke severity on 
admission (NIHSS) 
1.0 2.8 [1.9-4.2] <0.001 0.8 2.3 [1.5-3.6] <0.001 0.9 2.6 [1.9-3.5] <0.001 
Infectious 
complications 
2.5 11.8 [4.5-31.2] <0.001 1.8 5.8 [2.1-16.3] 0.001 2.2 8.7 [4.3-17.3] <0.001 
Surgery     1.4 3.9 [1.3-11.5] 0.012 0.8 2.2 [1.1-4.5] 0.030 
Barthel Index at 
discharge 
N/A    -1.6 0.2 [0.1-0.7] 0.008 N/A    
Modified Rankin 
Scale 
N/A    1.5 4.7 [1.8-12.0] 0.001 N/A    
Recurrent stroke     1.0 2.8 [1.0-8.3] 0.057     
Hypertension 1.0 2.7 [0.8-8.9] 0.095 1.7 5.3 [0.7-40.2] 0.072 1.2 3.3 [1.2-9.3] 0.023 
Atrial Fibrillation     1.4 4.2 [1.5-11.9] 0.006     
Employment status        0.053    0.011 
Housewife      1 (Ref.)  1 (Ref.)  1 (Ref.)  1 (Ref.) 
Employed     -1.0 0.4 [0.1-7.1] 0.236 -1.4 0.2 [0.1-0.7] 0.011 
Retired     -0.8 0.6 [0.04-4.13] 0.680 -0.2 0.8 [0.3-2.3] 0.666 
Unemployed     2.5 2.5 [2.7-51.8] 0.114 0.5 1.6 [0.8-3.2] 0.175 
 
*Among 1-month survivors only. 
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Fig. 1-A Kaplan-Meier mortality curve for stroke patients at 1-month follow-up. 
 
Fig. 1-B Kaplan-Meier mortality curve for stroke patients at 1-year follow-up (for 1-month survivors only). 
 
Fig. 1-C Kaplan-Meier mortality curve for stroke patients at 1-year follow-up (overall mortality). 
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Table 4. Multivariate Cox survival regression for determinants of 1-month, 1-year and overall 
mortality in stroke patients 
 1-month mortality 1-year mortality* Overall mortality 
 B HR 95% CI P B HR 95% CI P B HR 95% CI P 
Stroke severity on 
admission (NIHSS) 
0.7 2.0 [1.3-3.2] 0.003     0.7 2.0 [1.4-2.7] <0.001 
Infectious 
complications 
1.4 4.2 [1.4-13.1] 0.013     1.4 4.1 [1.9-9.1] <0.001 
Barthel Index at 
discharge 
    -2.0 0.14 [0.04-0.50] 0.002     
Recurrent stroke     1.5 4.7 [1.2-17.7] 0.023     
Hypertension         1.0 2.7 [1.0-7.6] 0.059 
Atrial Fibrillation     1.5 4.6 [1.1-19.2] 0.035     
Employment status        0.003    0.002 
Housewife     1 (Ref.)   1 (Ref.)    1 (Ref.) 
Employed     -2.5 0.8 [0.1-7.1] 0.828 -0.8 0.4 [0.1-1.3] 0.128 
Retired     -0.8 0.4 [0.04-4.13] 0.465 -0.3 0.7 [0.2-2.1] 0.569 
Unemployed     2.5 11.7 [2.7-51.8] 0.001 1.0 2.8 [1.4-5.7] 0.005 
 
*Among 1-month survivors only. 
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The high death proportions 1-month and 1-year post-stroke urge the need to implement serious 
measures to improve stroke care. Dependency in daily living activities was one of the long-term 
mortality predictors. Dependency in daily living activities leads to decline in HRQOL and 
depression, therefore we thought to assess HRQOL and depression 1-year post-stroke for stroke 
survivors and the factors affecting them. 
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Abstract 
Background: Stroke has a major impact on survivors including Health Related Quality Of life 
(HRQOL). It is crucial to identify factors influencing HRQOL in stroke survivors in this setting 
so that such factors can be efficiently manipulated in order to maximize HRQOL improvement. 
We sought to assess HRQOL 1-year post-stroke and the factors affecting it for patients with 
stroke.  
Methods: This study was designed as a multicenter prospective cohort study in which 150 
stroke patients were followed up at hospital discharge, at 3, 6, and 12 months post-stroke. 
HRQOL levels were determined at 1-year using both generic scale: the Short Form-36 (SF-36) 
survey and disease-specific scale: the stroke-specific quality of life (SS-QOL) scale. HRQOL 
determinants were sought among variables such as age, gender, socio-economic status, side, 
type and number of strokes, NIHSS, modified Rankin scale, BI, and depression (using the 
geriatric depression scale (GDS-15)). 
Results: A total of 150 stroke patients were included. The mean SS-QOL was 3.7±1.1 and that 
of SF-36 was 57.2±25.5. More than 15% of stroke patients were depressed. The main 
determinants of HRQOL were functional status, dependency in daily living activities, stroke 
severity, age and depression. The main determinants of depression were functional status and 
HRQOL (physical component of SF-36). 
Conclusion: HRQOL of stroke patients is relatively low. The fact that the main determinant of 
HRQOL was functional status suggest that improving physical function may be helpful in 
providing a better HRQOL for stroke patients and therefore decrease the high depression rate. 
Keywords: Quality of life; predictors; stroke; Lebanon; SF-36; SS-QOL 
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Introduction 
Health is a state of complete physical, mental, and social well-being and not merely the absence 
of disease or infirmity (WHO). Quality of life is a multi–dimensional construct that consists of 
at least three broad domains: physical, mental and social. Researchers and physicians have often 
used the health–related quality of life (HRQOL) concept in the field of medicine, which 
specifically focuses on the impact of an illness and/or the treatment on the patients' perception, 
of their status of health, and, on subjective well–being or satisfaction with life (Jaracz and 
Kozubsi, 2003). To assess HRQOL several instruments have been developed. Most of them are 
questionnaires based on a patient's subjective self–report or self–evaluation. The distinction is 
made between generic and specific measures. The latter involve items concerning a particular 
disease or health problem and are considered more sensitive than the generic ones, especially 
when detecting changes or differences among treatments (Opara and Jaracz, 2010). While the 
generic ones are used to evaluate quality of life for many types of diseases and for calculating 
utility values in cost-effectiveness analysis (Mehta et al., 2003). 
Innovations and major improvements in acute stroke care have been raising post-stroke survival 
rates (van Eeden et al., 2015). Stroke is often catastrophic and affects all aspects of an 
individual’s life, and unlike other disabling conditions the onset of stroke is sudden leaving the 
individual and family ill-prepared to deal with the sequelae (Mayo et al., 1999). Accordingly, 
more people experience long-term difficulties in terms of quality of life (Carod-Artal et al., 
2000), social reintegration (Hommel et al., 2009), life satisfaction (Ostwald et al., 2009), and 
emotional functioning, including depression and anxiety (Bergersen et al., 2010). 
HRQOL measurements are potentially more relevant to patients than measurements of 
impairments or disability and are an important index of outcome after stroke that can facilitate 
a broader description of disease and outcome (Abubakar and Isezuo, 2012). Quality of life 
related to stroke and life satisfaction after stroke is important health care issues that have not 
received sufficient attention in Lebanon. 
It is crucial to identify factors influencing HRQOL in stroke survivors so that such factors can 
be efficiently manipulated in order to maximize HRQOL. Therefore, variables that predict 
HRQOL are of special interest. However, no study on HRQOL of Lebanese stroke patients exist 
to date. Therefore the aim of this study was to determine the HRQOL 1-year after stroke and to 
identify the factors related with and determinants of HRQOL in Lebanese stroke patients. The 
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results may provide valuable information about strategies that professionals and provider of 
stroke care can address to improve HRQOL. 
Methods 
Study design 
This prospective study was conducted from 8 different hospitals in Beirut, over a period of 1-
year after approval from the Institutional Ethics Committee. Participants (or their responsible 
caregivers where not possible) provided written informed consent. 
All acute stroke patients over the age of 18 years admitted to each participating hospital from 
August 2015 with confirmed diagnosis of stroke (confirmed by a neurologist with radiological 
evidence by either CT scan and/or MRI) were recruited prospectively and followed up for 1-
year or until death. 
Stroke was defined according to the International Classification of Diseases (10th revision) and 
Transient Ischemic Attack (TIA) was defined as a brief episode of neurologic dysfunction 
resulting from focal temporary cerebral ischemia and not associated with cerebral infarction 
(Easton et al., 2009). 
Patients who did not want to be the part of the study (negative consent), or those who had a 
stroke of more than one week were excluded. Patients were also excluded if they were suffering 
from severe pathologies (cancer, fatal renal, hepatic or respiratory insufficiency), or having a 
moderate to severe cognitive decline before their stroke. 
Study tools 
National Institution of Health Stroke Scale (NIHSS) score was used to assess stroke impairment and 
severity (NINDS t-PA Stroke Study Group, 1998). Functional disability were assessed using the 
modified Rankin scale (mRS) and the Barthel Index (BI) (Sulter et al., 1999). Stroke etiology 
was classified using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria 
(Adams et al., 1993). 
HRQOL levels were determined at 1-year using both generic scale: the Short Form-36 (SF-36) 
survey and disease-specific scale: the stroke-specific quality of life (SS-QOL) scale. We used 
 172 
the validated Arabic version of the SF-36 (Sabbah et al., 2003). Since no validated Arabic 
version of SS-QOL exists to date, the SS-QOL was translated in this procedure: 
1- a forward translation of the original questionnaire (from English to Arabic language) by a 
qualified independent, native linguistic expert translator. 
2- a back translation (from Arabic language to English) by another translator (blinded to the 
original English version). 
3- the back translated questionnaire was discussed with the researchers R.A. and R.R. with both 
translators to come up with the final Arabic version of the SSQOL questionnaire. 
4- The questionnaire was pre-tested on a convenient sample of 5 patients who already had a 
stroke episode and modified the very few questions that sounded unclear for them or 
misunderstood by them. 
The validated Arabic version of the Geriatric Depression Scale (GDS) (Short Form 15-item) was 
used to assess depression (Chaaya et al., 2008). 
Statistical analysis 
Data were entered and analyzed using Statistical Package for the Social Sciences (SPSS), 
version 20.0 (IBM Corporation, Armonk, NY, USA). Two researchers audited 5% randomly 
selected questionnaires. Data entry showed high reliability (error rate <1%). Data were 
presented as means±SDs or as percentages. In bivariate analyses, Pearson correlation 
coefficients were used for two continuous quantitative variables, Student’s test for means 
comparison between two groups (for quantitative variables) and Chi-square test (or exact 
Fisher) for comparing percentages (for nominal, ordinal and categorical variables) were used. 
ANOVA (analysis of variance) test was used to compare between-group differences; followed 
by Bonferroni post-hoc when a significant difference was obtained. P≤0.05 indicated statistical 
significance. Bivariate analysis were done for the following dependent variables: SS-QOL, SF-
36 and GDS-15. HRQOL and depression predictors were determined through multivariable 
stepwise linear regressions, after ensuring sample and conditions adequacy. HRQOL 
determinants were sought among variables such as age, gender, socio-economic status, side, 
type and number of strokes, NIHSS, modified Rankin scale, BI, and depression. Independent 
variables with P<0.2 in the bivariate analysis were entered into the models. Regression was 
checked for collinearity (VIF<10 indicated non-collinearity). 
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Results 
Out of 203 recorded strokes, only 150 stroke patients were included in this study (dead =42; 
lost to follow up =11). The mean age of the study group was 67.3±12.2 years and there were 
more males than females (57.3%). No significant difference was observed between lost to 
follow up and followed up patients concerning socio-demographic (Table 1).  
HRQOL varied significantly between males and females in both SS-QOL and SF-36 where 
females tended to have low HRQOL than males (P<0.001). Older patients had significantly 
lower HRQOL (P<0.001). Patients with higer SES had better HRQOL scores in both specific 
(P=0.075) and generic (P=0.036) HRQOL scales. Patients with higher NIHSS and mRS had 
significantly lower HRQOL while patients with higher BI score had significantly higher 
HRQOL (P<0.001). Patients with TIA, SV and UC strokes had significantly higher HRQOL in 
both generic and specific scales (P=0.012 and 0.032 respectively). Patients with higher GDS-
15 scores had significantly lower HRQOL (P<0.001 in both SS-QOL and SF-36). Patients with 
high HRQOL on SS-QOL had also high HRQOL on SF-36 (Table 2). 
More than 15% of stroke patients were suffering from depression and more than 30% were 
suggested to being depressed. Females tended to be depressed more than males (P=0.039). 
However no significant difference was detected between age, SES, stroke type and depression. 
Patients with higher NIHSS and mRS had significantly more depressive symptoms while 
patients with higher BI score had significantly lower depressive symptoms (P<0.001). Patients 
with LA or CE stroke had significantly more depressive symptoms than those with SV or UC 
strokes (P=0.003). Depressed patients had significantly lower HRQOL (P<0.001 for both SS-
QOL and SF-36) (Table 3). 
Reliability (intra and inter), central tendency, and variability of the SS-QOL scale and the SF-
36 scale in this stroke study were good. Stroke patients had relatively low HRQOL scores on 
both scales (3.7±1.1 and 57.2±25.5 respectively) (Tables 4-5). 
Predictors of SS-QOL were mRS at 12 months, BI at 12 months and GDS-15 at 12 months. 
Predictors of SF-36 were age, SES (monthly home income), mRS at 12 months, BI at 12 months 
and GDS-15 at 12 months (Table 6). Predictors of GDS-15 were age, NIHSS at 12 months, BI 
at 12 months, type of stroke, and SF-36 (physical, general health and emotional components) 
(Table 7).  
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Discussion 
This study pioneers in analyzing the HRQOL of stroke patients in Lebanon and evaluating its 
predictors. The mean of HRQOL in both SF-36 and SS-QOL was relatively low. Several studies 
have shown that by far the largest part of the patients experience and report a decline in HRQOL 
after stroke (Duncan et al., 1997; Hackett et al., 2000; Jonkman et al., 1998; Kwon et al., 2018; 
Williams et al., 1999), and this even applies to persons who have suffered only a minor stroke 
(Duncan et al., 1997; Williams et al., 1999). In fact, the health change item in the SF-36 had 
the lowest mean. There are a number of factors which seem to be contributing towards a decline 
in HRQOL of stroke patients. 
In our study, age was negatively correlated to HRQOL (with SF-36 but not with SS-QOL); 
advanced age patients had a lower perceived HRQOL compared to younger patients. The effect 
of age on HRQOL in stroke survivors in the literature has remained inconclusive. Some studies 
showed that age had a strong influence on quality of life (Gurcay et al., 2009; Hackett et al., 
2000; Kwon et al., 2018; Lai et al., 2002), while others found that there was no negative 
influence of age in patients with stroke (Gokkaya et al., 2005; Langton Hewer, 1990). 
We found significant association between mRS (negative association), BI (positive association) 
and HRQOL (both SS-QOL and SF-36). The more patients had physical disability, the more 
they were dependent in acivities of daily living, the more they had lower HRQOL scores. In 
fact, many authors have reported a strong association between physical disability, dependency 
in activities of daily living and HRQOL (Anderson et al., 1996; Duncan et al., 1997; Hacket et 
al., 2000; Jeon et al., 2017; King, 1996; Kwa et al., 1996; Lopez-Espuela et al., 2015; Owolabi, 
2008; Williams et al., 1999). Moreover, stroke survivors, even if they are independent in their 
daily activities, have reported a decline in their HRQOL (Duncan et al., 1997). This seems to 
indicate that functional measurements only are not sufficient for determining stroke results. It 
is necessary too, in addition to the impartial assessment of physical impairments, to measure 
the HRQOL to provide a more accurate and complete picture of the post-stroke level of 
disability (Kranciukaite and Rastenyte, 2006).  
Post-stroke depression is common (Whyte and Mulsant, 2002). More than 15% of stroke 
survivors had self-reported depressive mood in our study which was a bit lower than that 
reported in a previous Korean study (Kwon et al., 2018). From 23 to 41% of stroke patients feel 
an immediate inception of depression in the period of the few months after the stroke event 
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(Wilkinson et al., 1997). The existence of depression has a strong correlation with the prognosis 
of declined HRQOL after stroke (Jonkman et al., 1998; King, 1996; Neau et al., 1998; Williams 
et al., 1999). In several previous studies, post-stroke depression was associated with worse 
recovery and outcomes in multiple functional domains such as activity limitations and 
participation restrictions (Chau et al., 2009; Parikh et al., 1990; van de Weg et al., 1999), which 
leads to worse HRQOL in stroke survivors (Jeon et al., 2017; Rastenyte and Kranciukait, 2007). 
Therefore, comprehensive medical attention including treatment of depression should be 
provided in post-stroke rehabilitation, and depression screening and community-based 
interventions with support from other family members or caregivers has to be considered in 
chronic stroke survivors (Kwon et al., 2018).  
SES was correlated to HRQOL, patients with higher monthly home income had higher 
HRQOL. Associations of SES with HRQOL have been previously reported in a number of 
chronic diseases (Mielck et al., 2014) including stroke (Baumann et al., 2014) 
In the bivariate analysis, females had significantly lower HRQOL. However, gender and 
HRQOL disappeared in the multivariate analysis. The correlation between gender and QOL has 
remained obscure. C. S. Anderson et al. showed that women had a better stroke outcome in 
terms of social functioning and mental health (Anderson et al., 1996), but most authors report 
QOL either to be independent of gender (Kwa et al., 1996) or lower in females (Angeleri et al., 
1996; Lopez-Espuela et al., 2015). 
Stroke severity (NIHSS) and physical disability (SF-36 physical component) were consistently 
associated with depression. Our results were consistent with previous studies (Hackett and 
Anderson, 2005; Shi et al, 2017; Vojtikiv-Samoilovska and Arsovska, 2018). When we include 
the emotional and general health components of SF-36 in the depression model, they eliminate all 
other depression predictors. This means that emotional and general status components are 
intermediate factors between physical component and depression. Physical problems are 
leading to lower general health and emotional HRQOL and the latters are leading to depression. 
Strengths and limitations of this study 
To our knowledge, this is the first study assessing HRQOL and its determinants in Lebanese 
stroke patients. We used both generic and disease-specific scales for HRQOL and a validated 
geriatric depression scale (GDS-15) for depression. We did not exclude aphasic patients which 
is a limitation in many previous studies. 
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This study does, however, have limitations. The first limitation is the relatively small number 
of patients. Another limitation of this study is that it was conducted only in Beirut. Therefore, 
maybe some of our results are not generalizable to other regions of Lebanon. A third limitation 
is that when mute or global aphasic patients couldn't give clear answers, their caregivers 
responded. A larger multicenter study covering the whole geographic area of Lebanon is 
recommended. 
Conclusion 
The impact of stroke on HRQOL may be disastrous; stroke can affect multiple domains of life. 
More efforts and means should be applied to improving this facet of after stroke care such as 
helping patients with their reintegration in the community and the readjustment of their lives in 
order to reduce post-stoke depression rates. A long-term treatment goal in stroke survivors is to 
achieve HRQOL scores that are as high as possible. 
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Table 1. Socio-demographic sample characteristics 
 At enrolment 
Survivors at 
1-year follow 
up 
Lost to 
follow up 
P-
value* 
Deceased at 
1-year 
P-
value** 
 N=203 N=150 N=11  N=42  
 
N/ 
mean 
%/SD 
N/ 
mean 
%/SD 
N/ 
mean 
%/SD  
N/ 
mean 
%/SD  
Age 68.8 12.9 67.3 12.2 62.4 15.0 NS 75.8 12.0 <0.001 
Gender       NS   NS 
 Male 117 57.6 86 57.3 9 81.8  22 52.4  
Female 86 42.4 64 42.7 2 18.2  20 47.6  
Marital status       NS   NS 
Single/ 
Divorced/ 
Widowed 
81 39.9 55 36.7 5 45.5  21 50.0  
Married 122 60.1 95 63.3 6 54.5  21 50.0  
Employment 
status 
      NS***   0.004 
Employed 61 30.0 51 34.0 6 54.5  4 9.5  
Housewife 82 40.4 61 40.7 1 9.1  20 47.6  
Retired 21 10.3 16 10.7 1 9.1  4 9.5  
Unemployed 39 19.2 22 14.7 3 27.3  14 33.3  
Education       NS***   NS 
Illiterate 37 18.2 28 18.7 2 18.2  7 16.7  
Elementary 86 42.4 59 39.3 4 36.4  23 54.8  
Secondary 35 17.2 28 18.7 2 18.2  5 11.9  
High school 27 13.3 23 15.3 1 9.1  3 7.1  
University 18 8.9 12 8.0 2 18.2  4 9.5  
Monthly home 
income (US$) 
      NS***   NS 
<500  60 29.6 40 26.7 3 27.3  17 40.5  
[500-1000] 62 30.5 50 33.3 3 27.3  9 21.4  
[1000-1500] 37 18.2 29 19.3 4 36.4  4 9.5  
>1500 44 21.7 31 20.7 1 9.1  12 28.6  
Living status       NS   NS 
With family 178 87.7 136 90.7 8 72.7  35 83.3  
Alone 25 12.3 14 9.3 3 27.3  7 16.7  
*comparison patients with full follow up (n=150) to lost to follow up (n=11). 
** comparison patients with full follow up (n=150) to dead (n=42). 
***non parametric test. 
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Table 2. Bivariable analysis of HRQOL (SS-QOL and SF-36) 
 Quality of Life 
 SS-QOL P-value SF-36 P-value 
Gender     
Male 3.9±1.0 
0.001 
63.0±26.4 
0.001 
Female 3.3±1.0 49.7±22.3 
Age -0.281 <0.001 -0.385 <0.001 
SES (USD)  NS (0.075)  0.036 
<500  3.5±1.1  51.9±25.3  
[500-1,000[ 3.5±1.1  55.0±26.0  
[1,000-1,500] 3.6±1.2  59.1±25.4  
>1,500 4.1±0.8  68.5±21.2  
NIHSS     
at admission -0.642 <0.001 -0.611 <0.001 
at 12 months -0.757 <0.001 -0.673 <0.001 
BI     
at discharge 0.668 <0.001 0.657 <0.001 
at 12 months 0.852 <0.001 0.761 <0.001 
mRS     
at discharge -0.601 <0.001 -0.619 <0.001 
  - Independent 4.3±0.6 
<0.001 
75.9±14.6 
<0.001 
  - Dependent 3.2±1.1 46.2±24.3 
at 12 months -0.855 <0.001 -0.821 <0.001 
  - Independent 4.5±0.5 
0.040 
78.6±12.2 
NS 
  - Dependent 4.2±0.6 72.7±17.5 
TOAST  <0.001a  <0.001 
LA 3.4±0.9  49.5±22.7  
CE 3.3±1.1  46.3±26.1  
SV 4.1±0.7  65.8±19.5  
UC 4.1±0.9  70.4±20.6  
Stroke type  0.012b  0.032b 
IS 3.6±1.0  56.2±25.1  
PICH 3.1±1.4  47.6±35.3  
SAH 3.5±1.4  55.5±24.5  
TIA 4.5±0.4  76.7±8.7  
GDS-15 at 12 months -0.705 <0.001 -0.741 <0.001 
SF-36 at 12 months 0.921 <0.001 - - 
 
SS-QOL= Stroke Specific Quality of Life Scale; SF-36= Short Form-36; SES= socioeconomic status; 
NIHSS= National Institution of Health Stroke Scale; mRS= modified Rankin Scale; BI= Barthel Index; 
TOAST= Trial of Org 10172 in Acute Stroke Treatment; LA= large-artery atherosclerosis; CE= 
cardioembolism; SV= small-vessel occlusion; UC= unclassified; IS= Ischemic stroke; TIA= Transit 
Ischemic Attack; PICH= Primary Intracerebral hemorrhage; SAH= Subarachnoid hemorrhage; 
GDS-15= Geriatric Depression Scale (Short Form 15 items). 
 
a LA vs. UC and SV; CE vs. UC and SV 
b TIA vs. ICH and IS 
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Table 3. Bivariable analysis of depression (GDS) 
 Geriatric Depression Scale (Short Form 15-item) 
 Normal 
Post-stroke 
depression 
suggestion 
Suggestion of 
depression 
Indicative of 
depression 
P-value 
 62(41.3%) 18(12.0%) 47(31.3%) 23(15.3%)  
Gender     0.039 
Male 43(50.0%) 9(10.5%) 20(23.3%) 14(16.3%)  
Female 19(29.7%) 9(14.1%) 26(41.3%) 9(14.1%)  
Age 65.7±13.6 65.9±13.8 69.0±10.0 68.4±11.5 NS 
SES (USD)     NS* 
<500  18(45.0%) 3(7.5%) 13(32.5%) 6(15.0%)  
[500-1,000[ 16(32.0%) 8(16.0%) 20(40.0%) 6(12.0%)  
[1,000-1,500] 12(41.4%) 3(10.3%) 8(27.6%) 6(20.7%)  
>1,500 16(51.6%) 4(12.9%) 6(19.4%) 5(16.1%)  
NIHSS      
at admission 4.5±5.3 6.8±5.0 10.8±8.5 14.2±10.5 <0.001a 
at 12 months 0.4±1.4 2.1±3.5 3.5±4.9 6.2±7.8 <0.001a 
BI      
BI at discharge 80.8±29.6 63.4±37.7 46.2±37.0 41.4±40.5 <0.001b 
BI at 12 months 94.4±12.0 81.7±30.1 67.8±36.4 56.4±41.1 <0.001a 
mRS      
at discharge 2.0±1.7 3.0±1.7 3.8±1.4 3.5±1.8 <0.001b 
  - Independent 38(66.7%) 7(12.3%) 7(12.3%) 5(8.8%) 
<0.001 
  - Dependent 24(25.8%) 11(11.8%) 40(43.0%) 18(19.4%) 
at 12 months 1.0±1.3 1.9±1.6 2.7±1.8 3.2±1.8 <0.001b 
  - Independent 49(55.7%) 12(13.6%) 19(21.6%) 8(9.1%) 
<0.001 
  - Dependent 13(21.0%) 6(9.7%) 28(45.2%) 15(24.2%) 
TOAST 54(41.9%) 16(12.4%) 42(32.6%) 17(13.2%) 0.003* 
LA 7(25.0%) 4(14.3%) 13(46.4%) 4(14.3%)  
CE 8(21.6%) 4(10.8%) 19(51.4%) 6(16.2%)  
SV 14(60.9%) 2(8.7%) 4(17.4%) 3(13.0%)  
UC 25(61.0%) 6(14.6%) 6(14.6%) 4(9.8%)  
Stroke type     NS* 
IS 45(38.5%) 15(12.8%) 40(34.2%) 17(14.5%)  
PICH 5(50.0%) 1(10.0%) 1(10.0%) 3(30.0%)  
SAH 3(27.3%) 1(9.1%) 4(36.4%) 3(27.3%)  
TIA 9(75.0%) 1(8.3%) 2(16.7%) 0(0%)  
SS-QOL at 12 months 4.4±0.6 3.8±0.8 3.1±0.9 2.5±0.9 <0.001 
SF-36 at 12 months 76.6±13.8 63.7±20.7 43.7±21.4 30.9±17.5 <0.001 
*non parametric test 
 
SES= socioeconomic status; NIHSS= National Institution of Health Stroke Scale; mRS= modified 
Rankin Scale; BI= Barthel Index; TOAST= Trial of Org 10172 in Acute Stroke Treatment; LA= large-
artery atherosclerosis; CE= cardioembolism; SV= small-vessel occlusion; UC= unclassified; IS= 
Ischemic stroke; TIA= Transit Ischemic Attack; PICH= Primary Intracerebral hemorrhage; SAH= 
Subarachnoid hemorrhage; SS-QOL= Stroke Specific Quality of Life Scale; SF-36= Short Form-36. 
 
a Normal vs. suggestion of depression and indicative of depression and post-stroke depression 
suggestion vs. indicative of depression 
b Normal vs. suggestion of depression and indicative of depression 
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Table 4. Reliability, central tendency, and variability of the SS-QOL scale in this stroke 
study. 
SS-QOL 
Scale Mean±SD Alpha Items 
Energy 3.0±1.4 0.914 3 
Family roles 3.3±1.6 0.867 3 
Language 4.4±1.3 0.985 5 
Mobility 3.5±1.5 0.949 6 
Mood 4.1±1.0 0.766 5 
Personality 3.1±1.3 0.730 3 
Self care 3.7±1.6 0.969 5 
Social roles 3.0±1.4 0.870 5 
Thinking 3.9±1.2 0.778 3 
Upper extremity function 3.9±1.6 0.964 5 
Vision 4.6±0.8 0.738 3 
Work/productivity 3.0±1.7 0.979 3 
Total 3.7±1.1 0.925 49 
Table 5. Reliability, central tendency, and variability of the SF-36 scale in this stroke 
study. 
SF-36 
Scale Mean±SD Alpha Items 
Physical functioning 53.7±34.4 0.933 10 
Role functioning physical 49.0±48.1 0.972 4 
Role functioning emotional 71.8±44.3 0.981 3 
Energy/fatigue 55.0±22.3 0.862 4 
Emotional well-being 60.0±21.9 0.860 5 
Social functioning 60.3±37.3 0.863 2 
Pain 78.1±25.8 0.864 2 
General health 57.0±22.7 0.830 5 
Health change 30.5±32.0 - 1 
Total 57.2±25.5 0.898 36 
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Table 6. Multivariable linear regression analysis of HRQOL (SS-QOL and SF-36) predictors. 
 SS-QOLa SF-36b 
Variables explained 86.9% of the variance of SS-QOL 82.7% of the variance of SF-36 
Anova <0.001 <0.001 
Independent variables 
Unstandardized 
Coefficients Standardized 
Coefficients 
P-value 
 
VIF 
 
Unstandardized 
Coefficients Standardized 
Coefficients 
P-value VIF 
Β SD Β SD 
(Constant) 3.526     85.933     
Age      -0.248 0.075 -0.120 0.001 1.1 
mRS at 12 months -0.211 0.033 -0.357 <0.001 3.5 -6.014 0.903 -0.430 <0.001 3.6 
BI at 12 months 0.013 0.002 0.391 <0.001 3.4 0.113 0.050 0.145 0.024 3.4 
GDS-15 at 12 months -0.087 0.009 -0.331 <0.001 1.4 -2.626 0.249 -0.424 <0.001 1.4 
Monthly home income      
3.598 1.790 0.070 0.046 1.0       ≤ 1000 USD (ref.)      
      > 1000 USD      
mRS= modified Rankin Scale; BI= Barthel Index; SF-36= Short Form-36; SS-QOL= Stroke Specific Quality of Life Scale; GDS-15= Geriatric Depression 
Scale (Short Form15 items) 
 
 
a Dependent variable: SS-QOL at 12 months 
Independent variables: sex, age, monthly home income, type of stroke (TIA vs. other), NIHSS at 12 months, mRS at 12 months, BI at 12 months and GDS-15 
at 12 months. 
 
b Dependent variable: SF-36 at 12 months 
Independent variables: sex, age, monthly home income, type of stroke (TIA vs. other), NIHSS at 12 months, mRS at 12 months, BI at 12 months and GDS-15 
at 12 months. 
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Table 7. Multivariable linear regression analysis of depression (GDS-15) predictors 
 GDS-15a GDS-15b 
Variables explained 34.5% of the variance of GDS-15 59.0% of the variance of GDS-15 
Anova <0.001 <0.001 
Independent variables 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
P-value VIF 
Unstandardized 
Coefficients Standardized 
Coefficients 
P-value 
 
VIF 
 Β SD    Β SD 
(Constant) 8.663     14.122     
NIHSS at 12 months 0.145 0.071 0.170 0.047 1.6      
SF-36 physical component at 12 
months 
-0.044 0.011 -0.330 <0.001 2.0      
SF-36 general health component at 
12 months 
     -0.052 0.014 -0.236 <0.001 1.4 
SF-36 emotional at 12 months      -0.096 0.010 -0.619 <0.001 1.4 
NIHSS= National Institution of Health Stroke Scale; SF-36= Short Form-36; Scale; GDS-15= Geriatric Depression Scale (Short Form15 items) 
 
a Dependent variable: GDS-15 at 12 months 
Independent variables: sex, age, monthly home income, type of stroke (TIA vs. other), NIHSS at 12 months, mRS at 12 months, BI at 12 months and SF-36 at 
12 months (physical component only; emotional and general health components were excluded). (SS-QOL at 12 months was removed from the model due to 
its high collinearity (VIF=10)). 
 
b Dependent variable: GDS-15 at 12 months 
Independent variables: sex, age, monthly home income, type of stroke (TIA vs. other), NIHSS at 12 months, mRS at 12 months, BI at 12 months and SF-36 at 
12 months (physical, general health and emotional components). (SS-QOL at 12 months was removed from the model due to its high collinearity (VIF=10)). 
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Physical functional status is the main important predictor of HRQOL. However emotional 
status affects HRQOL too. DALYs represent the burden of the disease for humans. Despite the 
relatively high stroke prevalence and burden in Lebanon, its cost is not known. Therefore, the 
fourth study was designed to quantify the burden of stroke by providing detailed financial data 
on the direct in-hospital cost of acute stroke care in Lebanon and evaluate its drivers. 
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Abstract 
Background and Aims: Stroke is a major social and health problem posing heavy burden on 
national economies. We provided detailed financial data on the direct in-hospital cost of acute 
stroke care in Lebanon and evaluated its drivers. 
Methods: This was an observational, quantitative, prospective, multicenter, incidence-based, 
bottom-up cost-of-illness study. Medical and billing records of stroke patients admitted to eight 
hospitals in Beirut over one year were analyzed. Direct medical costs were calculated and cost 
drivers were assessed using a multivariable linear regression analysis. 
Results: In total, 203 stroke patients were included (male: 58%; mean age: 68.8±12.9 years). 
The direct in-hospital cost for all cases was US$1,413,069 for 2626 days (US$538 per in-
hospital day). The average in-hospital cost per stroke patient was US$6961±15,663. 
Hemorrhagic strokes were the most costly, transient ischemic attack being the least costly. Cost 
drivers were hospital length of stay, intensive care unit length of stay, type of stroke, stroke 
severity, modified Rankin Scale, third party payer, surgery and infectious complications. 
Conclusion: Direct medical cost of acute stroke care represents high financial burden to 
Lebanese health system. Development of targeted public health policies and primary prevention 
activities need to take priority to minimize stroke admission in future and to contain this cost. 
 
Keywords 
Cost of Illness, Hospital Costs, Stroke, Lebanon, Prospective Studies, Health Policy, Incidence, 
Regression Analysis, Humans. 
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Introduction 
Stroke is the second most frequent cause of death1,2 and the major cause of disability2,3 
worldwide. Being a disease with long-term consequences, stroke creates considerable social 
and economic burden to individuals and society,3 resulting from its high prevalence, 
hospitalization rates, morbidity and mortality.4 Worldwide, stroke consumes about 2–4% of 
total healthcare costs.2 In the US, total annual costs of stroke are expected to increase by 129%, 
reaching US$240.67 billion by 2030.5 Taken the scarcity of healthcare resources, cost-of-illness 
(COI) studies in stroke care are needed to provide insights into the distribution of the cost and 
its impact on the national healthcare expenditure.6  
Since investigations into economic impact of stroke are lacking in Lebanon, this study aimed 
to estimate cost of medical care during hospital admission, and to identify important variables 
that influence the cost in Beirut hospitals. 
Methods 
This study received ethical approval from the Institutional Review Board of each participating 
hospital. Signed informed consent was obtained from each patient or his caregiver after 
explaining the purpose and methods of the study. 
Study Design 
This is an observational, prospective, incidence-based, multicentre, COI study. Adult patients 
(≥18 years), diagnosed with acute stroke or Transient Ischemic Attack (TIA) (primary or 
recurrent) supported by computed tomography scan (CT scan) and/or magnetic resonance 
imaging (MRI) were included in this study between August 2015 and August 2016 from 8 
hospitals in Beirut of whom 6 private university hospitals, 1 private community hospital and 1 
public university hospital. 
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Stroke was defined according to the International Classification of Diseases (10th revision) 
including subarachnoid hemorrhage (SAH), primary intracerebral hemorrhage (PICH) and 
cerebral infarction. TIA was defined as a brief episode of neurologic dysfunction resulting from 
focal temporary cerebral ischemia and not associated with cerebral infarction.7 
Patients admitted after seven days of symptoms onset or those who have difficulty accepting 
follow-up visits were excluded. Patients were also excluded if they were: already dependent 
regarding activities of daily living (Barthel Index (BI) score ≤85); suffering from severe 
pathologies with unfavorable 1-year prognosis; disabling and progressive neurological 
diseases; cognitive decline (score >1 on Heteroanamnesis list Cognition)8 before their stroke. 
Data Collection  
Patients demographic (sex, age), socioeconomic profile (housing situation, socioeconomic 
status, employment status, third party payer (TPP), education level), risk factors, medical 
history including medical treatments, laboratory and imaging data, complications and 
rehabilitation therapy (physiotherapy and speech therapy) were collected at baseline and/or 
during hospitalization period. Current smokers were defined as persons who reported smoking 
at least 100 cigarettes during their lifetime and who, at the time they participated in the study, 
reported smoking every day or some days. Former smokers were defined as those who have 
smoked at least 100 cigarettes in their lifetime but who have quit smoking since a minimum of 
28 days. A researcher pharmacist did the data collection. 
Billing data were collected using a bottom-up approach. Costs of hospitalization of patients 
admitted to another hospital before being transferred to a participating hospital were also 
included. Costs were calculated according to the quantity of resources consumed by each patient 
from admission till discharge from hospital. The total direct medical cost per patient for each 
resource item was calculated as follows: total direct cost=∑unit cost×resource use. The bills for 
each patient were provided by the hospitals' administration including information related to cost 
of hospitalization, laboratory, radiology and cardiology-related investigations, medication, 
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nursing charges, physicians fees, and rehabilitation services. Costs calculated in Lebanese 
Pound (LBP) were converted to US$ (exchange rate: US$1=LBP 1508).9 
Study tools 
Pre-stroke functional disability was defined according to BI at admission, while functional 
disability at discharge were assessed using modified Rankin scale (mRS) and BI. Patients were 
divided into 3 groups according to their mRS score: independence (mRS 0–2), dependence 
(mRS 3–5) and death (mRS=6) and into four groups according to their BI: independence (96-
100), mild dependence (75-95), moderate dependence (46-74) and severe dependence (0-
45).3,4,10  
National Institution of Health Stroke Scale (NIHSS) score was used to classify stroke severity 
at admission into five categories (0=no stroke symptoms, 1-4=minor stroke, 5-14=moderate 
stroke, 15-20=moderate/severe, and 21-42=severe stroke).11 
Patients were classified into five etiologic/pathophysiological categories according to the Trial 
of Org 10172 in Acute Stroke Treatment (TOAST system)12 and into 4 different stroke locations 
(lacunar stroke syndrome (LACS), partial anterior circulation stroke (PACS), posterior 
circulation stroke (POCS) and total anterior circulation stroke (TACS)) according to Bamford 
Scale (BS).13 Patients’ assessment for the mRS, BI, NIHSS, and stroke diagnosis, classification 
and locations were performed by  neurologists or neurologist resident. 
Statistical analysis 
Data were entered and analyzed using Statistical Package for the Social Sciences (SPSS), 
version 20.0 (IBM Corporation, Armonk, NY, USA). Cost data entry was doubled checked. 
Two researchers audited 5% randomly selected questionnaires. Data entry showed high 
reliability (error rate <1%). Data were presented as means±SDs, except financial data presented 
also as medians and ranges. In bivariate analyses, Pearson correlation coefficients (or 
Spearman) were used for two continuous quantitative variables, Student’s test (or Mann-
Whitney) for means comparison between two groups (for quantitative variables) and Chi-square 
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test (or exact Fisher) for comparing percentages (for nominal, ordinal and categorical variables) 
were used. ANOVA (analysis of variance) test (or Kruskal Wallis) was used to compare 
between-group differences; followed by Bonferroni post-hoc when a significant difference was 
obtained. P≤0.05 indicated statistical significance. Bivariate analysis were done for the 
following dependent variables: LOS, ICU LOS and Cost. 
Predictors of total hospital cost (all stroke type and IS only) and LOS were determined through 
multivariable stepwise linear regressions controlling for potential confounders, after ensuring 
sample and conditions adequacy. Logistic transformation ln(cost of stroke) and ln(length of 
stay (LOS)) were performed as their distributions were skewed. Transformed data were 
normally distributed, and were entered in each model as dependent variable. Independent 
variables with P<0.2 in the bivariate analysis were entered into the models. Regression was 
checked for collinearity (VIF<10 indicated non-collinearity). Confounders (age and sex) were 
entered to the model as independent variables. 
Results 
Demographic and clinical characteristics (Tables 1-2) 
In this study, 203 patients were enrolled (mean age: 69±13 years, men: 58%) (Table 1). 
Approximately 5% of eligible patients did not give their written consent and were therefore 
excluded from the study. The mean LOS was 13±18 days. More than 50% were admitted to an 
intensive care unit (ICU) with a mean LOS of 6±13 days (Table 2). 
The mean NIHSS at admission was 11±10 and 30% of the patients had an NIHSS≥15. Around 
79% had an IS (22% due to large-artery atherosclerosis (LA), 33% cardio-embolism (CE), 17% 
small-vessel occlusion (SV) and 28% unclassified (UC)), 6.9% had a PICH, 7.9% had a SAH and 
5.9% had a TIA. According to Bamford classification, the major affected territory was PACS 
(60%) (Table 2). 
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The mean mRS and BI scores at discharge were 3.5±2.0 and 58.6±38.8, respectively and 30.0% 
of patients were independent at discharge (Table 2). 
Patients with hemorrhage had more severe neurological deficits on admission, stayed longer in-
hospital, required more ICU admissions, and had higher mortality rate; the survivors had worse 
functional outcome at discharge (Table 2). 
Direct cost of stroke (Figure 1) 
The direct in-hospital cost for all cases was US$1,413,069 for a total stay of 2626 days (US$538 
per in-hospital day). The average cost per stroke patient was US$6961±15,663. Of the total 
cost, 26.8% was attributed to the cost of room and board, 22.3% to general exams (including 
stroke and vascular imaging and cardiology-related investigations), 15.7% to physicians' fees, 
14.4% to laboratory tests, 14.6% to pharmacy, and 6.2% to other expenses. 
Predictors of cost (Tables 3-4) 
Regarding stroke types, PICH were the most expensive (US$26,698±50,400) followed by SAH 
(US$21,257±14,625), which were significantly more expensive than IS (US$4248±4352) and 
TIA (US$1277±492) (Table 3). 
Among ischemic stroke subtypes, the mean total cost was significantly higher for CE 
(US$6064±5865) compared with SV and UC (US$1827±1092, P<0.001; US$3003±3251, 
P=0.003), respectively. According to Bamford classification, LACS had a significantly lower 
cost than POCS, TACS, PACS (P= 0.008, 0.008, <0.001 respectively) (Table 3). 
Patients with infectious complications (i.e. pneumonia, urinary tract infection), or who 
underwent surgical intervention (i.e. coiling, shunt, craniotomy, endarterectomy, gastrostomy, 
tracheotomy) had a higher cost (P<0.001 for both) (Table 3). 
LOS and total cost positively correlated with stroke severity. Patients who survived a severe 
stroke stayed in-hospital longer and had higher costs compared with those with less severe 
strokes (P<0.001 in both comparisons). The higher cost of severe strokes was also associated 
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with greater ICU use. Deceased patients used significantly more resources than survivors 
(US$17,237±36,370 vs. US$9166±11,388; P<0.001) (Table 3). 
Total hospital costs strongly correlated with LOS (r=0.835, P<0.001), and ICU LOS (r=0.794, 
P<0.001), and moderately with admission NIHSS, mRS and BI discharge scores (r=0.657, 
r=0.657, r= -0.634 respectively, P<0.001). Total hospital costs did not significantly correlate 
with age (r=0.052, P=0.459), unless when SAH patients were excluded (r=0.227, P=0.002) 
(Table 3). 
Total cost varied by discharge destination; those discharged to rehabilitation centers or nursing 
homes had a considerably higher cost than home and home with help (P<0.001) (Table 3). 
Hospital LOS, ICU LOS, private TPP, hemorrhagic stroke, increased stroke severity on 
admission, having a surgery, infectious complication occurrence and high mRS score at 
discharge were independent predictors of increased total cost after accounting for confounding 
factors. ICU LOS accounted for 57% of the variance in total cost. Hospital LOS, ICU LOS and 
private TPP independently correlated with higher cost in ischemic strokes. In addition, LA and 
CE strokes, compared with SV and UC, and low BI at discharge were predictors of increased 
total cost (Table 4). 
Predictors of LOS 
Predictors of higher LOS were high NIHSS at admission, high mRS score at discharge, ICU 
LOS, having a surgery, infectious complication, discharge destination to a rehabilitation center 
or nursing home or death and female gender (Table 4). 
Discussion 
To the best of our knowledge, this is the first COI study analyzing the direct cost of in-patient 
medical care due to stroke in Lebanon and evaluating its drivers. The average in-hospital cost 
per stroke patient was US$6961±15,663. Cost drivers were LOS, stroke types, severity, 
etiology, complications, dependency level and TPP. 
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Although a direct comparison is not possible, mean hospital cost per patient (US$6961±15,663) 
was close to that reported from high-income countries (Greece US$7130)14 or lower (USA 
US$9688),15 yet it was higher than figures reported from middle and low-income countries 
(Turkey US$1917,4 Pakistan US$1578,16 Brazil US$4687 for PICH and US$2174 for IS,17 
Argentina US$14904 for PICH and US$4717 for IS18) (all costs were adjusted to 2015 US$ by 
purchasing power parities and consumer prices index). 
The mean LOS for patients in this study was close to similar studies done in Turkey, Greece 
and Sweden,4,14,19 but considerably shorter than that reported in several high-income 
countries,20,21 though Spanish and US centers have reported shorter LOS.22,23,24 
As in other studies,16,22,25 hospital LOS accounted for a large proportion of the variance of total 
cost than other variables entered to the regression model. The costs for bed and staff accounted 
for more than a quarter of total cost. Thus, as it was expected, LOS was highly correlated, in a 
direct and linear relationship, with total cost. Our study confirms that cost of in-patient care is 
largely driven by LOS14,21; decreasing the LOS might reduce in-hospital costs.26 Investigating 
interventions aiming at decreasing LOS from the societal perspective on the long run are 
necessary to ensure that they do not simply result in shifting of costs to follow-up care, resulting 
from poor quality of care, more complications, or more frequent readmissions. 
Of interest, cost for beds and staffs was lower than in high and middle-income countries.4,17,20,22 
This might be partly due to the considerably shorter hospitalization in our study. In contrast, 
the cost for imaging and laboratory was similar or higher than in high and middle-income 
countries.4,20,22 
In this study, 53% of the patients were initially admitted to ICU with a mean LOS of six days. 
These figures are close to those from Japan20 and a bit lower than Argentina and Brazil.17,18 
Admission criteria to ICU were not clearly predefined and depended on physicians in charge 
and hospitals policy; patients with severely reduced level of consciousness, those who required 
continuous cardiac monitoring, and those with massive infarction were usually admitted. 
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Further studies are needed to elucidate the role of the stoke unit in acute stroke as a cost-
effective model of care among stroke patients in Lebanon and advocate its implementation if 
found to be cost-effective.27 In fact, stroke service may result in reduced LOS, and thus drive 
costs down. 
We showed marked differences in in-patient costs, mortality and LOS according to different 
stroke types. Patients with PICH incurred the greatest cost, averaging US$26,700; the median 
cost of PICH was 3 times higher than that of IS. Patients with a TIA were the least costly, 
averaging US$1300. Furthermore, mortality and LOS were significantly higher in patients with 
PICH and SAH than those with ischemic stroke and TIA. As found in other high and middle-
income countries,18,19,23,28-30 patients with PICH or SAH bore higher costs, mortality and LOS. 
Mean cost per discharge for PICH was higher than that in high-income countries,23,28,30 however 
costs of patients with SAH, TIA and IS were lower than those in high-income countries.22,23,28,30 
In opposition to USA studies,23,28 mean cost of PICH was higher than SAH, however, the 
median is in line with their results. This could be due to two outlier patients in PICH group who 
spent 131 and 143 days in hospital. When these patients were removed from the analysis, mean 
cost of SAH exceeded that of PICH. 
CE and LA strokes compared with SV and UC were predictors of increased total cost. As in 
previous studies, patients with CE stroke had more severe neurological deficits and poorer 
outcomes, resulting in greater resource utilization, relatively longer hospitalization and ICU 
LOS and higher medical costs,20,21 as opposed to SV stroke. 
As shown elsewhere,10,14,22 we found that cost of acute care rose with stroke severity, this was 
mostly driven by increased LOS. However, when these same factors were examined in 
multivariable analysis, stroke severity emerged as an independent predictor of cost after 
accounting for LOS effects. 
Cost and LOS are dependent of functional outcome at discharge. Similarly to other studies, they 
increased with higher mRS scores10,14 and lower BI scores.3,10 Similarly to high-income 
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countries,10,31 most patients (76%) were discharged home, however, more than half needed help. 
Patients were discharged from hospital mostly when their medical investigations were 
completed and their general medical condition was stable in order to continue domiciliary 
rehabilitation treatment. 
Similarly to other middle-income studies' findings,17,18 the cost of patients who underwent a 
surgery or developed infectious complication was significantly higher, due to the added cost of 
operating room and surgeons' fees, extended hospital LOS and antibiotic treatments. Katzan et 
al. reported extended care and an incremental cost of US$20,413 (2015 US$) in stroke patients 
with pneumonia compared with infection-free patients.15 
Patients who died in hospital had higher cost compared with survivors, as found elsewhere,14 
however mortality rate in this study was considerably lower than other middle-income 
countries,4 but higher than some high-income countries20,22 yet very close to Greece.14 
However, these former20,22 did not include hemorrhagic stroke patients, which show higher 
mortality rates than IS.32 Other possible reasons are the higher number of stroke severity in this 
study, the lack of stroke unit and the underuse of thrombolysis in Lebanese hospitals. 
Lebanon has a highly fragmented health care system and pluralistic.33 Many differences in 
health care system quality remain between rural and urban areas as well as between public and 
private health care with different types of managed healthcare plans. In Lebanon, 46.8% of the 
population reported having some form of insurance (either social or private).33 If one excludes 
the non-Lebanese population that is estimated at 7.6%, the government is responsible for the 
remaining 45.6% of the population.33 The total contribution of the public TTPs represented 
approximately 45% (US$634626) of the total cost. TPP type significantly influenced total cost. 
In fact, in Lebanon, the cost of each resource varies based on TPP coverage tariffs. Public payers 
have lower tariffs for the same resource use compared to private. 
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Strengths and limitations of this study 
The first strength of this study was related to the prospective data collection using validated 
tools used in previous similar research for data collection. It pioneered in assessing cost of 
stroke predictors through multivariable analysis. Additionally, we estimated costs, including 
physicians' fees, based on actual bills vs. using proxy methods, rather than predetermined 
charges. We conducted a multicenter incidence-base study including a diversified population, 
hence increasing the generalizability of our results. 
This study does, however, have limitations. Even though patients came from all governorates, 
hospitals were limited to Beirut region. In this study, we could not exclude some unintentional 
bias in patient care, due to its observational nature. Also, we did not have strict guidelines for 
the clinical management of patients, which depended primarily on the physician in charge. 
Conclusion 
This study is an important first step in evaluating the economic impact of hospitalization due to 
stroke in Lebanon. Cost of care is significantly influenced by level of stroke severity and LOS. 
This information may help policy makers to develop health care plans to minimize economic 
burden on health system. Future studies should focus on modifiable, often unmeasured 
parameters, related not only to stroke characteristics, but also to hospital operational policies, 
potentially influencing LOS. Because stroke often results in permanent dependence, cost 
analysis of long-term care from a societal perspective should be established. 
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Table 1. Demographic characteristics. 
 All 
(n=203;100%) 
IS 
(n=161;79.3%) 
TIA 
(n=12;5.9%) 
PICH 
(n=14;6.9%) 
SAH 
(n=16;7.9%) 
P-value 
Age (mean±SD) 68.8±12.9 70.3±12.3 62.3±16.0 72.6±9.4 55.0±9.9 <0.001a 
Gender–Male 
(n(%)) 
117(57.6%) 96(59.6%) 8(66.7%) 9(64.3%) 4(25.0%) 0.048 
TPP      NS 
Public 166(81.8%) 129(80.1%) 11(91.7%) 11(78.6%) 15(93.8%)  
Private 37(18.2%) 32(19.9%) 1(8.3%) 3(21.4%) 1(6.3%)  
Marital status      NS* 
Single/ Divorced 19(9.4%) 13(8.1%) 1(8.3%) 3(21.4%) 2(12.5%)  
Widowed 62(30.5%) 54(33.5%) 2(16.7%) 2(14.3%) 4(25.0%)  
Married 122(60.1%) 94(58.4%) 9(75.0%) 9(64.3%) 10(62.5%)  
Education      NS* 
Illiterate 37(18.2%) 34(21.1%) 1(8.3%) 1(7.1%) 1(6.3%)  
Elementary 86(42.4%) 67(41.6%) 4(33.3%) 7(50.0%) 8(50.0%)  
Secondary 35(17.2%) 27(16.8%) 4(33.3%) 2(14.3%) 2(12.5%)  
≥High school 45(22.2%) 33(20.5%) 3(25.0%) 4(28.5%) 5(31.3%)  
Professional 
condition 
     NS* 
Employed 61(30.0%) 46(28.6%) 5(41.7%) 6(42.9%) 4(25.0%)  
Housewife 82(40.4%) 63(39.1%) 4(33.3%) 4(28.6%) 11(68.8%)  
Retired 21(10.3%) 16(9.9%) 1(8.3%) 4(28.6%) 0(0%)  
Unemployed 39(19.2%) 36(22.4%) 2(16.7%) 0(0%) 1(6.3%)  
Monthly home 
income (US$) 
     NS* 
<500  60(29.6%) 52(32.3%) 2(16.7%) 2(14.3%) 4(25.0%)  
[500-1,000] 62(30.5%) 48(29.8%) 5(41.7%) 5(35.7%) 4(25.0%)  
[1,000-1,500] 37(18.2%) 26(16.1%) 2(16.7%) 3(21.4%) 6(37.5%)  
>1,500 44(21.7%) 35(21.7%) 3(25.0%) 4(28.6%) 2(12.5%)  
 
IS=ischemic stroke; TIA=transit ischemic attack; PICH=primary intracerebral hemorrhage; 
SAH=subarachnoid hemorrhage, TPP=third party payer. 
*Non-parametric test 
aSAH vs. PICH and SAH vs. IS 
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Table 2. Clinical characteristics. 
 All 
(n=203;100%) 
IS 
(n=161;79.3%) 
TIA 
(n=12;5.9%) 
PICH 
(n=14;6.9%) 
SAH 
(n=16;7.9%) 
P-value 
Risk factors       
-Hypertension 153(75.7%) 126(78.3%) 10(83.3%) 10(76.9%) 7(43.8%) 0.020 
-Dyslipidemia 76(37.6%) 60(37.3%) 9(75.0%) 4(30.8%) 3(18.8%) 0.020 
-Diabetes 
Mellitus 
83(41.1%) 70(43.5%) 4(33.3%) 7(58.3%) 2(12.5%) NS 
-Atrial 
Fibrillation 
26(12.9%) 22(13.7%) 3(25.0%) 1(7.7%) 0(0%) NS 
-Smoker      NS* 
 ▪former smoker 31(15.3%) 24(14.9%) 3(25.0%) 4(28.6%) 0 (0%)  
 ▪current smoker 102(50.5%) 82(50.9%) 5(41.7%) 4(28.6%) 11(68.8%)  
First ever 
stroke/TIA 
171(84.2%) 132(82.0%) 11(91.7%) 12(85.7%) 0(0%) NS 
Pre-stroke BI 
(mean±SD) 
98.7±3.0 98.8±3.0 98.3±3.3 97.9±3.8 99.4±1.7 NS 
NIHSS on 
admission 
(mean±SD) 
10.8±9.9 10.0±8.6 0.7±1.0 19.4±12.3 19.7±12.7 <0.001*
a 
LOS (mean±SD) 12.9±18.5 9.9±8.8 3.4±1.6 37.4±46.9 30.1±28.3 <0.001*
b 
ICU admission 107(52.7%) 78(48.4%) 1(8.3%) 12(85.7%) 16(100%) <0.001 
ICU LOS 
(mean±SD) 
5.9±13.2 3.6±6.8 0.2±0.6 20.2±32.2 20.8±20.9 <0.001*
c 
mRS at discharge 
(mean±SD) 
3.5±2.0 3.5±1.9 0.6±0.9 4.5±1.8 4.6±1.1 <0.001*
c 
BI at discharge 
(mean±SD) 
58.6±38.8 58.5±38.1 97.9±4.5 38.0±43.8 38.5±35.1 <0.001*
c 
TOAST 
classification 
     0.014* 
LA 37(21.4%) 36(22.4%) 1(8.3%)    
CE 55(31.8%) 53(32.9%) 2(16.7%)    
SV 27(15.6%) 27(16.8%) 0(0%)    
UC 54(31.2%) 45(27.9%) 9(75.0%)    
Discharge 
destination 
     <0.001* 
Home 72(35.5%) 56(34.8%) 12(100%) 3(21.4%) 1(6.3%)  
Home with help 82(40.4%) 69(42.9%) 0(0%) 5(35.7%) 8(50.0%)  
Rehabilitation 
center/Nursing 
home 
22(10.8%) 16(9.9%) 0(0%) 2(14.3%) 4(25.0%)  
Death 27(13.3%) 20(12.4%) 0(0%) 4(28.6%) 3(18.8%)  
Cost (US$)      <0.001*
d 
(mean±SD)/ 6961±15663 4248±4352 1277±492 26,698±50,4
00 
21,257±14,6
25 
 
median(25th-
75th) 
2751(1484-
6396) 
2578(1492-
5436) 
1234(947-
1436) 
8028(2382-
28462) 
14,746(1206
6-23957) 
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IS=ischemic stroke; TIA=transit ischemic attack; PICH=primary intracerebral hemorrhage; 
SAH=subarachnoid hemorrhage, LOS=length of stay; ICU=intensive care unit; NIHSS= National 
Institution of Health Stroke Scale; mRS=modified Rankin Scale; BI=Barthel Index; TOAST=Trial of 
Org 10172 in Acute Stroke Treatment; LA=large-artery atherosclerosis; CE=cardioembolism; 
SV=small-vessel occlusion; UC=unclassified. 
 
*Non-parametric test 
aExcept SAH vs. PICH 
bExcept SAH vs. PICH and TIA vs. IS 
cTIA vs. IS; PICH and SAH 
dExcept SAH vs. PICH 
 
Table 3. Bivariable analysis for hospital LOS, ICU LOS and cost of stroke. 
 N LOS ICU LOS Cost (US$) P-value~ 
Total 203 12.9±18.5 5.9±13.2 6961±15663 - 
Type of stroke     <0.001*a 
IS 161 9.8±8.8 3.6±6.8 4248±4352  
TIA 12 3.4±1.6 0.2±0.6 1277±492  
PICH 14 37.3±46.9 20.2±32.2 26698±50400  
SAH 16 30.1±28.3 20.8±20.9 21257±14625  
NIHSS     <0.001*b 
No stroke symptoms 13 5.1±4.7 2.5±4.7 3049±3764  
Minor stroke 63 4.8±3.0 0.7±1.7 2372±2214  
Moderate stroke 67 11.1±16.0 2.8±3.8 4451±5129  
Moderate/Severe stroke 18 14.7±10.9 7.8±10.3 7049±5764  
Severe stroke 42 29.7±28.0 18.7±23.4 19021±30734  
mRS     <0.001* 
Independent 61 4.4±2.8 0.8±2.5 1971±1741  
Dependent 115 14.9±18.4 5.6±9.1 7195±9647  
Dead 27 23.7±29.0 18.6±27.2 17237±36370  
BI     <0.001c 
Independence 49 4.3±2.5 0.6±1.9 1853±1263  
Mild dependence 32 5.2±3.3 1.4±3.2 2405±2070  
Moderate dependence 30 8.3±5.0 3.3±4.2 4779±4762  
Severe dependence 65 20.9±22.4 7.9±11.2 9793±11753  
BS     <0.001#d 
LACS 27 5.0±2.8 0.4±0.9 1827±1092  
POCS 31 10.5±8.6 5.6±8.7 4365±4188  
TACS 5 13.6±6.6 7.4±3.5 5732±1819  
PACS 96 10.9±9.8 3.6±6.9 4896±4854  
POCS+PACS 2 4.0±1.4 0±0 1546±107  
First ever vs. recurrent 
stroke 
    NS 
First ever 171 13.8±19.9 6.5±14.2 7495±16975  
Recurrent 32 8.6±5.2 2.7±4.1 4107±2914  
Infection status     <0.001 
Infection(-) 141 6.6±4.9 2.1±3.9 3192±3459  
Infection(+) 62 27.2±27.8 14.5±20.8 15532±26028  
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 N LOS ICU LOS Cost (US$) P-value~ 
Total 203 12.9±18.5 5.9±13.2 6961±15663 - 
Surgery     <0.001 
Surgery(-) 175 9.8±13.2 3.4±6.8 4335±6421  
Surgery(+) 28 32.3±31.4 21.3±26.7 23374±35295  
Gender     0.015e 
Male 117 12.6±20.8 5.6±14.5 6624±19009  
Female 86 13.3±14.8 6.2±11.2 7419±9462  
TPP     0.039e 
Private 37 13.7±19.6 5.9±13.4 8583±13061  
Public 166 12.8±18.3 5.6±12.1 6599±16199  
TOAST     <0.001#f 
LA 37 10.2±8.9 2.6±3.7 4166±2721  
CE 55 12.7±10.2 6.0±8.4 6064±5865  
SV 27 5.0±2.8 0.4±1.0 1827±1092  
UC 54 7.6±7.5 2.5±7.0 3003±3251  
Discharge destination     <0.001*g 
Home 72 4.5±2.7 0.7±2.3 1950±1607  
Home with help 82 12.5±12.9 5.6±9.5 6555±8864  
Rehabilitation 
center/Nursing home 
22 23.7±29.0 7.8±9.5 12258±12591  
Death 27 28.9±30.3 18.6±27.2 17237±36370  
 (mean±SD) 
IS=Ischemic stroke; TIA=Transit Ischemic Attack; PICH=Primary Intracerebral hemorrhage; 
SAH=Subarachnoid hemorrhage, LOS=length of stay; ICU=intensive care unit; TPP=third party payer; 
NIHSS= National Institution of Health Stroke Scale; mRS=modified Rankin Scale; BI=Barthel Index; 
TOAST=Trial of Org 10172 in Acute Stroke Treatment; LA=large-artery atherosclerosis; CE=cardioembolism; 
SV=small-vessel occlusion; UC=unclassified; LACS=lacunar stroke syndrome; PACS=partial anterior 
circulation stroke; POCS=posterior circulation stroke; TACS=total anterior circulation stroke. 
 
~For ICU LOS, non-parametric tests were used as the distribution couldn't be normal. LOS and cost 
were treated as ln(LOS) and ln(cost), parametric tests were used unless noted. 
*Non-parametric test used (due to non-homogeneity of variances) 
#Non-parametric test used, except for LOS (due to its homogeneity of variances) 
aNS for SAH vs. PICH 
bLOS: NS for no stroke symptoms vs. minor stroke and moderate stroke vs. moderate/severe stroke / 
ICU LOS: only for severe stroke vs. everything else / Cost: NS for no stroke symptoms vs. minor 
stroke and moderate stroke, moderate stroke vs. moderate/severe stroke 
cLOS and cost: NS for independence vs. mild dependence / ICU LOS: NS for independence vs. mild 
and moderate dependence and mild vs. moderate dependence 
dOnly for LACS vs. POCS, PACS and TACS 
eOnly for cost, NS for LOS and ICU LOS 
fLOS: NS for SV vs. UC, CE vs. LA, and LA vs. UC / ICU LOS: NS for LA vs. SV, LA vs. UC, SV 
vs. UC / Cost: NS for LA vs. UC and SV vs. UC 
gLOS and cost: NS for rehabilitation center/nursing home vs. death / ICU LOS: NS for home with help 
vs. rehabilitation center/nursing home. 
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Table 4. Multivariable linear regression analysis of overall hospital length of stay and cost for all type of strokes and for 
ischemic strokes. 
 All type of strokesa Ischemic strokesb Hospital LOSc 
Variables explained 77.8% of the variance of total cost (ln(cost)) 71.3% of the variance of total cost (ln(cost)) 73.4% of the variance of total LOS (ln(LOS)) 
Anova <0.001 <0.001 <0.001 
Independent 
variables 
Unstandardized 
Coefficients 
Standardize
d 
Coefficients 
P-
value 
VIF 
Unstandardized 
Coefficients 
Standardize
d 
Coefficients 
P-
value 
 
VIF 
 
Unstandardized 
Coefficients Standardized 
Coefficients 
P-value VIF 
Β SD    Β SD Β SD 
(Constant) 6.240     7.281     0.799     
LOS 0.013 0.003 0.218 <0.001 2.6 0.038 0.006 0.400 <0.001 1.9      
ICU LOS 0.026 0.008 0.213 0.001 3.2 0.061 0.010 0.351 <0.001 1.6 0.033 0.006 0.295 <0.001 2.1 
TPP    <0.001 1.0    <0.001 1.0      
Public - - -   - - -        
Private 0.444 0.089 0.181   0.529 0.086 0.284        
Surgery 0.609 0.135 0.208 <0.001 1.7      0.416 0.129 0.155 0.001 1.5 
Type of stroke 
IS+TIA 
PICH+SAH 
 
- 
0.320 
 
- 
0.135 
 
- 
0.114 
0.019 1.8           
NIHSS at admission 0.100 0.046 0.117 0.032 2.3      0.116 0.046 0.148 0.013 2.3 
mRS at discharge 0.109 0.026 0.207 <0.001 1.9      0.145 0.027 0.300 <0.001 2.1 
Infectious 
complication 
0.264 0.105 0.116 0.013 1.7      0.376 0.104 0.180 <0.001 1.6 
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 All type of strokesa Ischemic strokesb Hospital LOSc 
BI at discharge      -0.003 0.001 -0.164 0.005 1.6      
TOAST 
classification 
LA/CE 
UC/SV 
     
 
- 
-0.207 
 
- 
0.073 
 
- 
-0.142 
0.005 1.2      
Discharge destination 
Home (with or 
without help) 
Rehabilitation 
center/Nursing 
home/Death 
          
 
- 
 
0.419 
 
- 
 
0.116 
 
- 
 
0.159 
<0.001 1.3 
Sex (male reference)           -0.160 0.074 -0.090 0.033 1.2 
IS=Ischemic stroke; TIA=Transit Ischemic Attack; PICH=Primary Intracerebral hemorrhage; SAH=Subarachnoid hemorrhage, LOS=length 
of stay; ICU=intensive care unit; TPP=third party payer; NIHSS= National Institution of Health Stroke Scale; mRS=modified Rankin Scale; 
BI=Barthel Index; TOAST=Trial of Org 10172 in Acute Stroke Treatment; LA=large-artery atherosclerosis; CE=cardioembolism; SV=small-
vessel occlusion; UC=unclassified; LACS=lacunar stroke syndrome; PACS=partial anterior circulation stroke; POCS=posterior circulation stroke; 
TACS=total anterior circulation stroke. 
a Dependent variable: ln(cost) 
Independent variables: LOS, ICU LOS, TPP, Surgery, Type of stroke, NIHSS at admission, mRS at discharge, Infectious complication, BI at 
discharge, Discharge destination, Sex, Age  
b Dependent variable: ln(cost) 
Independent variables: LOS, ICU LOS, TPP, Surgery, NIHSS at admission, mRS at discharge, Infectious complication, BI at discharge, TOAST 
classification, Discharge destination, Sex, Age, Bamford classification (LACS vs. other) 
c Dependent variable: ln(LOS) 
Independent variables: ICU LOS, TPP, Surgery, Type of stroke, NIHSS at admission, mRS at discharge, Infectious complication, BI at discharge, 
Discharge destination, Sex, Age   
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Figure 1. In-hospital cost distribution. 
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5. Discussion 
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5.1 Discussion of the main results of the thesis 
In Lebanon, we found that stroke management is in line with evidence-based and clinical 
practice guidelines. However reperfusion therapy are still largely underused and remains a 
major challenge in achieving guideline-based reperfusion goals. In Lebanon, mortality due to 
stroke is relatively high compared to other countries (specially the short-term mortality). Public 
awarness campains (focusing on people with low education and SES) of stroke risk factors, 
warning symptoms, and importance of immediate modern concepts of time-dependent stroke 
treatment are needed. The implementation of stroke unit at the hospitals, as well as stroke 
management protocols, will be important steps toward improving the standard of care (both 
clinically and economically). This may limit the mortality rate and possible complications after 
stroke.  
More aggressive control of modifiable risk factors and needed in order the reduce stroke 
incidence and therefore stroke mortality. HT is an important factor in primary prevention for 
several reasons. HT is the most powerful risk factor for stroke, its prevalence is high in Lebanon 
and the management of hypertensive patients remains suboptimal. Thus, better management of 
hypertensive patients will reduce the risk of stroke.  
Improving rehabilitation in-hospital and highlighting the importance of rehabilitation after 
discharge is crutial for patients in order to improve their physical function impairments and 
reintegrate socially and professionally in the society. This will diminish the decline in QOL 
post-stroke that was relatively high in our study and therefore restrict the post-stroke depression 
rate. Being able to continu working after a stroke is crutial for the individual and the society, 
this will decrease the indirect costs (loss work productivity as well as loss of future productivity) 
and DALYs. 
Overall in-hospital stroke management did not differ between SES and private vs. public third 
party payer even though the in-hospital cost of stroke significantly differed. This means that 
patients receive the same care regardless of their SES and third party payer coverage.  
The sum of all these measures (incidence, prevalence, mortality, QOL, cost of illness, etc.) 
would give a complete picture of the burden of stroke in Lebanon. 
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5.2 Implications of outcomes for public health policy makers  
Our findings are important for health professionals and public health policy makers. When 
reliable data on stroke burden are available, health care planning can be more effectively 
undertaken, ideally with the generation of longitudinal data to usefully monitor the 
effectiveness of any interventions. Our findings reinforce the evidence for resource allocation 
for primary and secondary prevention programs and awareness campaigns on the danger of 
behavioral risk factors to reduce stroke morbidity and mortality.  
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6. Perspectives & Conclusion 
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Stroke is given currently a lower priority for clinical services and research compared with other 
diseases with a similar or lower public health impact. This is related to the lack of readily 
accessible comparative data to help mount a political case for the development of national 
strategies to address the burden of stroke. In the near future, it would be interesting to: 
Calculate exactly the incidence rate of stroke in Lebanon. 
Analyze the regional disparities in the epidemiology of stroke and their influence on risk factors 
and the management of the disease. 
Assess the knowledge of stroke symptoms and risk factors and attitude of the population toward 
stroke.  
Estimate the cost-effectiveness of integrated specialized stroke units in Lebanon: providing 
enhanced patient outcomes compared with conventional care.  
Evaluate the chronic management of stroke: secondary prevention (assessing short-term and 
long-term medication compliance of stroke patients to treatment, medical follow-up, routine 
examinations, control of risk factors among patients, stroke recurrence rate, etc.), chronic 
rehabilitative care, late mortality rate and disability prevalence.  
Research for more efficacious therapeutic options to prevent stroke sequelae are crucially 
needed. This includes the use of stem cells, and the search for new neuroprotective agents. 
More research in the areas of hypothermia (therapeutic cooling), stem cell therapies, and a 
polypill for secondary prevention of stroke are needed. 
Another intersting topic is to determine the quality of life of caregivers of stroke patients and 
its determinants. Moreover, determining the depression rate of caregivers of stroke patients and 
its determinants may be reasonable. 
The studies presented in this manuscript may possibly be repeated but in a way that allows their 
generalizability to the whole country (better sampling of all governorates, larger sample size, 
etc.) in the community and not just hospitals, measuring socio-economic risk factors (education, 
work, income), psychic factors (stress and anxiety), all comorbidities and potential risk factors.  
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It is absolutely necessary to develop our knowledge of the epidemiology of stroke in Lebanon, 
in order to limit the impact and burden of the disease in the years to come.  
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Appendix 2: NIH Stroke Scale 
 
  Instructions Scale Definition Score 
1a. Level of Consciousness  
The investigator must choose a response if a full 
evaluation is prevented by such obstacles as an 
endotracheal tube, language barrier, orotracheal 
trauma/ bandages. A 3 is scored only if the patient 
makes no movement (other than reflexive posturing) in 
response to noxious stimulation. 
0 = Alert; keenly responsive.  
1 = Not alert; but arousable by 
minor stimulation to obey, 
answer, or respond.  
2 = Not alert; requires 
repeated stimulation to attend, 
or is obtunded and requires 
strong or painful stimulation to 
make movements (not 
stereotyped).  
3 = Responds only with reflex 
motor or autonomic effects or 
totally unresponsive, flaccid, 
and areflexic.  
______ 
1b. LOC Questions  
The patient is asked the month and his/her age. The 
answer must be correct - there is no partial credit for 
being close. Aphasic and stuporous patients who do not 
comprehend the questions will score 2. Patients unable 
to speak because of endotracheal intubation, 
orotracheal trauma, severe dysarthria from any cause, 
language barrier, or any other problem not secondary 
to aphasia are given a 1. It is important that only the 
initial answer be graded and that the examiner not 
"help" the patient with verbal or non-verbal cues. 
0 = Answers both questions 
correctly.  
1 = Answers one question 
correctly.  
2 = Answers neither question 
correctly.  
______ 
1c. LOC Commands 
The patient is asked to open and close the eyes and 
then to grip and release the non-paretic hand. 
Substitute another one step command if the hands 
cannot be used. Credit is given if an unequivocal 
attempt is made but not completed due to weakness. If 
the patient does not respond to command, the task 
should be demonstrated to him or her (pantomime), 
and the result scored (i.e., follows none, one or two 
commands). Patients with trauma, amputation, or 
other physical impediments should be given suitable 
one-step commands. Only the first attempt is scored. 
0 = Performs both tasks 
correctly.  
1 = Performs one task 
correctly.  
2 = Performs neither task 
correctly.  
______ 
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  Instructions Scale Definition Score 
2. Best Gaze 
Only horizontal eye movements will be tested. 
Voluntary or reflexive (oculocephalic) eye movements 
will be scored, but caloric testing is not done. If the 
patient has a conjugate deviation of the eyes that can 
be overcome by voluntary or reflexive activity, the 
score will be 1. If a patient has an isolated peripheral 
nerve paresis (CN III, IV or VI), score a 1. Gaze is testable 
in all aphasic patients. Patients with ocular trauma, 
bandages, pre-existing blindness, or other disorder of 
visual acuity or fields should be tested with reflexive 
movements, and a choice made by the investigator. 
Establishing eye contact and then moving about the 
patient from side to side will occasionally clarify the 
presence of a partial gaze palsy. 
0 = Normal.  
1 = Partial gaze palsy; gaze is 
abnormal in one or both eyes, 
but forced deviation or total 
gaze paresis is not present.  
2 = Forced deviation, or total 
gaze paresis not overcome by 
the oculocephalic maneuver.  ______ 
3. Visual 
Only horizontal eye movements will be tested. 
Voluntary or reflexive (oculocephalic) eye movements 
will be scored, but caloric testing is not done. If the 
patient has a conjugate deviation of the eyes that can 
be overcome by voluntary or reflexive activity, the 
score will be 1. If a patient has an isolated peripheral 
nerve paresis (CN III, IV or VI), score a 1. Gaze is testable 
in all aphasic patients. Patients with ocular trauma, 
bandages, pre-existing blindness, or other disorder of 
visual acuity or fields should be tested with reflexive 
movements, and a choice made by the investigator. 
Establishing eye contact and then moving about the 
patient from side to side will occasionally clarify the 
presence of a partial gaze palsy. 
0 = No visual loss.  
1 = Partial hemianopia.  
2 = Complete hemianopia.  
3 = Bilateral hemianopia (blind 
including cortical blindness).  
______ 
4. Facial Palsy  
Ask – or use pantomime to encourage – the patient to 
show teeth or raise eyebrows and close eyes. Score 
symmetry of grimace in response to noxious stimuli in 
the poorly responsive or non-comprehending patient. If 
facial trauma/bandages, orotracheal tube, tape or other 
physical barriers obscure the face, these should be 
removed to the extent possible. 
0 = Normal symmetrical 
movements.  
1 = Minor paralysis (flattened 
nasolabial fold, asymmetry on 
smiling).  
2 = Partial paralysis (total or 
near-total paralysis of lower 
face).  
3 = Complete paralysis of one 
or both sides (absence of facial 
movement in the upper and 
lower face).  
______ 
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  Instructions Scale Definition Score 
5. Motor Arm 
The limb is placed in the appropriate position: extend 
the arms (palms down) 90 degrees (if sitting) or 45 
degrees (if supine). Drift is scored if the arm falls before 
10 seconds. The aphasic patient is encouraged using 
urgency in the voice and pantomime, but not noxious 
stimulation. Each limb is tested in turn, beginning with 
the non-paretic arm. Only in the case of amputation or 
joint fusion at the shoulder, the examiner should record 
the score as untestable (UN), and clearly write the 
explanation for this choice. 
0 = No drift; limb holds 90 (or 
45) degrees for full 10 seconds.  
1 = Drift; limb holds 90 (or 45) 
degrees, but drifts down 
before full 10 seconds; does 
not hit bed or other support.  
2 = Some effort against 
gravity; limb cannot get to or 
maintain (if cued) 90 (or 45) 
degrees, drifts down to bed, 
but has some effort against 
gravity.  
3 = No effort against gravity; 
limb falls.  
4 = No movement.  
UN = Amputation or joint 
fusion, explain: 
_____________________  
 
5a. Left Arm  
5b. Right Arm  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______ 
______ 
6. Motor Leg  
The limb is placed in the appropriate position: hold the 
leg at 30 degrees (always tested supine). Drift is scored 
if the leg falls before 5 seconds. The aphasic patient is 
encouraged using urgency in the voice and pantomime, 
but not noxious stimulation. Each limb is tested in turn, 
beginning with the non-paretic leg. Only in the case of 
amputation or joint fusion at the hip, the examiner 
should record the score as untestable (UN), and clearly 
write the explanation for this choice. 
0 = No drift; leg holds 30-
degree position for full 5 
seconds.  
1 = Drift; leg falls by the end of 
the 5-second period but does 
not hit bed.  
2 = Some effort against gravity; 
leg falls to bed by 5 seconds, 
but has some effort against 
gravity.  
3 = No effort against gravity; 
leg falls to bed immediately.  
4 = No movement.  
UN = Amputation or joint 
fusion, explain: 
__________________________
________________ 
 
6a. Left Leg  
6b. Right Leg  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______ 
______ 
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  Instructions Scale Definition Score 
7. Limb Ataxia 
This item is aimed at finding evidence of a unilateral 
cerebellar lesion. Test with eyes open. In case of visual 
defect, ensure testing is done in intact visual field. The 
finger-nose-finger and heel-shin tests are performed on 
both sides, and ataxia is scored only if present out of 
proportion to weakness. Ataxia is absent in the patient 
who cannot understand or is paralyzed. Only in the case 
of amputation or joint fusion, the examiner should 
record the score as untestable (UN), and clearly write 
the explanation for this choice. In case of blindness, test 
by having the patient touch nose from extended arm 
position. 
0 = Absent.  
1 = Present in one limb.  
2 = Present in two limbs.  
UN = Amputation or joint 
fusion, explain: 
__________________________
________________  
______ 
8. Sensory 
Sensation or grimace to pinprick when tested, or 
withdrawal from noxious stimulus in the obtunded or 
aphasic patient. Only sensory loss attributed to stroke is 
scored as abnormal and the examiner should test as 
many body areas (arms [not hands], legs, trunk, face) as 
needed to accurately check for hemisensory loss. A 
score of 2, “severe or total sensory loss,” should only be 
given when a severe or total loss of sensation can be 
clearly demonstrated. Stuporous and aphasic patients 
will, therefore, probably score 1 or 0. The patient with 
brainstem stroke who has bilateral loss of sensation is 
scored 2. If the patient does not respond and is 
quadriplegic, score 2. Patients in a coma (item 1a=3) are 
automatically given a 2 on this item.  
0 = Normal; no sensory loss.  
1 = Mild-to-moderate sensory 
loss; patient feels pinprick is 
less sharp or is dull on the 
affected side; or there is a loss 
of superficial pain with pinprick, 
but patient is aware of being 
touched.  
2 = Severe to total sensory 
loss; patient is not aware of 
being touched in the face, arm, 
and leg.  
______ 
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  Instructions Scale Definition Score 
9. Best Language 
A great deal of information about comprehension will 
be obtained during the preceding sections of the 
examination. For this scale item, the patient is asked to 
describe what is happening in the attached picture, to 
name the items on the attached naming sheet and to 
read from the attached list of sentences. 
Comprehension is judged from responses here, as well 
as to all of the commands in the preceding general 
neurological exam. If visual loss interferes with the 
tests, ask the patient to identify objects placed in the 
hand, repeat, and produce speech. The intubated 
patient should be asked to write. The patient in a coma 
(item 1a=3) will automatically score 3 on this item. The 
examiner must choose a score for the patient with 
stupor or limited cooperation, but a score of 3 should 
be used only if the patient is mute and follows no one-
step commands.  
 
0 = No aphasia; normal.  
1 = Mild-to-moderate aphasia; 
some obvious loss of fluency or 
facility of comprehension, 
without significant limitation on 
ideas expressed or form of 
expression. Reduction of 
speech and/or comprehension, 
however, makes conversation 
about provided materials 
difficult or impossible. For 
example, in conversation about 
provided materials, examiner 
can identify picture or naming 
card content from patient’s 
response.  
2 = Severe aphasia; all 
communication is through 
fragmentary expression; great 
need for inference, questioning, 
and guessing by the listener. 
Range of information that can 
be exchanged is limited; 
listener carries burden of 
communication. Examiner 
cannot identify materials 
provided from patient 
response.  
3 = Mute, global aphasia; no 
usable speech or auditory 
comprehension.  
______ 
10. Dysarthria 
If patient is thought to be normal, an adequate sample 
of speech must be obtained by asking patient to read or 
repeat words from the attached list. If the patient has 
severe aphasia, the clarity of articulation of 
spontaneous speech can be rated. Only if the patient is 
intubated or has other physical barriers to producing 
speech, the examiner should record the score as 
untestable (UN), and clearly write an explanation for 
this choice. Do not tell the patient why he or she is 
being tested.  
0 = Normal.  
1 = Mild-to-moderate 
dysarthria; patient slurs at least 
some words and, at worst, can 
be understood with some 
difficulty.  
2 = Severe dysarthria; patient's 
speech is so slurred as to be 
unintelligible in the absence of 
or out of proportion to any 
dysphasia, or is mute/anarthric.  
UN = Intubated or other 
physical barrier, 
explain:___________________
_________________  
______ 
  
247 
  Instructions Scale Definition Score 
11. Extinction and Inattention (formerly Neglect) 
Sufficient information to identify neglect may be 
obtained during the prior testing. If the patient has a 
severe visual loss preventing visual double 
simultaneous stimulation, and the cutaneous stimuli 
are normal, the score is normal. If the patient has 
aphasia but does appear to attend to both sides, the 
score is normal. The presence of visual spatial neglect 
or anosagnosia may also be taken as evidence of 
abnormality. Since the abnormality is scored only if 
present, the item is never untestable.  
0 = No abnormality.  
1 = Visual, tactile, auditory, 
spatial, or personal inattention 
or extinction to bilateral 
simultaneous stimulation in 
one of the sensory modalities.  
2 = Profound hemi-inattention 
or extinction to more than one 
modality; does not recognize 
own hand or orients to only 
one side of space.  
______ 
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?????????????????????????????????????????????????????????????????????????????????????????????
??????????
??????????????????????????
? ????????????????
? ?????????????????
? ???????????????????????
? ?????????????????
? ?????????????????????????
? ?????????????????
?????????????????????????????????????
? ????????????????
? ?????????????????
? ???????????????????????
? ?????????????????
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 A little bit of the time 
 None of the Time 
Have you felt so down in the dumps that nothing could cheer you up? 
 All of the time 
 Most of the time 
 A good Bit of the Time 
 Some of the time 
 A little bit of the time 
 None of the Time 
Have you felt calm and peaceful? 
 All of the time 
 Most of the time 
 A good Bit of the Time 
 Some of the time 
 A little bit of the time 
 None of the Time 
Did you have a lot of energy? 
 All of the time 
 Most of the time 
 A good Bit of the Time 
 Some of the time 
 A little bit of the time 
 None of the Time 
Have you felt downhearted and blue? 
 All of the time 
 Most of the time 
 A good Bit of the Time 
 Some of the time 
 A little bit of the time 
 None of the Time 
Did you feel worn out? 
 All of the time 
 Most of the time 
 A good Bit of the Time 
 Some of the time 
 A little bit of the time 
 None of the Time 
Have you been a happy person? 
  
????
? ????????????????
? ?????????????????
? ???????????????????????
? ?????????????????
? ?????????????????????????
? ?????????????????
????????????????????
? ????????????????
? ?????????????????
? ???????????????????????
? ?????????????????
? ?????????????????????????
? ?????????????????
???????????????????
????????????????????????????? ??????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????? ???????????????????????????????
? ????????????????
? ?????????????????
? ???????????????????????
? ?????????????????
? ?????????????????????????
? ?????????????????
???????? ???????
???????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????
???????????????? ???????????? ??????????? ????????????? ?????????????????
??????????????????????????????????
???????????????? ???????????? ??????????? ????????????? ?????????????????
????????? ??????????????????????
???????????????? ???????????? ??????????? ????????????? ?????????????????
???????????????????????
???????????????? ???????????? ??????????? ????????????? ?????????????????
  
  
253 
Appendix 4: Stroke Specific Quality of Life Scale (SS-QOL) questionnaire 
Scoring: each item shall be scored with the following key 
Total help - Couldn't do it at all - Strongly agree        1 
A lot of help - A lot of trouble - Moderately agree       2 
Some help - Some trouble - Neither agree nor disagree       3 
A little help - A little trouble - Moderately disagree       4 
No help needed - No trouble at all - Strongly disagree       5 
 
Energy 
1. I felt tired most of the time.         ____ 
2. I had to stop and rest during the day.        ____ 
3. I was too tired to do what I wanted to do.      ____ 
Family Roles 
1. I didn't join in activities just for fun with my family.     ____ 
2. I felt I was a burden to my family.        ____ 
3. My physical condition interfered with my personal life.     ____ 
Language 
1. Did you have trouble speaking? For example, get stuck, stutter, stammer, or slur  
your words?           ____ 
2. Did you have trouble speaking clearly enough to use the telephone?    ____ 
3. Did other people have trouble in understanding what you said?    ____ 
4. Did you have trouble finding the word you wanted to say?     ____ 
5. Did you have to repeat yourself so others could understand you?    ____ 
Mobility 
1. Did you have trouble walking? (If patient can't walk, go to question 4 and score  
questions 2-3 as 1.)          ____ 
2. Did you lose your balance when bending over to or reaching for something?  ____ 
3. Did you have trouble climbing stairs?        ____ 
4. Did you have to stop and rest more than you would like when walking or using a   
wheelchair?           ____ 
5. Did you have trouble with standing?        ____ 
6. Did you have trouble getting out of a chair?       ____ 
Mood 
1. I was discouraged about my future.        ____ 
2. I wasn't interested in other people or activities.      ____ 
3. I felt withdrawn from other people.        ____ 
4. I had little confidence in myself.        ____ 
5. I was not interested in food.         ____ 
Personality 
1. I was irritable.          ____ 
2. I was inpatient with others.         ____ 
3. My personality has changed.         ____ 
Self Care 
1. Did you need help preparing food?       ____ 
2. Did you need help eating? For example, cutting food or preparing food?   ____ 
3. Did you need help getting dressed? For example, putting on socks or shoes,  
buttoning buttons, or zipping?         ____ 
4. Did you need help taking a bath or a shower?      ____ 
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5. Did you need help to use the toilet?        ____ 
Social Roles 
1. I didn't go out as often as I would like.       ____ 
2. I did my hobbies and recreation for shorter periods of time than I would like.   ____ 
3. I didn't see as many of my friends as I would like.      ____ 
4. I had sex less often than I would like.        ____ 
5. My physical condition interfered with my social life.      ____ 
Thinking 
1. It was hard for me to concentrate.        ____ 
2. I had trouble remembering things.        ____ 
3. I had to write things down to remember them.      ____ 
Upper Extremity Function 
1. Did you have trouble writing or typing?       ____ 
2. Did you have trouble putting on socks?       ____ 
3. Did you have trouble buttoning buttons?       ____ 
4. Did you have trouble zipping a zipper?       ____ 
5. Did you have trouble opening a jar?        ____ 
Vision 
1. Did you have trouble seeing the television well enough to enjoy a show?   ____ 
2. Did you have trouble reaching things because of poor eyesight?    ____ 
3. Did you have trouble seeing things off to one side?      ____ 
Work/Productivity 
1. Did you have trouble doing daily work around the house?     ____ 
2. Did you have trouble finishing jobs that you started?      ____ 
3. Did you have trouble doing the work you used to do?      ____ 
            TOTAL SCORE ____ 
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Appendix 5: Geriatric Depression Scale (Short Form) questionnaire 
Patient’s Name:       Date:  
Instructions: 
Choose the best answer for how you felt over the past week. Note: when asking the patient to 
complete the form, provide the self-rated form (included on the following page). 
 
Scoring: 
Answers indicating depression are in bold and italicized; score one point for each one selected. A 
score of 0 to 5 is normal. A score greater than 5 suggests depression.  
Sources:  
• Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a 
shorter version. Clin Gerontol. 1986 June;5(1/2):165-173.  
• Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull. 1988;24(4):709-711.  
• Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression 
screening scale: a preliminary report. J Psychiatr Res. 1982-83;17(1):37-49.  
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Appendix 6: In-hospital questionnaire 
ADMISSION CARD 
Date of completion of the questionnaire: ____ / ____ / ____ 
          dd        mm        yy 
Date of admission: ____ / ____ / ____ 
          dd       mm        yy 
INCLUSION CRITERIA 
□ Diagnosis of ischemic or hemorrhagic stroke or subarachnoid hemorrhage or TIA according to the 
criteria of the WHO 
□ Confirmation of the diagnosis on the basis of the report of a computed tomography or a magnetic 
resonance imaging 
□ Age over 18 years 
□ Consent of the patient and/or family members to participate in the study 
□ Lebanese 
The patient to be included in the study must meet all of the above conditions. 
 
EXCLUSION CRITERIA 
□ Serious pathologies with poor 1-year prognosis (ex. cancers, severe kidney, liver or respiratory 
insufficiency) 
□ Disabling and progressive neurological diseases (ex. multiple sclerosis, Parkinson's disease) 
□ Dementia 
□ Presence of logistical factors that could prevent the follow-up (residence outside the region, 
foreign language, discharge or transfer to a non-participating hospital within 24 h) 
□ Refusal of the patient or family members to participate in the study 
□ Presentation after 7 days of symptom onset 
Also by ticking one of the boxes, the patient cannot be included in the study. 
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Hospital Name: _______________________________________    File number: __________________ 
ID number: ________________  
PERSONAL INFORMATION 
Name: ____________________________________  Father name: _________________ 
SEX:   M □  F □  DATE OF BIRTH: |_ _ |_ _ | _ _ _ _ | 
Address: _______________________________ Province: ______________________ 
Telephone: ________________________ Cell phone: ________________________ 
Third party payer:   □ NSFF   □ MOPH   □ Military       □ Gov (COOP) ⁯ □ Gov (ISF)  
         □ Private Insurance ⁯    ⁯     □ Out of pocket        □ Other: _____________ 
(multiple choices possible)   ⁯ 
Weight : ________ Kg              Height: ________ cm 
Marital status:  □ Single □ Married □ Divorced □ Widowed 
Housing situation: 
□ Alone 
□ With family 
□ In an institution, specify:  _______________________ 
□ Other, specify: _______________________ 
Education: 
□ Illiterate 
□ Elementary school 
□ Secondary school 
□ High school 
□ University 
Professional conditions:     If the patient has a job, specify activity: 
□ Employed        EMPLOYED 
□ Student        □ Worker 
□ Housewife*       □ Employed 
□ Retired        □ Executive, manager, director 
□ Unemployed       □ Other 
        SELF EMPLOYED 
        □ Entrepreneur 
        □ Freelancer 
        □ Other 
* In category "housewife" includes all patients who actually carry out domestic activities. 
 
Monthly personal income:  □ < 750.000 L.L.   □ [750-1.500.000] LL  
    □ [1.500.000–2.250.000] LL    □ > 2.250.000 LL 
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Monthly home income:  □ < 750.000 L.L.   □ [750-1.500.000] LL  
    □ [1.500.000–2.250.000] LL    □ > 2.250.000 LL 
 
CLINICAL DATA 
Where was the patient when he had a stroke attack (symptoms onset)?  
□ at work   □ at home  □ other, specify_______________________ 
Specify please the distance (in Km) between this place and the hospital: ________ 
What were the symptoms he felt? 
_________________________________________________________ 
How was the patient transported to the hospital? 
□ taxi 
□ service 
□ bus 
□ his car 
□ his family/neighbors drove him 
□ red cross ambulance 
□ other, specify: ____________________________________________ 
How many hours have elapsed between the stroke attack and hospitalization: | _ | _ | | _ | _ | 
           hours     minutes 
How many hours have elapsed between hospital arrival and imaging (MRI/CT scan): | _ | _ | | _ | _ | 
                     hours    
minutes 
The patient underwent thrombolytic therapy? 
□  No  □ Yes, if yes, how many hours have elapsed between the stroke attack and 
hospitalization: | _ | _ | | _ | _ | 
  hours     minutes 
Type of stroke:    □ TIA  □ Ischemic □ Hemorrhagic: □ Intracerebral hemorrhage 
        □ Subarachnoid hemorrhage 
Clinical severity (Classification of Bamford) 
 
□ LACS (lacunar syndrome): 
 Category: 
 □ pure motor stroke: pure motor deficit that must involve at least half of the face and the 
 arm or upper limb and lower 
 □ pure sensory stroke: sensory deficit, even subjective, which must involve at least half of 
 the face and the arm or upper limb and lower 
 □ mixed sensorimotor stroke: motor stroke + sensory stroke  
 □ ataxic hemiparesis (including ataxia-paresis ipsilateral femoral syndrome) 
 □ dysarthria/clumsy hand syndrome 
□ POCS (posterior circulation syndrome) 
□ TACS (total anterior circulation stroke) 
□ PACS (partial anterior circulation syndrome) 
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PAST MEDICAL HISTORY 
Pathology Details 
□ Hypertension Therapy: 
□ None 
□ Diet 
□ Diuretic 
□ B-blocker 
□ Ca-antagonist  
□ ACE Inhibitor  
□ Angiotensin II receptor blockers (ARB) 
□ Atrial Fibrillation □ Permanente 
□ Paroxysmal 
Therapy: 
□ None 
□ Anti-platelet 
□ Oral Anticoagulants 
□ _______________ 
INR:    □ <2.0;      □ 2.0-3.0;  □ > 3.0 
□ Hyperlipidemia □ Total cholesterol > 200 mg/dL 
Indicate triglycerides value ___________ 
Drug treatment:   □ No   □ Yes, specify them: 
___________________________________  
□ Reduced glucose tolerance □ Fasting glucose > 126 mg/dL 
□ Diabetes Mellitus □ IDDM 
□ NIDDM 
□ Previous stroke Number _______ 
1st year of stroke: _________ 
□ Previous TIA Number _______ 
1st year of TIA: _________ 
□ Previous MI Number _______ 
1st year of MI: _________ 
□ Other, specify: ______________________ Therapy:  ______________________________ 
□ Other, specify: ______________________ Therapy:  ______________________________ 
□ Other, specify: ______________________ Therapy:  ______________________________ 
Is the patient a smoker? No □  Yes □  Ex-smoker □ 
Was the patient previously subjected to surgery? No □  Yes □ If yes, specify which: 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
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LEVEL OF DISABILITY AT ADMISSION 
1. Barthel Index 
(Fill the scale with respect to the patient's ability before the stroke) 
Date of completion of the scale: ____ / ____ / ____ 
        dd        mm       yy 
NOT DETERMINED □ 
 
Activity          Score 
FEEDING 
0 = unable 
5 = needs help cutting, spreading butter, etc., or requires modified diet 
10 = independent         ______ 
BATHING 
0 = dependent 
5 = independent (or in shower)        ______ 
GROOMING 
0 = needs to help with personal care 
5 = independent face/hair/teeth/shaving (implements provided)   ______ 
DRESSING 
0 = dependent 
5 = needs help but can do about half unaided 
10 = independent (including buttons, zips, laces, etc.)     ______ 
BOWELS 
0 = incontinent (or needs to be given enemas) 
5 = occasional accident 
10 = continent          ______ 
BLADDER 
0 = incontinent, or catheterized and unable to manage alone 
5 = occasional accident 
10 = continent          ______ 
TOILET USE 
0 = dependent 
5 = needs some help, but can do something alone 
10 = independent (on and off, dressing, wiping)      ______ 
TRANSFERS (BED TO CHAIR AND BACK) 
0 = unable, no sitting balance 
5 = major help (one or two people, physical), can sit 
10 = minor help (verbal or physical) 
15 = independent         ______ 
MOBILITY (ON LEVEL SURFACES) 
0 = immobile or < 46 meters 
5 = wheelchair independent, including corners, > 46 meters 
10 = walks with help of one person (verbal or physical) , > 46 meters 
15 = independent (but may use any aid; for example, stick),  > 46 meters  ______ 
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STAIRS 
0 = unable 
5 = needs help (verbal, physical, carrying aid) 
10 = independent         ______ 
               TOTAL (0–100): ______ 
 
2. Barthel Index 
(Fill the scale with respect to the patient's ability at admission to the ward) 
Date of completion of the scale: ____ / ____ / ____ 
        dd        mm       yy 
Activity          Score 
FEEDING 
0 = unable 
5 = needs help cutting, spreading butter, etc., or requires modified diet 
10 = independent         ______ 
BATHING 
0 = dependent 
5 = independent (or in shower)        ______ 
GROOMING 
0 = needs to help with personal care 
5 = independent face/hair/teeth/shaving (implements provided)   ______ 
DRESSING 
0 = dependent 
5 = needs help but can do about half unaided 
10 = independent (including buttons, zips, laces, etc.)     ______ 
BOWELS 
0 = incontinent (or needs to be given enemas) 
5 = occasional accident 
10 = continent          ______ 
BLADDER 
0 = incontinent, or catheterized and unable to manage alone 
5 = occasional accident 
10 = continent          ______ 
TOILET USE 
0 = dependent 
5 = needs some help, but can do something alone 
10 = independent (on and off, dressing, wiping)      ______ 
TRANSFERS (BED TO CHAIR AND BACK) 
0 = unable, no sitting balance 
5 = major help (one or two people, physical), can sit 
10 = minor help (verbal or physical) 
15 = independent         ______ 
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MOBILITY (ON LEVEL SURFACES) 
0 = immobile or < 46 meters 
5 = wheelchair independent, including corners, > 46 meters 
10 = walks with help of one person (verbal or physical), > 46 meters 
15 = independent (but may use any aid; for example, stick), > 46 meters  ______ 
STAIRS 
0 = unable 
5 = needs help (verbal, physical, carrying aid) 
10 = independent         ______ 
               TOTAL (0–100): ______ 
 
3. NIHSS (National Institute of Health Stroke Scale) 
(Fill in the scale with respect to the patient's ability at admission to the ward) 
Date of completion of the scale: ____ / ____ / ____ 
        dd       mm        yy 
 
Instructions Scale Definition Score 
1a. Level of 
Consciousness  
0 = Alert; keenly responsive.  
1 = Not alert; but arousable by minor stimulation to 
obey, answer, or respond.  
2 = Not alert; requires repeated stimulation to attend, 
or is obtunded and requires strong or painful 
stimulation to make movements (not stereotyped).  
3 = Responds only with reflex motor or autonomic 
effects or totally unresponsive, flaccid, and areflexic.  
______ 
1b. LOC Questions  0 = Answers both questions correctly.  
1 = Answers one question correctly.  
2 = Answers neither question correctly.  
______ 
1c. LOC Commands 0 = Performs both tasks correctly.  
1 = Performs one task correctly.  
2 = Performs neither task correctly.  
______ 
2. Best Gaze  0 = Normal.  
1 = Partial gaze palsy; gaze is abnormal in one or both 
eyes, but forced deviation or total gaze paresis is not 
present.  
2 = Forced deviation, or total gaze paresis not 
overcome by the oculocephalic maneuver.  
______ 
3. Visual 0 = No visual loss.  
1 = Partial hemianopia.  
2 = Complete hemianopia.  
3 = Bilateral hemianopia (blind including cortical 
blindness).  
______ 
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Instructions Scale Definition Score 
4. Facial Palsy  0 = Normal symmetrical movements.  
1 = Minor paralysis (flattened nasolabial fold, 
asymmetry on smiling).  
2 = Partial paralysis (total or near-total paralysis of 
lower face).  
3 = Complete paralysis of one or both sides (absence 
of facial movement in the upper and lower face).  
______ 
5. Motor Arm  0 = No drift; limb holds 90 (or 45) degrees for full 10 
seconds.  
1 = Drift; limb holds 90 (or 45) degrees, but drifts down 
before full 10 seconds; does not hit bed or other 
support.  
2 = Some effort against gravity; limb cannot get to or 
maintain (if cued) 90 (or 45) degrees, drifts down to 
bed, but has some effort against gravity.  
3 = No effort against gravity; limb falls.  
4 = No movement.  
UN = Amputation or joint fusion, explain: 
_____________________  
5a. Left Arm  
5b. Right Arm  
 
 
 
 
 
 
 
 
 
 
 
 
______ 
______ 
6. Motor Leg  0 = No drift; leg holds 30-degree position for full 5 
seconds.  
1 = Drift; leg falls by the end of the 5-second period but 
does not hit bed.  
2 = Some effort against gravity; leg falls to bed by 5 
seconds, but has some effort against gravity.  
3 = No effort against gravity; leg falls to bed 
immediately.  
4 = No movement.  
UN = Amputation or joint fusion, explain: 
__________________________________________ 
6a. Left Leg  
6b. Right Leg  
 
 
 
 
 
 
 
 
 
 
 
______ 
______ 
7. Limb Ataxia 0 = Absent.  
1 = Present in one limb.  
2 = Present in two limbs.  
UN = Amputation or joint fusion, explain: 
__________________________________________  
______ 
8. Sensory 0 = Normal; no sensory loss.  
1 = Mild-to-moderate sensory loss; patient feels 
pinprick is less sharp or is dull on the affected side; or 
there is a loss of superficial pain with pinprick, but 
patient is aware of being touched.  
2 = Severe to total sensory loss; patient is not aware of 
being touched in the face, arm, and leg.  
______ 
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Instructions Scale Definition Score 
9. Best Language 0 = No aphasia; normal.  
1 = Mild-to-moderate aphasia; some obvious loss of 
fluency or facility of comprehension, without significant 
limitation on ideas expressed or form of expression. 
Reduction of speech and/or comprehension, however, 
makes conversation about provided materials difficult 
or impossible. For example, in conversation about 
provided materials, examiner can identify picture or 
naming card content from patient’s response.  
2 = Severe aphasia; all communication is through 
fragmentary expression; great need for inference, 
questioning, and guessing by the listener. Range of 
information that can be exchanged is limited; listener 
carries burden of communication. Examiner cannot 
identify materials provided from patient response.  
3 = Mute, global aphasia; no usable speech or auditory 
comprehension.  
______ 
10. Dysarthria 0 = Normal.  
1 = Mild-to-moderate dysarthria; patient slurs at least 
some words and, at worst, can be understood with 
some difficulty.  
2 = Severe dysarthria; patient's speech is so slurred as 
to be unintelligible in the absence of or out of 
proportion to any dysphasia, or is mute/anarthric.  
UN = Intubated or other physical barrier, 
explain:____________________________________  
______ 
11. Extinction and 
Inattention 
(formerly Neglect) 
0 = No abnormality.  
1 = Visual, tactile, auditory, spatial, or personal 
inattention or extinction to bilateral simultaneous 
stimulation in one of the sensory modalities.  
2 = Profound hemi-inattention or extinction to more 
than one modality; does not recognize own hand or 
orients to only one side of space.  
______ 
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HOSPITALIZATION DATA 
During the hospitalization, was the patient submitted to instrumental diagnostic tests due to stroke?  
□ No  □ Yes, If Yes, specify: 
Type Number Expenditure 
Brain computed tomography (CT) including that of 
diagnosis 
Brain computed tomography with contrast 
Brain imaging (MRI) 
Supra-aortic Doppler  
Transcranial Doppler 
Cerebral angiography 
Magnetic resonance angiography (MRA) 
Electro-cardiogram 
Dynamic electro-cardiogram type Holter (24 hours) 
Transthoracic  echocardiogram  
Transesophageal echocardiogram 
Electro-encephalogram 
Chest X-ray 
Neuropsychological evaluation (cognitive, language 
disorders, etc.) 
Other, specify: 
Other, specify: 
Other, specify: 
Other, specify: 
Other, specify: 
Other, specify: 
  
During the hospitalization, was the patient submitted to laboratory tests due to stroke?   
□ No   □ Yes, If Yes, specify: 
Type Number Expenditure 
Glycemia 
HbA1c 
INR  
T. Quick (TP) 
Activated Partial Thromboplastin Time 
Fibrinogen 
Platelet aggregation 
BUN 
Creatinine 
Blood count 
SGOT 
SGPT 
GGT 
Alkaline phosphatase 
LDH 
Bilirubin 
CPK 
ESR (erythrocyte sedimentation rate) 
APC (activated protein C) PCR 
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Type Number Expenditure 
Blood Gas 
Total cholesterol 
Triglycerides 
Urine analysis (specify if with culture) 
ANA 
Other specify: 
Other specify: 
Other specify: 
Other specify: 
Other specify: 
During the hospitalization, was the patient referred to a rehabilitation therapy specialist because of 
stroke?  
□ No   □ Yes, If Yes, specify: 
Type of therapy Therapy initiation 
date 
No. of overall sessions Expenditure 
Physical rehabilitation    
Occupational therapy    
Speech therapy    
    
During the hospitalization, was the patient visited by a specialist due to stroke?  
□ No   □ Yes, If Yes, please specify: 
Visit type Number Expenditure 
   
   
   
   
       
During the hospitalization, did the patient receive any drug therapy? 
 □ No   □ Yes, If Yes, please specify: 
Molecule Dose and 
frequency 
(daily/weekly 
etc.) (tablets, 
ampoule, drops, 
etc.) 
Duration of 
treatment 
(days) 
Correlation 
with stroke 
(Yes/No) 
The patient 
was taking 
it the 
previous 
stroke 
(Yes/No) 
Expenditure 
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During the hospitalization, was it necessary to do these actions because of stroke: 
□ Pencutaneous Endoscopic Gastrostomy  number of days   ______   cost per day ______ 
□ Nasogastric tube    number of days ______    cost per day ______ 
□ Catheter     number of days ______    cost per day ______ 
□ Parenteral nutrition    number of days ______    cost per day ______ 
□ Elastic stocking    number of days ______    cost per day _______ 
□ Monitoring vital functions   number of hours _____    cost per hour _______ 
□ ____________________     ______   cost per day/h _______ 
□ ____________________     ______   cost per day/h _______ 
 
During the hospitalization, has critical events occurred (ex. infarction, fractures, heart failure, 
bronchopneumonia etc.) because of stroke that have required additional health services?  
□ No    □ Yes, If Yes, specify: 
Event Description Health Service Expenditure 
   
   
   
During hospitalization, was the patient submitted to surgery?  
□ No    □ Yes, If Yes, please specify: 
□ Neurosurgery 
□ Carotid surgery 
□ Vascular surgery, specify __________________________________ 
□ Another surgery, specify __________________________________ 
□ Number of hour using the operating room: ________ 
In the scope of the same hospital, was the patient transferred to another division/ward of the same 
hospital (even the return of the patient to the department/ward he was first admitted to is 
considered a transfer)?  
□No   □ Yes, If Yes, please specify: 
Transfer Date of transfer From (Ward) To (Ward) 
1st Transfer    
2nd Transfer    
3rd Transfer    
4th Transfer    
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HOSPITAL DISCHARGE DATA 
 
The patient was admitted in: ______________________________________division/ward 
Total days the patient spent in the division/ward: ______ 
Discharge date: ____ / ____ / ____ 
    dd       mm       yy 
Drug therapy at discharge: 
MOLECULE DOSE AND FREQUENCY 
(ex. DAILY / WEEKLY) 
(tablets, ampoule, drops) 
DURATION OF TREATMENT 
(DAYS) 
   
   
   
   
   
   
   
   
   
Neurological diagnosis: 
□ Hemorrhagic stroke:  □ in typical site  □ in atypical site 
□ Ischemic stroke (TOAST criteria, 1993) 
  Atherosclerosis of vessels of large caliber  □ 
  Cardioembolic (possible / likely)   □ 
  Occlusion of small vessels    □ 
  Stroke by different causes   □ 
  Stroke from causes not certain: 
   a. identification of two or more causes  □ 
   b. negative evaluation    □ 
   c. incomplete evaluation   □ 
How to discharge the patient from the hospital in which he was admitted: 
□ Ordinary to the patient's home 
□ Transfer directly to another institution of hospitalization and treatment, public or private (in the 
case of direct transfer, arranged by the hospital). 
Indicate name of the institution: ________________________________________ 
□ Death of the patient on --/--/---- 
□ Discharge ordinary at a nursing home 
□ Discharge to the patient's home with home hospitalization 
□ Transfer to another type or system of hospitalization (day hospital - rehabilitation or long-term 
care), inside the institution 
□ Transfer to another public or private institution to begin a rehabilitation therapy. 
Indicate name of the institution: ________________________________________ 
□ Discharge ordinary with an integrated home care (nursing care at home) 
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How did the patient leave the hospital? 
□ taxi 
□ service 
□ bus 
□ his car 
□ his family/neighbors took him 
□ other, specify: ____________________________________________ 
Specify please the distance (in Km) between the hospital and the next destination: _________ 
 
PATIENT OUTCOME MEASURE 
at discharge of hospitalization 
1. Barthel Index 
DATE OF COMPLETION OF SCALE: ____ / ____ / ____ 
         dd       mm       yy 
NOT DETERMINED □ 
Activity          Score 
FEEDING 
0 = unable 
5 = needs help cutting, spreading butter, etc., or requires modified diet 
10 = independent         ______ 
BATHING 
0 = dependent 
5 = independent (or in shower)        ______ 
GROOMING 
0 = needs to help with personal care 
5 = independent face/hair/teeth/shaving (implements provided)   ______ 
DRESSING 
0 = dependent 
5 = needs help but can do about half unaided 
10 = independent (including buttons, zips, laces, etc.)     ______ 
BOWELS 
0 = incontinent (or needs to be given enemas) 
5 = occasional accident 
10 = continent          ______ 
BLADDER 
0 = incontinent, or catheterized and unable to manage alone 
5 = occasional accident 
10 = continent          ______ 
TOILET USE 
0 = dependent 
5 = needs some help, but can do something alone 
10 = independent (on and off, dressing, wiping)      ______ 
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TRANSFERS (BED TO CHAIR AND BACK) 
0 = unable, no sitting balance 
5 = major help (one or two people, physical), can sit 
10 = minor help (verbal or physical) 
15 = independent         ______ 
MOBILITY (ON LEVEL SURFACES) 
0 = immobile or < 46 meters 
5 = wheelchair independent, including corners, > 46 meters 
10 = walks with help of one person (verbal or physical) , > 46 meters 
15 = independent (but may use any aid; for example, stick),  > 46 meters  ______ 
STAIRS 
0 = unable 
5 = needs help (verbal, physical, carrying aid) 
10 = independent         ______ 
               TOTAL (0–100): ______ 
 
2. Modified Rankin Scale 
DATE OF COMPLETION OF SCALE: ____ / ____ / ____ 
          dd        mm       yy 
Score   Description 
0   No symptoms at all 
1   No significant disability despite symptoms; able to carry out all usual duties and  
  activities 
2  Slight disability; unable to carry out all previous activities, but able to look after own 
affairs without assistance 
3   Moderate disability; requiring some help, but able to walk without assistance 
4   Moderately severe disability; unable to walk without assistance and unable to  
  attend to own bodily needs without assistance 
5   Severe disability; bedridden, incontinent and requiring constant nursing care and 
  attention 
6   Dead 
 
TOTAL (0–6): _______ 
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Appendix 7: Submitted article 
 
 
